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Abstract 
 
Melanoma is a dangerous form of skin cancer that can spread throughout the body 
without treatment. The population of melanoma survivors has grown for several reasons 
including rising melanoma incidence, earlier detection, and treatment advances. The eastern 
Tennessee area is designated as an Appalachian region of the country where many people still 
live in abject poverty and lack access to adequate healthcare resources. Eight counties were 
found to have the highest melanoma incidence rates in Tennessee. Currently, post-treatment 
melanoma surveillance is disjointed, and falls on a variety of healthcare providers. The health-
related experiences and post-treatment needs of melanoma survivors are essentially unknown in 
Tennessee. While additional resources are needed, there are limited local providers and facilities 
in rural Tennessee. The purpose of this qualitative interpretive description study was to 
understand the experiences related to melanoma survivorship from the perspective of the patients 
themselves. 
Thorne’s (2008) framework for interpretive description research was used for this 
qualitative study. Sixteen participants were interviewed from counties in the east Tennessee 
Appalachian region. Qualitative data analysis using interpretive description recommendations 
allowed the identification of four themes: 1) Sitting in the driver’s seat of follow-up care, 2) 
Living in a skin world, 3) Once bitten, twice shy, and 4) Watch me like a hawk. Melanoma 
survivors living in east Tennessee experience follow-up similarly to other individuals living with 
cancer who also have specific cultural, geographical, and regional barriers to surveillance. Their 
implicit needs are basic and consistent with the standard of care we offer other cancer survivors. 
Future research suggestions include taking a closer look at types of melanoma in other diverse 
populations, less invasive or less urgent post-treatment management options, and best practice 
programs that benefit melanoma survivors with psychosocial distress in long-term follow-up. 
 
Key words: melanoma survivors, melanoma follow-up, post-treatment experiences and needs, 
East Tennessee Appalachian Region (ETAR) 
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Chapter One: Introduction 
  Melanoma is a form of skin cancer that, without treatment, can spread throughout the 
body (Nouri, 2008; Levine & Shapiro, 2012). As the most lethal form of skin cancer, melanoma 
is responsible for 80% of all skin cancer-related deaths despite accounting for only 4% of all skin 
cancer cases (Guy et al., 2015; SEER, 2017). In fact, this year in the U.S., melanoma is expected 
to result in more than 10,000 deaths from an estimated 87,000 new cases this year (SEER, 2017, 
ACS, 2017).  
 The Centers for Disease Control and Prevention (CDC) report that, unlike that of other 
skin cancers, melanoma incidence has been steadily increasing for the last 30 years (CDC, 2013; 
Guy et al., 2015; Siegel, Miller, & Jemal, 2016). While the melanoma incidence rate has doubled 
since 1976, the overall five-year survival rate has increased significantly in the same period 
(CDC, 2013; Liu & Soong, 1996). This increased overall survival rate has led to growth in the 
number of melanoma survivors, estimated at more than one million nationally (DeSantis et al., 
2014). In Tennessee, the number of melanoma survivors exceeded 15,500 in 2014 and that 
number is expected to increase each year through 2024 (American Cancer Society [ACS], 2016; 
DeSantis et al., 2016; Surveillance, Epidemiology and End Results Program [SEER], 2017).  
 For this study, the primary investigator (PI) focused on understanding the post-treatment 
health-related experiences and needs of melanoma survivors residing in a designated 
underserved area in the East Tennessee Appalachian Region (ETAR) (Appalachian Regional 
Commission [ARC], 2016). Some ETAR counties are have double the national and state 
estimates for melanoma incidence (ACS, 2017; NCI, 2017; SEER, 2017) and are designated as 
lacking adequate healthcare access and resources to meet basic needs (ARC, 2016). Melanoma 
survivors diagnosed at a later stage of the disease require a variety of healthcare resources and 
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access to tertiary care not available more locally for follow-up (National Comprehensive Cancer 
Network [NCCN], 2016). Additionally, aging melanoma survivors face side effects from 
extensive treatments, effects from other chronic conditions, ongoing costly monitoring, and work 
limitations affecting their livelihood (Livingstone et al., 2011). The effectiveness and quality of 
care directly for post-treatment melanoma survivors in urban and rural ETAR counties is 
unknown. Understanding this population’s particular experiences with post-treatment 
uncertainty, recurrence, and follow-up care could help inform treatment changes to improve 
quality of life (QOL) for individuals, families, and communities in the ETAR (Ludke, 2012; 
Miller, 2014a; Miller, 2014b). Additionally, research on melanoma survivors in this region is 
needed to alleviate barriers to ongoing continuity of care and disparities during follow-up care 
(Ludke, 2012; NCI, 2004; Parikh, Kirch, & Browley, 2015). 
Background 
 For more than a decade, melanoma research has focused mainly on prevention, early 
detection, and treatment
 
(Little & Eide, 2012; Palesh et al., 2014; Siegel, Ma, & Jemal, 2014; 
Yang, Barnholtz-Sloan, Chen, & Bordeauz, 2011). Because of such research, approximately 84% 
of melanomas are diagnosed at a local stage, when they are most curable (DeSantis et al., 2014). 
Once thin melanomas are detected and surgically removed, ongoing skin examination and 
symptom monitoring is critical for melanoma survivors (Youl et al., 2011; NCCN, 2016; ACS, 
2017; NCI, 2017). Although commonly thought of as cancer that affects only the skin, melanoma 
is particularly prone to spread (metastasize) via blood or lymphatics to subcutaneous tissues, 
lungs, brain, and the gastrointestinal tract (Levine & Shapiro, 2012; UpToDate, 2016). 
Moreover, depending on a melanoma’s size and location, removal can be disfiguring (DeSantis 
et al., 2014). 
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 Generally, melanoma lesions are categorized into four subtypes: acral melanoma (occurs 
on the palms of the hands, soles of the feet, or nail beds); lentigo melanoma (usually occurs on 
the face or scalp); nodular melanoma (lumpy, often blue-black in color, and grows rapidly 
downward toward the dermis); and superficial spreading melanoma (grows outward at first to 
form an irregular pattern) (ACS, 2017; NCI, 2017). Regardless of type, it is critical to detect and 
surgically remove melanoma before it grows, when it is small and thin (localized) (NCCN, 2016; 
National Institutes of Health [NIH], 2016; ACS, 2017; NCI, 2017). The five-year survival rate in 
patients diagnosed with localized melanoma exceeds 94% and drops to 16% when it spreads 
(Guy et al., 2015; CDC, 2015; SEER, 2017).  
 Anyone can get melanoma, but some people have a higher risk. Important risk factors for 
melanoma include being male or having a fair complexion (fair skin that freckles or burns easily 
and does not tan; blue or green eyes; red or blonde hair), multiple or large moles, or a family 
history of melanoma (mother, father, brother, sister) (ACS, 2017). An important modifiable 
melanoma risk factor is intermittent, intense exposure to sunlight or artificial sunlight (tanning 
beds), especially on skin usually covered by clothing (Lin, Wang, Li, & Kolker, 2012; ACS, 
2017). Experiencing multiple, blistering sunburns, especially as a child or teen also is associated 
with a higher risk of eventual melanoma development (ACS, 2017). Generally, increased thin 
melanoma lesions have been associated with patients who have skin cancer awareness, provider 
skin examinations, and higher socioeconomic status (Liu & Soong, 1996; Balch et al., 2001; 
UpToDate, 2016; ACS, 2017). However, thicker melanoma lesions are associated with patients 
with lower socioeconomic status, lower education levels, and healthcare access inequalities. 
These latter characteristics are common to people in ETAR, especially in more rural Tennessee 
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(Kirby, Taliaferro, & Zuvekas, 2006; Pollitt, Clarke, Shema, & Swetter, 2008; Zell et al., 2008; 
Wich et al., 2011, ARC, 2016).  
 Although there are no universally accepted guidelines that define post-treatment 
surveillance for individuals diagnosed with melanoma, the National Comprehensive Cancer 
Network (NCCN) does offer recommendations (Linette & Cornelius, 2013; McCabe & Jacobs, 
2012; NCCN, 2016). The NCCN Clinical Practice Guidelines in Oncology consists of 
multidisciplinary cancer experts and an alliance of leading cancer centers devoted to patient care, 
research, and education. The NCCN’s recommendations are evaluated periodically by NCCN 
associates who review current research, examine practice, and contribute to cancer care 
improvement. For example, once diagnosis is confirmed by biopsy, NCCN treatment plan 
recommendations include referral to a tertiary, multidisciplinary center based on the lesion 
thickness and pathology specifics (NCCN, 2016) (Table 1.1, Appendix A). 
 A thin melanoma is defined as a tumor less than 1.0 mm thick and a thick melanoma as a 
one more than 1.0 mm thick. Individuals diagnosed with thicker lesions and advanced stage 
disease have a poor prognosis (Geller & Annas, 2003; Levine & Shapiro, 2012; Matzke, Bean, & 
Ackerman, 2009; ACS, 2017). Once a melanoma lesion has been biopsied, the cancer is staged 
according to the American Joint Committee on Cancer (2016) as stage I, II, III, or IV. The 
disease is staged by tumor thickness and/or metastasis: stage IA (1mm or less); stage IB (1–
2mm); stage IIA (2–4mm); IIC (>4mm); stage III (any size+lymph node involvement); and stage 
IV (any size+lymph node involvement+metastasis) (NCCN, 2016; ACS, 2017). Survival is 
strongly related to melanoma thickness with higher mortality occurring in patients with lesions 
thicker than one millimeter (mm) (Aitken, Elwood, Baade, Youl, & English, 2010). 
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 Following diagnosis and treatment, NCCN panel experts (2016) suggest lifelong skin 
examinations and education for melanoma survivors. In 2017, there were more than one and half 
million melanoma survivors living in the U.S. (Miller, 2017; ACS, 2017). The population of 
melanoma survivors has grown for several reasons including increased incidence of patients 
diagnosed with thin melanoma, earlier detection initiatives, and treatment advances (Howlader et 
al., 2014; Mariotto, Yabroff, Shao, Feuer & Brown, 2011; U.S. Cancer Statistics Working 
Group, 2014).  
 Although clear data and varying expert opinions exist regarding appropriate surveillance 
for melanoma survivors there is a need for ongoing follow-up (NCCN, 2016). Specifically, the 
NCCN recommends that melanoma patients diagnosed with stage IA (thin lesion) who have no 
evidence of disease after surgical removal have at least annual skin exams for life; education in 
regular self-skin and lymph nodal examination; and a history and physical with emphasis on skin 
and lymph nodes every 6–12 months for the first five years and then annually thereafter. Routine 
blood tests or radiographic imaging for asymptomatic disease is not recommended. Follow-up 
for stage IIA patients includes all the recommendations for IA (except the history), and a 
physical every 3–6 months for two years then every 3–12 months for three years. 
Recommendations for stage IIB–IV patients include considering the following scans every 3–12 
months screening for recurrent or metastatic disease: chest radiography (CXR), computerized 
axial tomography (CAT) scan, magnetic resonance imaging (MRI), and or positron emission 
tomography (PET/CT) scans. The recommendations for stage IIB–IV patients also includes no 
routine radiologic screening for asymptomatic disease after 3–5 years. Melanoma survivors need 
ongoing monitoring for recurrence and/or new malignancies with regular comprehensive skin 
exams, nodal assessment, symptom management, as well as psychological evaluation and 
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treatment (DeSantis et al., 2014; Mrazek & Chao, 2014). Patients with disfigurement usually 
have burdensome progressive symptoms that can affect their quality-of-life (QOL) (Kemp et al., 
2012; Chung-Yuan, 2013). 
 Routine follow-up for patients after treatment for melanoma is standard practice; 
however, globally there is also debate about appropriate surveillance methods, frequency of 
exams, or additional testing (Dancey, Rayalt, Courthold, & Roberts, 2005; Franchken, 
Bastiiaannet, & Hoekstra, 2005; NCCN, 2016). The current plan for melanoma follow-up in the 
U.S. is fractured, with the burden falling inconsistently on a variety of healthcare providers: 
primary care physicians, nurse practitioners, physician assistants, dermatologists, medical 
oncologists, surgical oncologists, general surgeons, and plastic surgeons
 
(Francken, Bastiaannet, 
& Hoekstra, 2005; Gamble et al., 2010; Mrazek & Chao, 2014; Rueth, Cromwell, & Cormier, 
2014). Although most melanoma survivor post-treatment follow-up is provided with 
dermatologists, the availability of services is unknown. There is insufficient research in some 
populations regarding melanoma survivors’ long-term quality of life needs. Specifically, the 
threat of recurrence, the meaning associated with recurrence, supportive care, economic 
constraints, psychological issues, provider availability, symptom control, and/or disfigurement 
concerns
 
(Francken, Bastiaannet, Hoekstra, 2005; Wheeler, 2006; McLoone et al., 2012; Linette 
& Cornelius, 2013; Rychetnik, McCaffery, Morton, & Irwig, 2013; Kasparian, 2013; McLoone 
et al., 2013; Oliveria et al., 2013; Trotter et al., 2013; Tan, Butow, Boyle, Saw, & O’Reilly, 
2014; Hamel et al., 2016).  
Economic Burden 
 The continuing cost of follow-up care for melanoma patients is projected to be over $226 
billion by 2025, representing a 48% increase from 2010 (Howlander et al., 2014). According to 
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the CDC, melanoma detection, treatment, and recurrence accounts for approximately $4 billion 
in lost productivity each year (CDC, 2012). The physical, psychological, and socioeconomic 
impacts along with lost productivity following melanoma treatment depend on many factors 
including regional incidence rates, available treatment resources, healthcare access, and research 
investments (Eide, Weinstock, & Clark, 2009; Greenlee & Howe, 2009; Linos, Swetter, 
Cockburn, Colditz, & Clarke, 2009; Little & Eide, 2012; Reyes-Ortiz, Goodwin, & Freemen, 
2005; Youl et al., 2011). More than half of the melanoma survivors in the U.S. (approximately 
710,000) are younger than 70 years of age, including 220,000 survivors who are younger than 50 
(CDC, 2014; SEER, 2014). 
 Following a melanoma diagnosis, patients live with a lifetime of monitoring that includes 
uncertainty and watching for signs of recurrence and/or relapse (Mishel, 1988; Mishel, 1990; 
McLoone et al., 2012). Melanoma patients and their families face physical, emotional, social, 
and economic challenges that may result from the diagnosis and treatment (Hetz & Tomasone, 
2012; Plescia, Berman, & White, 2011; McLoone et al., 2012; Morton, Rychetnik, McCaffery, 
Thompson, & Irwig, 2013). Specifically, survivors’ experiences include enduring pain and 
fatigue, declines in physical and emotional functioning, and a decrease in over well-being. 
(Beutel et al., 2015; Bird, Coleman, & Danson, 2015; Blanchard, Courney, & Stein, 2008; 
Hamma-Raz & Solomon, 2006; Hamma-Raz, Solomon, Schachter, & Azizi, 2007; Oliveria & 
Berwick, 2009; Oliveria et al., 2013; Palesh et al, 2014; Tan, Butow, Boyle, Saw, & O’Reilly, 
2014; Wheller, 2006). Between 1990 and 2011, the overall cost of melanoma diagnosis and 
treatment was approximately $932.5 million per year for the general population, with $44.9 
million per year for Medicare beneficiaries (Guy, Donatus, Ekwueme, Tangka, & Richardson, 
2012).  
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Regional Differences 
 Melanoma is now considered the third leading cause of cancer in men and the sixth in 
women in the U.S. (ACS, 2016; National Cancer Institute [NCI], 2016). The melanoma 
incidence rate (number of new cases of melanoma per 100,000 people) in the U.S. is 16.9% for 
women and 28.5% for men (NCI, 2017). Utah has the highest state melanoma incidence rate at 
34.6% (CDC, 2012). However, many U.S. counties are burdened with higher incidence rates that 
exceed the national rates and even approach international incidence rates. Compared to U.S. 
melanoma incidence rates, Australia and New Zealand have the highest melanoma rates in the 
world (59.9% and 63.8%, respectively). In fact, Queensland, Australia has an incidence rate of 
82.1% for males and 54.8% for women, figures that exceed all other areas nationally and 
internationally (Australian Institute of Health and Welfare [AIHW], 2016; Queensland 
Government, 2015).  
 The melanoma incidence rate is reportable to the state and federal registry (NCI, 2016; 
USHHS, 2016; NIH, 2017). However, little research is available about where treatment might 
occur and even less is known about where or by whom survivors are followed long-term. The 
state of Tennessee has a higher melanoma incidence rate when compared to the overall U.S. rate 
(20.8% and 19.9%, respectively). Some Tennessee counties, especially those in Appalachia, have 
melanoma incidence rates double that of the state and national rate (Figure 1.1, Appendix A) For 
example, Grainger, Hamblen, Hawkins, Jefferson, Sevier, Sullivan, Unicoi, and Washington 
counties have melanoma incidence rates ranging from 30.8% to 42.4% (Figure 1.2, Appendix A). 
The Appalachian Region is a 205,000-square-mile area that extends along the Appalachian 
Mountains from southern New York to northern Mississippi (Figure 1.3, Appendix A). More 
than 25 million people live in this region, where 42% of the population lives in a rural area, 
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compared with only 20% of the national population (ARC, 2016). Knight (2012) described the 
Appalachian Region as an area with high levels of unmet basic human needs and insufficient 
services. The counties with high melanoma incidence rates are considered to be in either 
economically at-risk areas that include the worst 10–25% of U.S. counties, or transitional areas 
where the county has moved from having a weak economy to a stronger one (ARC, 2016).  
 Many counties across the U.S. including rural Tennessee have substantially higher 
poverty rates or significantly lower income levels than national averages, which may affect 
melanoma survivors in need of post-treatment follow-up services (Livingstone et al., 2011; Wich 
et al., 2011; Cromwell et al., 2012; Linette & Cornelius, 2013; CDC, 2015; SEER, 2017; ARC, 
2017). The cluster of eight counties with high melanoma incidence in the northeast corner of 
Tennessee was reported to the state cancer registry but no additional information is available 
related to where follow-up is obtained or by which provider locally or regionally.  
 Individuals from Appalachia are more likely to have several risk factors that increase 
cancer incidence and mortality: tobacco use, a high-fat diet, physical inactivity, and inadequate 
access to medical care (ARC, 2016). Ludke (2012) explained that health encompasses more than 
medical care and may be necessary to look at a much broader definition for cancer survivors. 
The Tennessee Cancer Coalition’s (2016) acknowledges, “There are unmet needs and disparities 
in knowledge, access, treatment, and survival among some populations in Tennessee” (p. 6). The 
State of Tennessee’s 2013–2017 cancer plan included skin cancer (melanoma and non-
melanoma) initiatives along with initiatives to decrease incidence and improve outcomes by 
increasing education about prevention, early detection, and treatment.  
 The National Cancer Institute (NCI) defines cancer health disparities as adverse 
differences in incidence, prevalence, mortality, cancer survivorship, and the burden of cancer or 
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related health conditions that exist among specific U.S. population groups. From 2005–2009, 
Tennessee ranked 19
th
 in cancer incidence and third in cancer deaths when all races and sexes 
were combined. Many factors contribute to the complexity with ranks and ratings varying by 
race, ethnicity, geography, gender, age, and socioeconomic status. Some differences in rates are 
known, but the identity of specific factors that cause disparities and how these factors are 
interrelated is complex and poorly understood. 
 In general, the entire Appalachian region has a higher mortality rate for all cancers 
combined compared to the overall U.S. rate (178.6 and 171.4 per 100,000 respectively; 
Whiteside, 2007; SEER, 2014). For some cancers—such as lung, colorectal, breast, prostate, and 
melanoma—Appalachian counties have significantly higher mortality rates than non-
Appalachian counties (Whiteside, Murray, & Crowley, 2007). In the Appalachian Region, 
barriers to cancer care include lack of primary and specialty care services at the local and 
regional levels (ARC, 2016). While the number of providers in the Appalachian Region has 
grown, many are clustered in urban areas. Other barriers to care include physical distance, 
mountainous terrain, and lack of public or private transportation to and from healthcare facilities, 
lack of health insurance, and the inability to pay for prescription cancer drugs. Overall survival 
(OS) has improved in both black and white populations, although there is disparity in survival 
rates between these two groups (70.3% for blacks versus 85.3% for whites). Part of the disparity 
is due to the stage of disease at diagnosis, with 82% of whites diagnosed with melanoma at the 
early, localized stage compared to only 60% of blacks (Whiteside et al., 2007; ACS, 2017; 
SEER, 2017). The poorer survival rate among black individuals suggests the need to develop 
greater melanoma awareness in this population in order to promote early diagnosis and reduce 
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mortality (Friedman, Rigel, Silverman, Kopt, & Vossaert, 1991; Liu & Soong, 1996; Vayer & 
Lafor, 1993).  
Cancer Survivorship 
NCI-Office of Cancer Survivorship (2017) defined a survivor as an individual from the 
time of diagnosis, through the balance of their life. This group includes not only the patients but 
also their family members, friends, and caregivers. The term “survivor” was not used prior to 
1986, but today survivorship begins once cancer is diagnosed (Mullan, 1985; NCI, 2004). Cancer 
survivorship also has been described as living with, thru, or beyond cancer (the extended, post-
treatment stage) (NCI, 2004). Generally, cancer survivorship stages have been identified as 
acute, extended, permanent, and end-of-life (Mullan, 1985). One of the goals identified by the 
Tennessee Cancer Coalition (2013) was to coordinate an interdisciplinary effort “involving 
administration, basic and clinical research, evaluation, health education, program development, 
surveillance, public policy, clinical services, and health communication” related to cancer 
surveillance (Whitehead, 2007, p. 6). The Tennessee cancer plan also included the following 
three specific aims: increasing cancer survivors’ awareness of academic medical center 
resources, educating selected providers about cancer survivors’ long-term needs, and educating 
researchers and providers about funding opportunities focused on cancer survivors.  
Research within Tennessee focused on the post-treatment phase of survivorship is absent. 
Cancer survivorship research has been focused on survivors’ experiences such as  QOL factors, 
behavior changes, lack of exercise, decreased motivation for usual activities, fatigue, chronic 
pain, depression, impaired interpersonal relationships, difficulty coping, and, lack of secondary 
prevention strategies to preserve function (Earle, 2007; Blanchard, Courneya, & Stein, 2008; 
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Blanchard, Stein, & Courneya, 2010). Earle offered three questions that could be used in 
research to focus on improving survivorship care:  
 Do disparities exist in the quality of care provided to survivors of different ages, racial 
and ethnic groups, sexes, socioeconomic status, and diagnosis? 
 What is the effect of cancer on a survivor’s family and caregivers? 
 What is the cost-effectiveness of different survivorship care-plan strategies?  
Additionally, the development and validation of instruments to capture important outcomes and 
quality measures related to survivorship care plans also are also an important area for cancer 
survivorship research (Hewitt & Ganz, 2006). The HRQoL for long-term cancer survivors in the 
U.S. is an area about which little is known; consequently, no studies have been conducted that 
examine any of the common or secondary survivorship issues for individuals in Tennessee or the 
ETAR. 
 Hewitt & Ganz (2006) included recommended goals for future cancer survivor research 
in collaboration with the Institute of Medicine (IOM): “raising awareness; ensuring a plan of 
care; establishing surveillance guidelines; defining quality cancer survivor care; managing 
healthcare system challenges; addressing survivorship as a public health concern; providing 
education and training to healthcare professions; addressing employment challenges and success 
options; and improving access to adequate and affordable health insurance for continuity of care 
and follow-up” (pp 485-489). Additionally, research is needed to find ways to increase 
monitoring of secondary cancers with support from primary care and specialty practitioners to 
address short- and long-term preventable pain, disability, and psychological distress (NCI, 2004; 
Jacobs et al., 2009). Hewitt and Ganz (2006) summarized the IOM report as an initiative to 
“address quality concerns for cancer survivors with an emphasis on what happens following the 
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primary treatment of cancer” (p. 16). However, the specific needs of melanoma survivors in 
Tennessee or Appalachia have not been addressed.  
Philosophical Perspective 
 Theory is an essential element for framing a problem and guiding research such as efforts 
to understand follow-up experiences in melanoma survivorship. The philosophical model that 
informed this research is symbolic interactionism (SI) and naturalistic inquiry (NI). Blumer 
(1969) provided the groundwork for SI and NI, an approach that ideally explores the interactions 
of daily life and experience. Stated briefly, SI’s basic precepts are that 
1. “individuals act based on the meanings objects have for them;  
2. interaction occurs within a particular social and cultural context in which physical and 
social objects (persons), as well as situations, must be defined or categorized based on 
individual meanings;  
3. meanings emerge from interactions with other individuals and with society; and  
4. meanings are continuously created and recreated through interpreting processes during 
interaction with others” (Carter & Fuller, 2015, pp 1–2). 
Blumer defined SI as “social products, as creations that are formed in and through the defining 
activities of people as they interact” (p. 5). Interestingly, in SI, the meaning of experiences is 
“derived by the person from that interaction,” which involves an interpretative process that 
arrives at their “perspective” (p. 5). Symbolic interactionism is an integral part of research in 
which an individual (the researcher) interprets another’s gestures and acts based on the meaning 
yielded by that interpretation. In naturalistic inquiry, there is heavy reliance on the human as the 
instrument. The researcher should be thoroughly familiar with the field site or setting the study 
will be referenced (Lincoln & Guba, 1985). 
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 Bruner (1986), noted for his cognitive development studies, contended that human beings 
think in two fundamentally different ways. One way is paradigmatic or thinking through a 
propositional argument; the other is narrative or interpreting through storytelling. The difference 
between these two types of thinking involves how human beings make sense of and explain what 
they see. Narrative inquiry is viewed as human beings’ primary way of making sense of 
experience through an interpretation of human concerns, intents, and motives (Clandinin & 
Connelly, 2000). Narrative inquiry and specifically “experience,” which was addressed by John 
Dewey, “grows out of other experiences, and [these] experiences lead to further experiences” 
(Clandinin & Connelly, p. 2). As human beings, we “move back and forth between the personal 
and social, simultaneously thinking about the past, present, and future” (p. 3). Only by 
understanding the meaning people attribute to their illness, their ways of coping, and their sense 
of future possibilities can sensitive and appropriate care be provided (Barkwell, 1991). 
 Thorne (2008) encouraged the use of diverse perspectives during data analysis to extend 
interpretation. The iterative processes of reading, listening, thinking, and writing yields an 
understanding of the phenomenon that reflects the researcher’s thoughts and ideas, not just the 
specific properties the data possess. To explore the potential for a greater depth of interpretation, 
this study’s data analysis involved questioning what other meanings could be present. 
Additionally, the naturalistic approach affirms the mutual influence that the researcher, 
participants, and environment have on each other, creating a deeper understanding.  
Nursing Perspective 
 Although this study was influenced by SI and NI, a nursing perspective also was used 
throughout the study. The nursing perspective is a reflection of nursing culture, education, 
professional experiences, and values that influence a nurse’s view of a situation (Rodgers, 2005). 
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Such disciplinary perspective shapes what is observed in the field, what is seen during 
observation, and what sense is made of the observations (Thorne, 2008). Four defining 
characteristics of the nursing perspective are that nursing is 
1. a human science,  
2. a practice-oriented discipline,  
3. a caring discipline that encourages relationships between nurses and patients, and  
4. a health and wellness-oriented pursuit.  
This perspective is useful for establishing general knowledge that can be used within the 
profession. Professional and advanced practice nurses share a larger role in monitoring cancer 
survivors and coordinating their care (Schlesinger-Raab, et al., 2010). The focus of nursing on 
health and health-related experiences fits with the focus of this study (Rodgers, 2005). Moreover, 
the strong foundation from the PI’s 25 years of nursing experience contributed to the quality of 
inquiry and data analysis of this study’s topic. 
 Insight and understanding are derived from the subjective experience of the participant, 
expressed in his or her own words. In the SI epistemology, the nursing perspective provided a 
lens for establishing a relationship with the knower and interpreting or constructing meaning 
from the contextual surroundings. The nursing perspective helped the PI establish a professional 
relationship with participants as they shared their health experiences.  
Research Question and Definitions 
 This study’s research question was What are the health-related experiences and post-
treatment needs of melanoma survivors living in the ETAR? Following is an alphabetical list of 
the terms and definitions used for this study. 
Dermatologist – a doctor who specializes in skin diseases (ACS, 2017). 
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Experience is defined in the dictionary as actually living through an event or events; actual 
enjoyment or suffering; the effect upon the judgment or feeling produced by personal and direct 
impressions; or the sum total of the conscious events which compose an individual’s life (Oxford 
Dictionary, 2015). 
Healthcare provider – a licensed person or organization that provides healthcare services (NCI, 
2017). Specifically, healthcare providers include doctors of medicine or osteopathy, podiatrists, 
dentists, chiropractors, clinical psychologists, optometrists, advanced practice nurses, or clinical 
social workers. 
Health-related – The World Health Organization (WHO, 2017) defines health as “complete 
physical, mental, and well-being, not merely the absence of disease or infirmity” (p. 1). The 
dictionary definition of related is connected by reason of an established or discernable relation 
(Oxford Dictionary, 2015). For this research, health-related was defined as toward a state of 
complete physical, mental, and overall well-being including other connected issues as designated 
by individuals. 
Health-related quality of life (HRQOL) is a construct that measures an individual’s level of 
physical and mental health perceptions, health risks and conditions, obesity, functional status, 
social support, and socioeconomic status. 
Medical oncologist – a doctor who is specially trained to diagnose and treat cancer with 
chemotherapy and other drugs (ACS, 2017). 
Melanoma cancer survivor – an adult from the time of melanoma diagnosis through the rest of 
his or her life 
Melanoma survivorship includes surveillance for cancer spread, recurrence, or second cancers, as 
well as intervention for cancer treatment effects.  
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Need – a requirement that is essential or very important to an individual, family, or a community 
at-large. Needs can be economic, physical, psychosocial, or educational.  
Quality of care – the degree to which health services for individuals and populations increase the 
likelihood of desired health outcomes and are consistent with current professional knowledge 
and standards. 
Quality of life (QOL) – an overall enjoyment of life; an individual’s sense of well-being, ability 
to participate in activities, and functionality.  
Surgical oncologist – a doctor who specializes in using surgery to treat cancer (ACS, 201). 
Survivorship research encompasses studies related to the physical, psychosocial, and economic 
sequelae of cancer diagnosis and its treatment, including issues related to healthcare services, 
access, and follow-up care. 
Assumptions 
 This study was conducted assuming the following six statements were true.  
1. People are capable of communicating accurately about their healthcare experiences, 
within the usual limits of memory.  
2. Current melanoma clinical practice guidelines (NCCN, 2016) indicate that following 
melanoma patients intensively for metastatic disease beyond five years is not cost 
effective. 
3. Melanoma survivors continue to require dermatologic (not dermatology) surveillance 
commensurate with their recurrence risk throughout their lifetime because of the illness 
course and the fact that it is already a systemic cancer at diagnosis (NCCN, 2016). 
4. Melanoma survivors are monitored following treatment by various local or regional 
healthcare providers.  
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5. Most recurrences are detected by patient recognition or provider full-body skin exam 
findings. 
6. Research does not support melanoma surveillance as a way to improve overall survival 
(NCCN, 2016). 
Limitations and Delimitations 
 When human beings are used as the instrument for gathering data of subjective 
experiences, steps should be taken to account for potential problems that are beyond the 
researcher’s control. The potential for biases from the researcher and participant perspectives 
was a consideration for this study (Creswell, 2009). Interviewers come with “histories and 
cultural value systems; on many levels, the cultural and social expectations of both the 
interviewer and interviewee” will affect what is said and what is heard (Streubert & Carpenter, 
2011, p. 35). While study limitations can be viewed as weaknesses, the strengths of qualitative 
research such as gaining historical information along with a subjective perspective can outweigh 
the conditions that influence the findings. 
Participant bias may be introduced when individuals are responding to questions. 
Consideration was given to the fact that participants may offer responses they think the 
researcher wants to hear, not what they actually experienced. Awareness of influences, including 
any cultural or social differences between the researcher and participant can also add to the 
findings’ credibility. An understanding of the meaning of the experience moved beyond the 
words and socially acceptable answers toward building trust, triangulating the information, and 
persistence toward data saturation (Thorne, 2016). While researcher bias may be introduced at 
any time during a study, the probability increases during the data analysis. Steps were taken to 
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reduce researcher bias for this study using recommended strategies such as reflective journaling, 
memos in the margin, detailed project notes, and expertise consulting.  
 The focus of the study was to understand the health-related experiences and post-
treatment needs of melanoma survivors. Setting boundaries to achieve this purpose included 
making decisions regarding the sample, method, and data collection procedures. In addition, the 
study was conducted in one region in the southeastern United States. Another important attribute 
for this study included a varied group of men and women with different stages of self-reported 
melanoma. Private face-to-face semi-structured interviews were conducted to elicit the 
subjective stories from participants to speak freely without peer pressure that may be present in a 
focus group setting. This method of data collection provided consistency in the questions asked 
and allowed participants to give their own story rather than just nodding or agreeing with others. 
Using specific criteria (inclusions and exclusions) to select the sample further defined the 
population boundaries.  
Purpose of the Study  
 The problem that prompted this study was a lack of understanding of the post-treatment 
experiences and needs (physical, mental, and overall well-being) of melanoma survivors living in 
Tennessee. One observation identified by the PI when caring for melanoma survivors was the 
amount of travel for follow-up from patients in the eastern part of the state to the central and 
western parts of the state. Further inquiry identified the eastern part of Tennessee was designated 
Appalachia by the United States government as part of a protected area where lack of needed 
resources and basic needs exist alongside the economic constraints of higher poverty and income 
levels lower than the national average (Ludke, 2012, Roehrich-Patrick & Moreno, 2016). The 
researcher found no studies that identified health-related experiences or post-treatment needs in 
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Tennessee or Appalachia. Without this information, it is difficult to establish best practice 
guidelines for meeting this population’s post-treatment needs or help improve health outcomes. 
Failing to understand the link between the socioeconomic and culture-specific needs in the 
ETAR may contribute to this region’s increased disparities, rising mortality, and a higher 
economic burden locally, regionally, and statewide.  
 Based on the significance and lack of understanding about the problem, the purpose of 
this study was to increase nursing and interdisciplinary knowledge about the follow-up care 
plans for melanoma survivors’ in the ETAR from the patients’ perspectives. This purpose 
included gaining understanding about post-treatment health-related experiences that could affect 
follow-up care. Insight gained from understanding the link between post-treatment 
socioeconomic, cultural, and economic factors could be useful for designing or enhancing 
interventions to address survivors’ needs promptly, which in turn could affect their mental, 
physical, and social conditions. This unique perspective could promote an understanding of how 
healthcare delivery for melanoma survivor’s links across time, place, and settings.  
Study Significance  
 A specific, holistic description of melanoma survivors’ health-related experiences and 
post-treatment needs living in ETAR is not currently available. “Nursing always and inherently 
requires knowledge about patterns and themes in general, so that it can better inform the care of 
the unique and distinct individual” (Thorne, 2008, p. 25). A major follow-up component for 
melanoma survivors is monitoring for recurrence and/or new malignancies with regular 
comprehensive skin exams, nodal assessment, and symptom and psychological evaluation. This 
study’s findings can be used to help improve care delivery and continuity for this group of 
survivors. The findings also could be used by clinicians to inform their assessment of patient 
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needs and care planning, and by policy and decision makers to inform decisions about ongoing 
healthcare system changes and reform.  
Chapter Summary 
The continuing cost of care for melanoma patients is projected to be over $220 billion in 
2020, a statistic that is driving the quest for more efficient and cost-conscious ways of managing 
this population’s care (Mariotto, Yabroff, Shao, Feuer, & Brown, 2011). Professional and 
advanced practice nurses will continue to share a larger role in monitoring cancer survivors and 
coordinating their care as patient navigators or providers. The findings of this study could 
support the development of best practices and provide high quality follow-up care for melanoma 
survivors in the Appalachian region of the southeastern U.S. Based on this study’s findings, the 
researcher plans to continue research on related topics. 
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Chapter Two: Literature Review 
 Over the past 20 years, research on the topic of melanoma survivorship has focused more 
on patients’ psychological needs and quality-of-life during diagnosis and treatment, and less on 
their long-term post-treatment experiences and needs. National and international melanoma 
studies have provided a broad look at adjustment and support issues during melanoma diagnosis 
and treatment (AIHW, 2016; Balch et al., 2011; Boyle, 2003; Clarke, McKinley, Keegan, & 
Glaser, 2014; Hamama-Raz & Solomon, 2006; Hetz & Tomasone, 2012; Linden, Vodermaier, 
Mackenzie, & Greig, 2012). The few related studies fall into three areas of interest for the 
current study: post-treatment QOL, examinations of psychological adjustments and the influence 
of personality, gender, uncertainty, and mental health issues on melanoma survivorship; and 
melanoma survivors’ post-treatment health practices. 
Review of the Literature 
 The electronic databases used in the literature search were CINAHL, ERIC, PubMed, 
PsycInfo, and Sociological Abstracts. Key search terms were melanoma survivorship, melanoma 
follow-up, patient experiences with melanoma after treatment, nursing care and melanoma, 
psychological issues in melanoma survivors, melanoma post-treatment experiences, and 
melanoma survivor needs. After reviewing the published literature, several additional key terms 
were added: cancer survivorship, melanoma survivorship outcomes, and Tennessee melanoma 
survivors. To capture a wide range of national and international studies, publication dates were 
not limited. Publications found during the search were examined to find those focusing on 
melanoma survivors’ post-treatment care episodes, encounters with healthcare providers, follow-
up experiences, and needs. Twenty studies fit this profile with literature excluded that focused on 
health-related experiences and needs during the diagnostic and treatment period only. 
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Additionally, after evaluating the literature an additional search was conducted to look for 
Tennessee cancer survivor-specific studies that involved participants from within the state or the 
East Tennessee Appalachia Region (ETAR). No additional studies were found in that additional 
search. The current gap in the research on the health-related experiences and post-treatment 
needs of melanoma survivors living in the ETAR became the impetus for the current study.  
Regional History Literature 
 The region identified in the current study required some discovery related to the 
geography of the east Tennessee area and Appalachian culture. The Appalachian region includes 
13 states and 420 counties that span 205,000 square miles (ARC, 2016). Although the 
Appalachian boundaries have changed over the inception in 1890, the region starts at the 
southernmost mountains of New York and continues south to northern Mississippi. Initially 
dependent on mining, forestry, and agriculture, Appalachia has become more diverse to include 
manufacturing, services industries, and tourism. However, because of its sprawling mountainous 
land, the economic status of the Appalachian region varies from county to county and includes 
some remote areas with widespread poverty. The Appalachian region includes eastern 
Tennessee, where the study participants were recruited. Portions of Appalachia continue to have 
widespread poverty and limited local or regional access to healthcare, which is in stark contrast 
to other regions of the Tennessee or the US.  
  Culturally, eastern Appalachia family culture is dynamic, complex, diverse, and rich 
(Abramson & Haskill, 2006). The family remains an essential component of local and regional 
society in Appalachia. Some common characteristics include humility, modesty, rugged 
independence, prideful and having love of family, community, and nature. More rural 
Appalachians generally are distrustful of outsiders and often are misunderstood and stereotyped 
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as being ‘hillbillies’, ‘mountain folk’, ‘white trash’ or ‘rednecks’ (Shackelford, Weinberg, 
&Anderson, 1977; Burns, Scott, & Thompson, 2006; Biggers, 2006; Huber, 2008; Presely, 
2013). In Our Appalachia (Shackelford et al., 1977), a philanthropist doctor from Appalachia 
was interviewed in 1980, 
One of our congressmen was evaluated by Ralph Nader as ‘typically hillbilly.’ What 
the hell does that mean? If you are reading that in Ohio it means a whole lot different 
thing that it does [in Tennessee]…What we have lacked in the mountains is people 
who can relate to the technically advanced aspect of society but still retain the 
personal characteristics that are necessary to relate to people down here. You have got 
to separate people’s minds from people’s way of living. If the way of living means 
that they are not getting the right kind of food, they don’t have a decent place to live, 
they don’t have a chance to get an education, to get a job, then I think something has 
to be done about that. But loving your family, liking your country, [and liking] soup-
beans, cornbread, and onions, I don’t think people ought to be put down for having 
those kinds of ways. (p. 360) 
 While southern Appalachia was thought to be too mountainous and unsettled, Biggers, 
(2006) noted that much of the white migration to the eastern U.S. in the 1700s and 1800s were 
from Europe (British Isles & Ireland) and many settled in the southern portion of rural 
Appalachia Phipps, 2016). For the many settlers who called rural Appalachia home, there was a 
sense that the area’s terrain and ruggedness gave them a sense of freedom from the persecution 
they experienced in their previous lands over religious, social, or economic divergence (Watson, 
Griffin, Eveleigh, & Shaw, 2008). In modern times, while some changes and modernization have 
taken place, Appalachia remains a mountainous, rugged region often misunderstood. Rural 
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Appalachians distrust outside influences, cherish the solitude of their environment, and stay close 
to family with some maintain a fundamentalist religious doctrine.  
The East Tennessee Appalachian Region (ETAR) literature reflects a proud people with 
strong connections to family and community relationships. Although Appalachia’s population 
has become increasingly concentrated in urban areas, the region’s “small towns and communities 
continue to be inhabited by related families who have sometimes lived there for hundreds of 
years and have personal connections to local history” (Burns, Scott & Thompson, 2006, p.149). 
Melanoma Post-Treatment Literature 
The search for research about post-treatment melanoma survivors in Tennessee 
uncovered a large gap in regional indices. One study from Tennessee about skin cancer from the 
early 1970s was identified. Zagula-Mally, Rosenberg, and Kashganan (1974) compared 
epidemiology skin cancer rates (for all types of skin cancer, not just melanoma) with a 
representative rural population using cluster analysis in West Tennessee’s Tipton County. Other 
than this study, Tennessee melanoma survivors have not been included in the research looking 
specifically at their experiences or needs.  
Quality of Life  
 Survivors’ experiences and care issues were explored in a qualitative study conducted in 
Sydney, Australia. Morton, Rychetnik, McCaffery, Thompson, and Irwig (2013) completed in-
depth interviews with 29 melanoma survivors from a clinic that provided long-term follow-up 
after melanoma treatment. The impetus for the study was to understand the commitment of time 
and effort that melanoma survivors invest and practitioners provide. The research aims included 
capturing patients’ perspectives of the value of follow-up care including its benefits, limitations, 
and potential downsides; survivors’ thoughts and feelings about changes to follow-up frequency; 
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and patient-centered recommendations for improving follow-up care. Enrollment occurred 
during May and June of 2010 with all ages of stage I and II melanoma survivors (median age 
62). Most participants were followed-up by a melanoma unit general physician and the others by 
a surgeon.  
 The interview guide questions focused on positive and negative follow-up experiences, 
such as what happened during follow-up visits, and what the follow-up experience meant to the 
survivors. Following are examples of typical participant responses: “he checks everything… he 
checks between my toes… through my hair thoroughly,” “he always checks the lymph glands 
under my arms and in the groin…,” and “…those cancer clinics… the doctors are just there to 
make the dough [money], they want to cut everything out of everyone because they get more 
money” (Morton et al., 2013). 
 Participants reported that the benefits of long-term follow-up included reassurance, early 
detection of recurring or new cancers, education about skin self-examination, an opportunity to 
ask questions, and reinforcement of sun protection behaviors. Participants also indicated that 
their anxiety increased as the visit date grew closer, and the inconvenience of traveling to attend 
visits often included lost work time. Melanoma survivors performed skin self-examinations 
infrequently and had conflicting views on multiple skin excisions. Access to specialists for 
unscheduled visits consistently was reported as beneficial (Morton et al., 2013).  
 Based on Morton et al.’s (2013) study results, the Melanoma Institute in Australia stated 
that melanoma follow-up could be extended to 12 months for patients with stage I, as long as 
they could access a melanoma specialist at short notice. The health-related experiences and needs 
identified in this study included reassurance, early detection of recurrences, education, and 
anxiety (Morton et al., 2013).  
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  Murchie and colleagues (2010a) conducted a randomized controlled trial in Ireland that 
demonstrated positive patient satisfaction with general practitioners (GPs) providing post-
treatment follow-up versus routine follow-up with specialists. The control group was followed 
by specialists at the Aberdeen Royal Infirmary in Northeast Scotland from 2005–2006. The 
participants (n=142) received care from 35 different general practices where the physicians 
received specialized training and instructions in follow-up for melanoma survivors who were no 
further than 10 years post-treatment without any recurrence. Baseline satisfaction was measured 
in both groups at the beginning of the study and at 12 months using a self-completed, mail-in 
patient questionnaire measuring demographics and socioeconomic status, a patient satisfaction 
questionnaire, the 36-item Short Form Health Survey (SF-36), and the Hospital Anxiety and 
Depression Scale (HADS). The participants’ medical records were reviewed for information 
regarding the initial melanoma diagnosis, treatment, and use of primary and secondary care 
services in the previous 12 months (Murchie et al., 2010a).  
 As a whole, the physicians, treatment, and control groups followed the protocol without 
any incident (Murchie et al., 2010a). Participants adhered to the protocol to see a GP first and 
receive a specialist referral if needed. No statistically significant differences were found between 
the treatment and control groups’ health status and psychological well-being. The researchers 
also examined within-group differences between baseline and follow-up and found no 
statistically significant differences (Murchie et al., 2010a).  
 In a subsequent study, Murchie, Delaney, Campbell, and Hannaford (2010b) interviewed 
18 melanoma survivors from the randomized controlled study with the same first author. The 
treatment group participants were interviewed to explore their practical post-treatment 
experiences with the study protocol. Generally, participants reported positive experiences, citing 
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the protocol advantages of convenience, less rushed appointments, more thorough examinations, 
a more pleasant atmosphere, and greater continuity of care from the GPs. The main concern 
expressed by participants was the awareness that the GPs had less experience. The researchers 
identified three broad themes: the practicalities of GP follow-up, a comparison of the two 
systems, and the participants’ personalities and feelings. One study limitation was the fact that 
the interviewer was a GP, which may have affected how he handled negative views about the GP 
protocol (Murchie, et al., 2010b).  
 In a nationwide prospective longitudinal descriptive study, Livingstone et al. (2015) 
examined Germany’s follow-up plan for melanoma survivors. The four-year study focused on 
describing current melanoma treatment and follow-up, the value of this follow-up care for 
patients without recurrence, and melanoma patients’ psychological effects and needs. All 
patients (1,264 registered in the database) who had been diagnosed with melanoma between 
April 1, 2008 and June 30, 2008, signed a consent form at the time of diagnosis and completed 
several self-reported questionnaires. The European Organization for Research and Treatment of 
Cancer’s (EORTC) Quality of Life Questionnaire (QLQ-C30) was administered. The EORTC 
QLQ-C30 has a Cronbach’s alpha coefficient for its quality of life measure ranging from 0.86 
and 0.89. Anxiety and depression also were assessed using the German version of the HADS, a 
widely accepted questionnaire that is designed to “assess clinically relevant symptoms of anxiety 
and depression in patients with somatic diseases” (p. 655). The instrument’s sensitivity (83.3%) 
and specificity (61.5%) for identifying psychiatric cases was acceptable.  
 Complete data was available for 668 patients from 67 centers “of whom 96% were in 
regular melanoma surveillance” (follow-up) at the two-year mark (Livingstone et al., 2010, p. 
1982). In addition to the questionnaires, sociodemographic information (sex, age, marital status, 
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educational level, and employment status), disease-specific health information sources, and 
health-behavior information were “ascertained with self-constructed questions” (Livingstone et 
al., 2010, p. 1985). Patients with stage I–IIC melanoma were included in the study with a similar 
number of men (50.9%) and women (49.1%). The men’s mean age was 64.3 years and the 
women’s was 59.4 years. Tumor thickness average for men was 1.67mm and 1.55mm for 
women. Therefore, the study included slightly fewer women, who were younger than were the 
men, and had thinner tumors. The follow-up frequency included quarterly (35%), half-yearly 
(40%), and yearly (16%) follow-ups. After four years, 93% of participants were alive. Only 6.6% 
died, but only 50% of these deaths were caused by melanoma. Prevalent comorbidities included 
cardiovascular diseases (14.3%), other cancers (9%), and diabetes (4.3%). Autoimmune diseases 
and depression reported in less than 5% of participants (Livingsone et al., 2015).  
 Most participants received melanoma follow-ups with surgeons at centers throughout 
Germany, with 25.3% of the survivors referred to dermatologists, and only 1% referred to GPs or 
medical oncologists. The researchers calculated the cost of providing follow-up for 550 patients 
without recurrence for over four years at $257,992.82 (228,155.75€). Through its 
Commonwealth Fund, Germany provides universal healthcare services for melanoma survivors 
with surgical follow-up an integrated part of post-treatment care. The researchers’ 
recommendations included decreasing follow-up frequency for low-risk (stage I–IIB) melanoma 
patients. They also recommended that melanoma surveillance resources be focused on providing 
patient education and psychosocial support to patients with high psychological stress. The 
objective of cancer follow-up care is the early detection of tumor recurrence with the aim of 
improving OS. Many melanoma patients have tumor recurrences within the first three years after 
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diagnosis. While patient-detected recurrences are believed to be as high as 60–70%, this study 
showed that less than one-third were detected by the patients (Livingsone et al., 2015). 
 Oliveria et al. (2013) was interested in melanoma survivors’ experiences with sun-
protection behaviors and follow-up practices. The sample was taken from patients treated at a 
major cancer center in the Northeast U.S. who were diagnosed with primary cutaneous 
melanoma (stages I–III) between1996 and 2005. Eight focus groups were assigned from a 
stratified, random sample based on survivor’s age at diagnosis. Two hundred and twenty eligible 
participants were contacted and 48 individuals participated in the focus groups. Focus groups 
questions concerned topics identified as important in or absent from the literature: melanoma’s 
impact on patient health behaviors; lifestyle and quality of life issues; practices related to 
physician skin screening and skin self-examination; patient concerns for family members 
including their risk for developing melanoma; economic issues arising from diagnosis and 
treatment; and post-treatment anxieties including recurrence concerns. While most participants 
did not conduct routine skin self-examinations, some experienced anxiety if caught unprotected 
in the sun. Many survivors did not discuss risk reduction with family or friends. Findings 
indicated that the melanoma diagnosis elevated the importance of retaining health insurance and 
purchasing life insurance for younger survivors (Oliveria et al., 2013). 
 In a descriptive quantitative study, Palesh and colleagues (2014) explored melanoma 
survivors’ long-term symptoms, sun protection practices, and support needed from their 
healthcare providers. Melanoma survivors treated at the Pigmented Lesion and Melanoma 
program at the Stanford Cancer Center in Marin County, California from 1995 to 2011 were 
asked to complete a health-needs survey with an 18% response rate (N=893). The enrollment 
period was from July through September of 2012 and 160 surveys were completed and de-
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identified. The survey was a non-validated online instrument with usability issues. Researchers 
compared the responses between gender, education, and time since diagnosis (Palesh et al., 
2014).  
 Several outcomes within the Palesh et al. (2014) remained consistent with prior research 
in melanoma survivors. On average, the participants were highly educated (75%), non-Hispanic 
whites (94%). Several conclusions were drawn from the health survey data. First, melanoma 
survivors experience continuing symptoms long after treatment ends, especially anxiety (34%). 
Next, participants expressed a need for more information about long-term melanoma effects 
(43%), additional psychosocial support (12%), and ways to prevent recurrence (19%). The 
researchers recommended greater healthcare provider involvement to address patients’ physical 
and psychosocial needs, increased education to prevent the possible long-term effects of 
melanoma, and treatment guidelines for clinically relevant levels of post-treatment distress 
(Palesh et al., 2014).  
 Although the Marin County, California sample was homogenous—predominantly 
educated, non-Hispanic whites with a high socioeconomic status—U.S. researchers report 
consistently that this population is typical of Americans diagnosed with melanoma (Siegel, Ma, 
Zou, &Jemal, 2014). In 2012, Marin County melanoma incidence rates were 46.2% compared 
with the state melanoma incidence rate of 21.1%. Stanford University, where the study 
originated, is a major area provider of post-treatment care for melanoma survivors in the regional 
area. 
 McLoone et al. (2012) explored the psychosocial experiences of melanoma survivors at 
high risk of developing new primary disease. Twenty-two survivors participated in semi-
structured telephone interviews in which the researchers explored melanoma-related beliefs, 
32 
 
experiences, psychological adjustment, and supportive care needs. Participants were recruited 
from a high-risk melanoma clinic in Sydney, Australia where the melanoma incidence rate tis 
three times that of U.S. (CDC, 2015). The researchers used the transactional model of stress and 
coping (Folkman & Greer, 2000), which predicted that psychological stress will be greater if an 
individual is at higher risk of developing melanoma and the threat is perceived as severe 
(McLoone et al., 2012).  
 Miles and Huberman’s (1994) conceptual framework was used to guide the qualitative 
content analysis and coding of the transcribed text. After sorting the data into hierarchical 
categories to form organized and meaningful clusters, several themes emerged. The themes were 
fear, persistent uncertainty, threat perceived as pervasive, causal attributions, controllability and 
behavioral responses to threat, low confidence in ability to detect melanoma (self-efficacy), 
specialized medical care, barriers to accessing emotional support, and feeling misunderstood. 
Although participants reported adjusting to their melanoma risk using an active coping response, 
the researchers commented, “it is concerning that a substantial proportion also reported 
concurrent and persistent uncertainty, anxiety, and fears regarding recurrence” (McLoone et al., 
2012, p. 1110). 
 McLoone et al.’s (2012) study questions were designed to elicit responses that would 
help the researchers understand melanoma survivors’ experiences. Survivors were asked to 
discuss their thoughts, beliefs, and experiences regarding melanoma and its cause, their level of 
risk, health behaviors, and general beliefs about moles (skin). The researchers commented that 
although the participants reported specific psychological issues, “none of the survivors in this 
study reported seeking or receiving professional emotional support, despite a desire for such 
support on the part of some individuals” (McLoone et al., 2012, p. 1110). One explanation given 
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for this finding was “patients’ perceptions that—because melanoma is a visible cancer, and 
therefore detectable at an early, curable stage—the term cancer survivor” may not apply to them, 
a perception that could impose considerable issues in follow-up (McLoone et al., 2012, p. 1110).  
Psychological Impact 
 Hetz and Tomasone (2012) focused their study on understanding the supportive care 
needs of a sample of 31 Canadian melanoma survivors. For this cross-sectional, descriptive, 
correlational, quantitative study, patients were selected from the Melanoma Network of Canada, 
a patient-led organization providing melanoma information and resources. Participants 
completed the Supportive Needs Questionnaire–Melanoma Supplementary Module. Most survey 
questions dealt with initial diagnosis and treatment; only one addressed post-treatment needs. 
Results revealed unmet needs related to lack of information, particularly among individuals with 
less formal education. Descriptive statistics using ANOVA and Pierson Chi-square found a 
statistical correlation between individuals without a post-secondary education and the need for 
more information in the diagnosis and treatment phases (Hetz & Tomasone, 2012).  
 Participants without post-secondary education had a higher need for information about 
surgical treatment of the skin (p=.04), surgical removal of lymph nodes (p=.004), non-surgical 
treatments (p=0.1), melanoma spreading from the skin (p=.0001), and pain control (p=.01) (Hetz 
& Tomastone, 2012). The only post-treatment question on the online survey was, “Do you 
conduct regular self-checks to screen for melanoma, skin cancers, or a recurrence?” Results 
showed that the individuals who performed more regular self-checks generally were college 
educated and felt comfortable asking for information. Melanoma patients were referred more 
often from dermatology offices for psychological support in the Netherlands (Korner & Fritzshe, 
2012).   
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Bird, Coleman, and Danson (2015) explored melanoma survivors’ experiences, support 
needs, and the processes that met their needs. The study focused on a follow-up program for 
melanoma survivors conducted by advanced practice nurses in the United Kingdom. A grounded 
theory approach was used with in-depth interviews that examined melanoma-related worry. This 
worry was identified as a need to have their concerns believed by others prior to and after 
diagnosis, the desire to avoid being a burden, and lack of self-reassurance. The purposive sample 
was from melanoma clinics at a specialist cancer center in England where the incidence of 
melanoma is 26.7% (cancerresearchuk.org, 2016). Initially, open-ended questions were asked 
with some probing, and then additional questions about melanoma-related worry from earlier 
interviews were added (Bird et al., 2015).  
 Interview responses were organized into categories and subcategories of melanoma-
related worry. The researchers noted that “regardless of whether patients experienced a 
recurrence, the thought that the melanoma could come back” was identified as a concern or 
worry (Bird et al., 2015, p. 941). Additionally, being believed was identified as the need to have 
“someone verify that their concerns were real or justified” (p. 941), a need that continued 
throughout the patients’ experience. For example, patients felt that because “melanoma was not 
seen as being as serious as other cancers” (p. 941), other cancer patients, family, and friends did 
not acknowledge their fears. Self-assurance stemmed from “a need to actively do something to 
prevent recurrence” (p. 944), to offset melanoma-associated worry (Bird et al., 2015).  
 The eleven patients interviewed in this study were evenly distributed between females 
and males with a mean age of 61 and averaging from one to 11 years from initial diagnosis (Bird 
et al., 2015). The stage at diagnosis was between II–IIIB (thick lesion). Patients had between two 
to seven surgeries, and two had radiotherapy, interleukin, or interferon. Researchers concluded 
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that participants viewed their needs as unique from those of people with other types of cancer. 
Participants described the uncertainty of the future and the possibility of disease recurrence, “… 
it was hard. I just felt as if I were a bit out on a limb” or “… then it meant the 40% chances of… 
it spreading further…” (p. 942). This research’s relevance to clinical practice is related to its 
findings about the lack of public awareness of melanoma, and how it differs from other types of 
cancer. This study answered some questions about melanoma survivors’ post-treatment 
experiences and needs in England. The melanoma-related worry, concern, or anxiety fits with 
patients’ psychological need for information, reassurance, and validation of melanoma as a 
cancer diagnosis. Nurses can help identify such worry, concern, or anxiety when they interact 
with melanoma survivors in a variety of settings. Patients will choose “whomever they feel best 
able to talk to at that time, whether this is a specialist nurse or someone independent of their 
cancer care” (Bird et al., 2015, p. 945).  
McLoone et al. (2013) interviewed 22 Australian melanoma survivors who had at high 
risk for recurrence. Semi-structured interviews were conducted via telephone to determine their 
satisfaction with post-treatment care. Miles and Huberman’s qualitative framework was used to 
develop study themes (Denzin & Lincoln, 2000). This study was the first to assess patients’ 
satisfaction with a particular follow-up model—The Health-Related Clinic [HRC]—that was 
designed specifically for melanoma survivors at high risk of developing new primary disease. 
This specialized clinical facility provides expert care, including dermoscopy imaging, sequential 
digital imaging, and total body digital photography to patients at least bi-annually, and free of 
charge. Patients’ satisfaction with their clinical care was high. Several contributing factors were 
identified including rapid and regular access to physicians who were perceived as experts, and 
the development of confidence, trust, and a sense of being cared about and understood. While the 
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melanoma survivors did not seek formal psychological support, many expressed long-standing 
melanoma-related fears and concerns. The importance of “accessible, expert medical attention, 
delivered in a patient-centered manner was integral to melanoma survivors’ satisfaction with 
clinical management” (McLoone et al., 2013, p. 1994). 
 Many patients felt they needed more education and training to perform skin self-
examination adequately (McLoone et al., 2013). Participants frequently reported being satisfied 
with the clinics’ continuity of care. Patients also expressed a clear need to be informed of 
changes to their prognosis as well as advances in melanoma treatment. Researcher suggestions 
included developing best practice protocols for the management of depression and anxiety to 
offer more referrals. 
Health and Well-being 
In their quantitative study, Zucca, Boyes, Linden, and Girgis (2012) examined whether 
multiple concurrent symptoms (clusters) exist in long-term cancer survivors and made 
comparisons to global QOL. The researchers’ aims were to assess patient-reported QOL and 
identify of clusters of physical cancer-related symptoms by cancer type among long-term breast, 
prostate, colorectal, and melanoma cancer survivors. The researchers used a population-based 
cross-sectional random sample of 863 adult cancer survivors from Australia’s Central Cancer 
Registry who were five to six years post-diagnosis. The survivors completed the EORTC QLQ-
C30. The results showed this sample had higher global QOL scores than general population 
norms, and a majority did not report any cancer-related physical symptoms across cancer types 
(71%). Melanoma survivors represented 15% (n=131/863) of the study’s participants. The results 
from a comparison between pre-treatment and long-term melanoma survivors showed a higher 
global QOL for the latter group. The physical symptom frequency in melanoma survivors was 
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largely no symptoms at 89%, with one symptom at 6.6%, and multiple symptoms at 4%. The two 
major symptoms reported were insomnia and memory trouble. The limitations of such large-
scale population-based studies are revealed in its one-dimensional examination of physical 
effects or symptoms frequency that does not assess symptom severity or distress (Zucca et al., 
2012).  
Kent and colleagues (2014) conducted a large population-based study examining health 
outcomes in older adult cancer survivors. Cancer survivor was defined as an individual with any 
history of cancer. Researchers selected less frequently occurring cancers for this study including 
those of the kidney, bladder, pancreas, UGI, oral cavity and pharynx, uterus, cervix, and thyroid 
as well as melanoma (19% or 3,019 survivors), leukemia, non-Hodgkin’s lymphoma, and 
multiple myeloma. The researchers identified a gap in the literature regarding the QOL indicators 
for older adult survivors who had cancer in less frequently occurring sites. Ten cohorts, 
beginning in 1998 and ending in 2009, were included in the data set from the SEER National 
Cancer Registry System linkage with the Medicare Health Outcomes Survey (MHOS). The 
heterogeneous data set included 16,095 survivors along with 1,224,549 individuals without a 
cancer history for comparison. The results showed poorer health outcomes among older adult 
cancer survivors (Kent et al., 2014).  
 Melanoma survivors scored similarly on the SF-36 and Veterans RAND 12-Item Health 
Survey (VR-12) as individuals without a cancer history (Kent et al., 2014). For vitality, 
individuals with no cancer history scored 49.4%, and melanoma survivors scored 49.6. For 
social functioning, individuals with no cancer history scored 48.0%, and melanoma survivors 
scored 47.6%. For emotional well-being, individuals with no cancer history scored 45.2%, and 
melanoma survivors scored 45.7%. Finally, for mental health, individuals with no cancer history 
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scored 51.4%, and melanoma survivors scored 51.8%. Although the SF-36 and the VR-12 
instruments lack cancer-specific measures, they were used for this study because they are widely 
accepted and have been evaluated in multiple disease and treatment contexts allowing for 
comparisons between SEER-MHOS subgroups. This study has several limitations including its 
lack of data related to fee-for-service and Medicare HMO older adults in the cohorts. The 
authors’ research recommendations included the need to address sociodemographic, biological, 
and clinical factors that may contribute to overall health status impairments along with 
longitudinal data to examine changes in health status over time. The SEER-MHOS data set 
contains essential information collected at the time of diagnosis that cannot be extrapolated in 
identifying post-treatment experiences or needs in melanoma survivors (Kent et al., 2014).  
Chapter Summary 
 Post-treatment melanoma survivors’ have received less attention in the body of research 
about melanoma and cancer survivorship. For more than a decade, melanoma research mainly 
has focused on prevention, early detection, and treatment. Although ongoing follow-up is critical 
for cancer survivors, there are currently no accepted guidelines defining best practice, post-
treatment care for individuals diagnosed with melanoma or the healthcare providers who care for 
them. A major component of melanoma survivors’ follow-up is monitoring for recurrence and/or 
new malignancies with regular comprehensive skin exams, nodal assessment, along with 
symptom and psychological evaluation and treatment. Currently, the responsibility for follow-up 
with melanoma survivors falls inconsistently on a variety of healthcare providers. Research is 
needed to understand this group of survivors and their needs within their community. 
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Chapter Three: Methods 
  For this study, the PI employed the interpretive description method, the preferred 
strategy when “new knowledge pertaining to the subjective, experiential, tacit, and patterned 
aspects of human health experience is needed” to inform understanding that can guide future 
decisions that “apply evidence to the lives of real people” (Thorne, 2008, p. 356). The 
understanding gained from this study could help inform and guide future decisions about how to 
apply evidence to improve the lives of melanoma survivors. In this chapter, the study’s method, 
participant sample, and ethical considerations are discussed. Next, data collection techniques and 
in-depth analysis processes are covered along with the steps used to maintain the study’s rigor 
and trustworthiness. 
Interpretive Description Method  
 The interpretive description method is a qualitative method with the flexibility to fit a 
variety of disciplinary perspectives (Thorne, 2008). One aim of interpretive description, a 
relatively new qualitative methodology, is to “generate knowledge relevant for the clinical 
context of applied health disciplines” (Hunt, 2009, p .1). This method involves seeking patterns 
and themes within “subjective human experience, not so much as to grasp its essence, as to 
understand what (practitioners) are likely to encounter in future clinical practice and to have 
some meaningful sensitivity around it” (p. 79). 
 By selecting analytical techniques from other qualitative methods, interpretive 
description promotes a deep understanding of study data through a rich, diverse, and robust 
process. An interpretive description qualitative method is the most appropriate and effective 
method for addressing the research question guiding this study and producing an “analysis of 
discovering associations, relationships, and patterns” within the post-treatment melanoma 
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survivor population (p. 33). Whereas the focus of phenomenology is to understand the essence of 
an experience (Creswell, 2013), interpretive description focuses more on generating new 
knowledge about clinically relevant human phenomena (Thorne, 2008). Generally, a qualitative 
research approach involves an interpretive, naturalistic approach to the world (Denzin & Lincoln, 
2000). A qualitative design is holistic and looks at the larger picture, which leads to a better 
understanding of the whole (Denzin & Lincoln). Interpretive description is the preferred strategy 
when new knowledge pertaining to the “subjective, experiential, tacit [implied], and patterned 
aspects of the human health” experience is needed (Thorne, 2008, p. 36). The interpretive 
description approach described by Thorne guides the researcher in moving beyond a straight 
description of the phenomenon to an analysis that seeks to discover associations, relationships, 
and patterns within the focus topic (Thorne, 2008).  
 Understanding the experiences of melanoma survivors through an interpretive approach 
can create visibility and meaning for individuals and the community at large (Denzin & Lincoln, 
2000). Interpretive description is an applied disciplinary approach that uses theoretical influences 
from naturalistic and narrative inquiries and to look at broader clinical problems or populations 
where the focus is to describe and interpret “patterns of experience, action, or expression” 
(Thorne, 2008, p. 68). As an applied science, nursing research pulls from many disciplines when 
“different approaches to discovery are needed” (p. 95). Qualitative researchers attempt to make 
sense of, or interpret phenomena in terms of the meanings people bring to them in a naturalistic 
setting rather than a laboratory (Denzin & Lincoln, 2000). In an interpretive description 
approach, an ongoing engagement with the data will “confirm, test, explore, and expand on the 
conceptualizations that begin to form” (Thorne, 2008, p. 99).  
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 To gain a better understanding of what melanoma survivors experience after treatment, 
they should be asked. Interpretive description is an “applied qualitative research approach that 
contributes to better understandings of complex experiential clinical phenomena” within nursing 
to establish rapport and field questions from within the industry (Thorne, 2008, pp. 26–27).  
 In qualitative research, the role of the researcher includes describing participant biases 
and ideological preferences in an “effort to get inside their world of meaning” (Denzin & 
Lincoln, p. 76). This task includes recording anything specific about the participant that would 
be pertinent in transcription, things that stands out about the interview, possible interruptions or 
unusual occurrences, and the researcher’s reactions. Additionally, specific notations about 
rapport, environment, flow of communication, and participants’ and researchers’ emotional 
responses should be recorded. Consistent with the interpretive description process, data 
collection and data analysis occur simultaneously. To gain knowledge of patients’ previously 
unexplored experiences, this method allows going beyond descriptions or essences in that 
interpretations are made relative to the patients’ perspective and to the group as a whole, noting 
clinical implications (Thorne, Kirkham, & MacDonald-Emes, 1997). 
Data Collection 
 Data was collected from participants within a 45-county area of eastern Tennessee 
designated part of Appalachia by the Appalachian Regional Commission (2016). The researcher 
has lived and worked in Tennessee for more than 20 years in both Appalachian and non-
Appalachian regions.  
Setting 
 The ETAR was the area of focus for this study, which included counties where the 
melanoma incidence is higher than state and national rates (Grainger, Hamblen, Hawkins, 
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Jefferson, Sevier, Sullivan, Washington, and Unicoi). The PI travelled to the eastern Tennessee 
Appalachian Region to distribute flyers and to engage in the interviews with participants. East 
Tennessee is a name given to a third of Tennessee, representing one of three grand divisions that 
has legal and economic implications for the state (West, 1998). East Tennessee is entirely located 
within the Appalachian Mountains with landforms that range from densely forested mountains to 
broad river valleys (Abramson & Haskell, 2006). The focus on the ETAR melanoma survivors is 
important for a number of reasons including the area’s higher melanoma incidence rate. Several 
indicators are important consideration for the focus on this area of Tennessee for this study, 
which includes the large income disparity in Appalachia versus non-Appalachian counties; the 
area’s relatively high unemployment, low educational attainment, and isolation due to lack of 
transportation access; and the outmigration of people (and workers) from the region (ARC, 
2016).  
Sample 
 A purposive convenience sample of melanoma survivors living in the ETAR was the 
participant focus area. Information on individuals diagnosed with melanoma was self-reported. 
The PI made efforts to achieve gender balance and diversity in age and race/ethnicity in the 
sample. This study was conducted with melanoma survivors age 18 and older. Individuals were 
invited to participate if they were diagnosed with melanoma (stages I–IV), were post-treatment 
or post-partial treatment; or had a melanoma recurrence and currently receiving treatment or in a 
clinical trial; were English speaking, and had access to a phone or computer. Participants were 
excluded if they were receiving treatment following primary or an initial melanoma diagnosis; 
were receiving ongoing treatment for cancer other than melanoma; were unable to communicate 
verbally; had acute emotional or physical distress from any cause; or were cognitively impaired. 
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Sample Size 
Thorne (2008) stated that any sample size could be appropriate for interpretive 
description, as the size is best justified by generating a rationale consistent with the research 
question. She concluded that most studies are relatively small with five to 30 participants. 
Considering the lack of current research with post-treatment melanoma survivors and the scant 
health-related research in the ETAR, the PI had a goal of a minimum of 15 participants.  
Recruitment  
 Flyers were distributed to cancer centers, cancer support groups, primary care providers, 
and dermatology practices in numerous counties within the eastern Tennessee Appalachian target 
area. The flyer invited study participation and included the study criteria along with the PI’s 
contact information. Interested melanoma survivors who were contacted by the PI (via mail, 
email, or phone) and were screened for inclusion criteria over the phone. After melanoma 
survivors indicated their desire to participate, the PI brought a consent form to the interview, 
where the PI reviewed the form with the participants and a copy was given for their future 
reference. After obtaining consent, the demographic information was collected and later recorded 
on a spreadsheet: age, gender, ethnicity, education, zip code, and employment status. 
Interviews  
The interviews were scheduled in a location agreed upon with the participant. The PI 
indicated that the interviews should take no more than 90 minutes. The PI allowed 20–30 
minutes for participants to review the informed consent document in her presence, complete the 
demographic date worksheet, and one hour for the interview. The PI also informed participants 
of their right to be notified of the study results. Once the consent was signed, the PI proceeded 
with the interview. Primary data collection included audiotapes from face-to-face interviews with 
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individual participants. Interviews were recorded using a voice or audio recorder; no video was 
recorded. The PI used semi-structured interviews with field notes to collect important data. 
Participants’ recorded interviews were transcribed. Participants were asked to contact the 
researcher to request a copy of the results.  
Ethical Considerations 
 This study was submitted to and approved by the University of Tennessee–Knoxville’s 
Institutional Review Board (IRB). Interview participation was voluntary and participants have 
the opportunity withdraw at any time. A detailed consent form was given to each participant and 
interviews were not conducted until it was signed. A copy of the consent form was given to the 
participant to keep. Each participant was given a pseudonym and no real name appeared 
anywhere except on the original consent form. Consent forms are stored separately in a secure, 
locked location. All interviews were digitally recorded and transcribed verbatim by a reliable 
transcriber who signed a confidentiality form.  
 Participants faced three minimal potential risks: they could experience a loss of 
confidentiality, become emotionally upset, or feel some sense of coercion. Several strategies 
were used to minimize to protect confidentiality. First, the PI completed the Collaborative 
Institution Training Initiative Program (CITI) for research ethics education and was the only 
person with access to the data. Additionally, all data was stored in a locked cabinet in the PI’s 
home office and on a computer with a digital access code known only to the PI. The PI de-
identified all data and separated the consent forms and lists of contacts from other research 
materials.  
 Another risk was that participants could become upset because of the sensitivity about 
their health experiences or illness narratives, and the difficulties associated with cancer as a fatal 
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illness. To prevent participants from feeling coerced or anxious about participating, the PI 
assured them they could end their participation or terminate an interview at any time, and decline 
to answer any individual questions. To promote participants’ comfort, breaks were offered every 
20 to 30 minutes and whenever participants requested one. The PI planned for the interviews to 
last approximately 90 minutes, but allowed more time when a participant had more to say. 
Interviews were scheduled in a location agreed upon by the participant. These results will be 
used for practice and scholarly purposes, and the results will be reported only in the aggregate. 
Particular quotes that might identify the participant based on specific or regional details were 
disguised.  
Data Analysis 
To become engaged with the interview data—including developing an understanding of 
the nuanced meaning of words, sounds and silent moments—the PI transcribed the initial three 
interviews and initiated the coding process manually (Throne, 2008). The PI did guard against 
any bias related to familiarity with the first three transcripts differently than the other transcripts. 
The review of all interviews and written transcripts were reviewed numerous times with the same 
level of scrutiny. The PI used NVivo software for data management. The remaining interviews 
were transcribed by a transcriptionist, which the PI reviewed closely which included listening to 
the interviews several times while simultaneously reviewing the written transcripts. The PI 
entered the study data and stored it on a password-protected computer on a secure research 
network housed in the PI’s locked office. Data will be maintained for three years after the study, 
and then destroyed. Any written and audio notes will be shredded. Audio files will be 
permanently deleted, as voices are identifiable. 
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 One of the most essential elements of a credible interpretive description study is the 
intensive process of analyzing the data to generate new constructions that are meaningful and 
relevant (Thorne, 2008). Interpretive description requires the researcher to see beyond the 
obvious questioning and test what is observed in the data. The initial analytic process began with 
a broad sorting of the data from individual transcripts. Words and phrases that reflected 
meaningful responses were underlined, circled, and highlighted. For this interpretive description 
study, inductive analysis continued through an iterative (repeated) process of formulating 
categories, themes, and recognizing patterns from the data.  
Initial Analysis  
 In the early phase of analysis, Thorne (2008) suggested organizing the data using few 
permanent labels. First, pieces of data that attracted attention and caused a reaction were noted 
by the PI. Thorne (2008) described this part of the analysis as an act of contrasting the expected 
with the unexpected, which stimulates the senses. For each transcript, the PI engaged in 
confirming an accurate recording of the transcripts and immersing herself in the data. As she 
analyzed the data, the PI also developed a sense of the whole, as this method requires the 
researcher to focus attention consciously in a sequential manner from the individual participant 
“cases” to the whole data set, and from groups of similarity among certain cases to various 
overall differences among other cases. This iterative process increased the level of clarity in 
understanding what relationships existed among and between instances within the data. Seeing 
the bigger picture is essential in qualitative research as the researcher looks for relationships and 
tensions within systems, cultures, and subcultures. Data analysis was deemed complete when the 
research question had been answered, questions that emerge during the study had been addressed 
adequately, and a clear picture had developed regarding the subjective health-related experiences 
47 
 
and needs of post-treatment melanoma survivors. Additional notes, such as the PI’s reflection 
journal entries and memos, were incorporated into similar categories and linked patterns or 
groupings were identified.  
Coding Process  
 Interpretive description requires a broad-based, generic coding process (Thorne, 2008) 
that allows groups to be established such as age categories, or participants diagnosed in similar 
medical settings or under similar circumstances. Thorne recommended generic identifiers be 
used to prevent assigning meaning too early and guiding the interpretation into false findings. 
The initial coding process was followed by descriptive coding (i.e., topic coding), which 
involves summarizing a qualitative data passage using a word, short phase, or basic topic rather 
than the content (Saldana, 2013). This approach is appropriate for qualitative studies and is 
particularly useful for novice researchers. Descriptive coding can help the researcher answer 
general questions aligned with the interpretive description design: What exactly is being shared 
here? and What does this mean within the scope of the study? Such questions were asked during 
the iterative process that included reading, listening, thinking, and writing and the responses 
were captured though journaling and memos (Thorne, 2008). 
Thorne (2008) does not promote the idea of data saturation. Rather, she endorses an 
analytic process of probing data for outliers to identify predictable and rare but relevant findings 
not present in current literature. Probing for outliers is described as a method of moving beyond 
typical questions that one might ask when testing the data. Looking for new possibilities or 
topics not previously discussed leading the researcher to look beyond the obvious for the 
undiscovered. This process requires analytical thinking that goes beyond the original findings or 
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the state of the science. This method can be used to determine if there is anything else to be 
known prior to ending data collection. 
Memos  
 The use of marginal memos involved categorizing text previously coded as potentially 
meaningful into categories using colored markers to represent thematic similarities (Thorne, 
2008). This method is consistent with the analytic thought process facilitated through interpretive 
description. Memos and short biographical sheets were initiated for each participant during 
analysis and expanded upon for use in findings.  
Evaluation Criteria for Findings 
 The steps taken to ensure a study’s rigor and trustworthiness can influence its overall 
quality. A qualitative study’s relevance and value ultimately should be determined by its rigor 
(Thomas & Polio, 2002). This study’s value is toward the scientific knowledge about an 
understudied population in a way that has the potential to help inform clinical practice. This 
study’s relevancy is found in the information it provides for promoting improved outcomes for 
regional melanoma survivors—information that has possible national and global implications, as 
well.  
 Several kinds of evaluative criteria can be applied to an interpretive description research 
approach. The first consideration Thorne described is epistemological integrity, which follows 
the line of reasoning from the assumptions regarding the nature of knowledge and the 
methodological decisions used. A second consideration is representative credibility that 
compares whether the theoretical claim remains consistent with the phenomenon under study. An 
inductive reasoning process also should include an audit trail to demonstrate the reasoning 
pathway. To ensure that the interpretations are free of bias, reflective journaling, memos in the 
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margins, and recorded field notes were employed by the PI and become part of the findings and 
discussion (Thorne, 2008). Analytic logic makes explicit the reasoning of the researcher based on 
what was learned. The audit trail, which included all conversations with faculty and consultants 
as well as the project journal with refinement of ideas and reflections during the entire process, is 
an important aspect of the transparency.  
 Interpretive authority included a strategy where members of the dissertation committee 
reviewed aspects of the data and findings for consistency (Thorne, 2008). The dissertation 
committee members—experts in research, nursing, and public health—were part of the ongoing 
rigor and trustworthiness process. The committee’s faculty chair advisor is a researcher with 
several NIH RO1 funded studies using mixed and qualitative research methods with skills in 
critically reviewing transcripts. The PI has a basic understanding of the research process and a 
good reading and working knowledge of qualitative analytic techniques.  
Chapter Summary 
 The generic nature of the interpretive descriptive approach can be both a challenge and an 
asset to a novice researcher. On one hand, its lack of prescribed methods can leave novices to 
question their research choices. On the other hand, it gives researchers the flexibility to explore 
the data in various ways in order to answer specific research questions. The use of the 
interpretive description approach allowed the PI to reflect on clinical experiences as participants 
described their personal experiences. This was important as the participants reflected on such 
experiences as physical limitations, emotional concerns, social constraints, and/or economic 
hardships. While the use of this disciplinary lens also introduced potential biases, the strategies 
of PI reflective journaling, recording of memos and field notes, along with the involvement of 
the dissertation committee members’ added validity to the findings. The understanding gained 
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from this research can help inform nursing care and guide future decisions in the care of 
melanoma survivors. 
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Chapter Four: Findings 
 The purpose of this study was to explore the post-treatment health-related experiences 
and needs of melanoma survivors in the ETAR. This chapter presents the research findings 
beginning with participant demographics. Sixteen participants were interviewed using an in-
depth, semi-structured format. The sample included participants who self-identified as melanoma 
patients living in the ETAR. These participants offered their perspectives of their experiences 
during melanoma diagnosis, treatment, and post-treatment periods. The transcribed interviews 
were coded systematically—manually and with NVivo® software—as guided by Thorne’s (2016) 
recommendations for analysis of interpretive description data. The survivorship trajectory 
(timeframe) includes the diagnosis and treatment periods that informed post-treatment 
experiences. The post-treatment needs were identified implicitly from participant dialogue and 
narratives. Four thematic patterns, supported by participant experiences as represented by 
essential summative quotes, are presented along with summaries of participants’ implicit needs.  
Overview 
Participant Demographics 
 Participants were recruited from the ETAR, which includes 54 counties. All participants 
(N=16) who self-identified as melanoma survivors willing to share their experiences were invited 
to participate. All participants spoke fluent English as their first language. Interviews were 
conducted in a private location chosen by the participant, typically a work setting or a familiar 
community location. The researcher collected the demographic data of age, gender, ethnicity, 
educational attainment, residential zip code, and employment status. Additional participant 
information collected during the interviews included specifics about the diagnosis, treatment, and 
post-treatment periods. Of the 16 participants, nine were females and seven were males, with a 
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mean age of 54.4 years. Twelve participants were from rural areas and four were from more 
urban areas. Participants identified as non-Hispanic or Latino with one listed as unknown. The 
education level was split evenly with eight college graduates and eight non-college graduates. 
Eleven participants worked full-time, two were retired, two were on disability, and one was 
unemployed (Table 4.1, Appendix A). 
The investigator analyzed the interview data to determine similarities and differences 
among participants along the cancer trajectory. The PI recorded such information as length of 
time since diagnosis, treatment type, melanoma location, family history, recurrence, travel time, 
and yearly follow-up schedule (Table 4.2, Appendix A). Twelve participants were diagnosed 
within the past 10 years and three were diagnosed more than 15 years ago. One participant was 
diagnosed 29 years ago. Regarding treatment type, seven participants had a wide excision with a 
negative sentinel lymph node biopsy (SLB). Two participants had a wide excision only without a 
SLB. Six participants had a wide excision and a positive SLB, and five had additional treatment 
removing all lymph nodes from the specific area (lymphadenectomy). One participant did not 
return to the clinic for additional recommended surgery. When she returned three months later, 
her disease had advanced to the point where surgery was no longer recommended. One 
participant diagnosed because of lymph node swelling without any metastasis had a wide 
excision of the mucosal lesion and lymphadenectomy. The location of the melanoma at diagnosis 
included five (n=5) on the back, three (n=3) on the forearm, two (n=2) on the thigh, one (n=1) on 
the abdomen, two (n=2) on the face, two (n=2) on the chest, and one (n=1) from a mucosal area. 
 Participant recurrences (n=8) included two on the back, two on the abdomen, one on the 
arm, one on the neck, and two as metastasis. Five participants with a negative SLB had a family 
history of melanoma. Eight college graduates had negative SLBs except for one, while the eight 
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non-college graduates had positive SLBs. Regarding travel time to healthcare providers, 14 
participants reported traveling one to two hours’ round trip, three traveled four hours round trip, 
and one traveled eight hours roundtrip. For follow-up, 12 traveled at least once or twice a year, 
and four traveled up to four times a year (Table 4.3, Appendix A). 
Melanoma Survivorship Trajectory Experiences 
 Participants told stories that went beyond their demographic information. Gaining a 
detailed description of each participant allowed the PI to set the stage for describing their 
collective narrative. Pseudonyms were assigned to each participant to protect their privacy. From 
some survivors’ perspectives, early sun-related experiences that may have placed them at risk of 
melanoma seemed important and relevant. Participants’ pre-diagnosis, diagnosis, and treatment 
experiences informed their post-treatment narratives.  
Typical Trajectory  
 Greta is a 42-year-old nurse practitioner who went to see her primary care provider for a 
biopsy after several friends at a conference told her a spot looked “funny.” She had a family 
history of melanoma in that her mother and cousin had the disease. She was sent to a surgical 
oncologist who performed a wide excision without an SLB. She was diagnosed with melanoma 
14 years ago and has not had a recurrence. She also has dysplastic nevus syndrome, a condition 
that causes her to have numerous moles that can become cancerous. Her follow-up consisted of 
seeing a photo dermatologist (one that photographs the moles and compares the photos to detect 
changes each visit) every three months, which has required her to make a two-hour roundtrip, 
four times a year for 14 years.  
 Robyn is a 56-year-old health educator who went to a dermatologist after a beach trip 
with friends. She had never seen a dermatologist and procrastinated in making the appointment. 
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Once she found out a friend’s husband had been diagnosed with melanoma, she made an 
appointment. After having 12 biopsies in the office, she was told to return four days later for the 
results. Three of the biopsies were melanoma, one each on her nose, cheek, and arm. She 
promptly called her plastic surgeon friend who saw her in the office four days later and 
performed surgery the following week. Her surgery consisted of a wide excision without a SLB 
on the three areas. For follow-up, she has seen her local dermatologist every six months for the 
last four years. While she has had no recurrence, she has had several biopsies and lesions excised 
since her diagnosis.  
 Heidi is a 60-year-old registered nurse (RN) whose husband noticed a “funny” area on 
her back before she noticed another on her abdomen. She decided to make an appointment with a 
surgeon who removed the abnormal areas. The pathology indicated melanoma. She then saw a 
surgical oncologist to have a wide excision and SLB, which was negative. Except for a two-year 
period when she cared for her elderly parents in Florida, her follow-up over the last five and a 
half years has included seeing a photo dermatologist every six months (a two-hour round trip).  
 Ethan is a 57-year-old civic engineer who once worked with city municipalities, but now 
works from home in his own business. His wife found a black spot on his back and he was seen 
by a dermatologist who removed the spot, and the pathology revealed melanoma. He was 
referred to a surgical oncologist who did a wide excision and a SLB that was negative. He has 
followed up yearly with a dermatologist. Some suspicious areas have been removed but none 
was melanoma.  
 Rosie, a 29-year-old physician resident who was initially diagnosed at the age of 18, first 
went to the dermatologist at the insistence of her mother. After a biopsy of a lesion on her chest 
indicated melanoma, she was referred to a surgical oncologist who performed a wide excision 
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without an SLB. One year later she had a suspicious area on her abdomen removed that also 
turned out to be melanoma. Another surgical oncologist did a wide excision and SLB, which was 
negative. For 11 years, her follow-up has consisted of seeing a dermatologist yearly. When 
changing healthcare providers she may have gone more than a year without an appointment.  
 Darron is a 61-year-old man and former pilot military who now works as a supervisor 
and park ranger. Twenty years ago, he developed a freckle on his chest that the general 
practitioner aboard a military ship in a U.S. harbor watched for a period. His wife also was in the 
service and was stationed in Puerto Rico. Eventually, the suspicious area was removed and tested 
positive for melanoma. A surgeon did a wide excision and SLB, which was negative. Five years 
later, he had a recurrence behind his ear and an additional SLB was done, which was negative. 
His follow-up care over the past 20 years has consisted of seeing a dermatologist every one to 
two years. His occasional breaks in visits happened when he was finding a new healthcare 
provider when he and his wife relocated during their time in the service.  
 Arlene is a 43-year-old woman who works as a therapist for individuals and families in 
crisis. Two years ago, she noticed a mole on her back and saw a dermatologist who did a biopsy. 
Two weeks later, she received a voicemail reporting that she had melanoma, and would be 
referred to an oncologist. She did not want to wait to speak with the dermatologist and made an 
appointment with her aunt’s surgeon who treats breast cancer and melanoma. She had an 
appointment within three days and surgery a week later with a wide excision and an SLB, which 
was negative. Her follow-up over the past two years has consisted of being seen by a 
dermatologist and surgical oncologist every three months initially, then every six months. A few 
weeks before the interview, she was being evaluated for breast cancer after her mammogram 
showed a small lesion.  
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 Linda is a 46-year-old real estate agent whose husband noticed an unusual area on her 
thigh. She saw her primary care doctor who referred her to a dermatologist. She had two 
biopsies: one on her thigh and one on her back, both of which were melanoma. She was referred 
to a surgical oncologist two hours from her home that performed a wide excision with SLB to 
both areas, which were negative. After she recovered from the surgery, her surgical oncologist 
moved the practice further away, which made her twice-yearly follow-up require a four-hour 
round trip. She continues to follow-up with her local dermatologist twice a year. She also 
continues to see the medical oncologist she initially saw after surgery once a year at a cancer 
center two hours from her home.  
 Taylor is a 64-year-old retired electrician. His wife noticed something on his back that 
seemed to be getting bigger. He saw the dermatologist and his biopsy showed melanoma. His 
surgical oncologist performed a wide excision and SLB, which was negative. His twin sister was 
diagnosed with melanoma a year before his diagnosis. Initially, his follow-up with a 
dermatologist was every three months, then every six months, and now yearly.  
Complicated Trajectory 
 Griffin is a 49-year-old who works as a computer programmer. Five years ago during tax 
season, his wife noticed a “funny looking” mole on his thigh. She made him an appointment with 
her dermatologist an hour away because he could not get a local appointment. The biopsy done 
in the office indicated he had the “bad kind of skin cancer,” and he was referred to a cancer 
center in central Tennessee. He saw a surgical oncologist and had a wide excision with an SLB, 
which was positive. He met with a medical oncologist after surgery and had a PET scan and MRI 
of his brain, which were negative. He then had further treatment with a lymphadenectomy and 
one year of Interferon therapy. His follow-up has consisted of seeing the surgical oncologist 
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yearly and the dermatologist twice yearly. The medical oncologist follows him once yearly close 
to home, but he travels two hours round trip to see the surgical oncologist and dermatologist.  
 Randall is a 94 year-old retired farmer who scratched his cheek in the barn and the area 
started bleeding. His son took him to the emergency room because it kept bleeding. The mole 
was removed and after the pathology showed melanoma, he was sent to a local plastic surgeon. 
A wide excision with skin graft and SLB was done on his neck, which tested positive for 
melanoma. Additional treatment was required, a lymphadenectomy to remove the lymph nodes 
on one side of his neck. For the last 10 years, he has been followed by his local primary care 
physician and dermatologist. 
 Karen is a 65-year-old RN who practices full-time. Twenty-nine years ago, she went to 
her primary doctor after a mole on her abdomen started bleeding. A biopsy was done in the clinic 
that day and the next day she was diagnosed with melanoma. She was admitted to the hospital 
and had a wide excision with SLB, which was positive. After a lymphadenectomy, she was fitted 
for a stocking to prevent lymphedema in her leg. Two years ago, she had a lesion on her back. 
After a wide excision with SLB, the results again were positive for melanoma. She required an 
additional lymphadenectomy. Her follow-up was complicated by a lesion identified on her 
kidney following a PET scan and MRI of the brain. She had a partial nephrectomy and after her 
recovery, her medical oncologist decided that she did not qualify for a clinical trial or any other 
immune therapy treatments. During the period after her initial diagnosis, she was followed by her 
primary provider each year. She sees a dermatologist and medical oncologist now for twice-
yearly follow-up.  
 Jeanie is a 58-year-old who worked in sales prior to going on disability for melanoma. 
Three years ago, her boyfriend saw a “funny” place on her arm. He pushed her to get it evaluated 
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even though she was hesitant because she had no insurance. She went to the health department 
for the biopsy. Although it “took a while” to get the biopsy results back, she finally had an 
appointment with a surgical oncologist at the cancer center two hours away. She had a wide 
excision, skin graft, and SLB, which was positive. No other melanoma was found internally on 
imaging. She then had a lymphadenectomy and additional surgery because the skin graft to her 
arm became infected. She saw a medical oncologist who recommended a clinical trial, but she 
was not able to tolerate the medication. She developed a local recurrence just above the incision 
area and had another excision and radiation treatment after the area healed. She now follows up 
with the medical oncologist and surgical oncologist every three months.  
 Clifton is a 60-year-old man retired from military service who now works as a 
paramedic. A mole was found on his back during a military physical 18 years ago and the biopsy 
indicated melanoma. A surgical oncologist at a Veterans Administration (VA) facility performed 
a wide excision with SLB, which was positive. He had a lymphadenectomy and, after recovering 
from surgery, met with a medical oncologist. After a year of Interferon therapy, his follow-up 
consisted of seeing a dermatologist and medical oncologist every three months initially and then 
every six months. He retired from the military last year and has continued his follow-up with 
either the medical oncologist or a dermatologist. Recently, his chest radiography showed a 
suspicious area in his lung. He then had a lung CT and a PET scan and MRI of the brain. These 
scans showed he had melanoma in his lung and brain.  
 Daisy is a 26-year-old who worked as a cashier before her melanoma diagnosis. Her 
obstetrician found a suspicious mole on her arm when she was six months pregnant. She had 
some difficulty getting the biopsy, as she did not have comprehensive insurance. Once she had 
the biopsy that verified she had melanoma, she was referred to the cancer center in central 
59 
 
Tennessee to see a surgical oncologist. The recommendation was to do the surgery after she 
delivered her baby. When her daughter was two months old, she had a wide excision and SLB, 
which was positive. She was told she needed additional surgery and to see a medical oncologist, 
and gave scans to make sure she did not have melanoma anywhere else. She admitted that 
hearing about more surgery and looking after her two-month old kept her from coming back for 
about three months. When she returned to talk about the surgery and the scan results, she was 
told that the melanoma was in her lungs and bone and that would need to be enrolled in a clinical 
trial or placed on systemic treatment. She was started on a systemic treatment, but she could not 
tolerate the medication as it made her very sick. She had an appointment to return to the medical 
oncologist a week after her interview for follow-up.  
 Hayden is a 61-year-old who worked repairing computers until he went on disability 
after melanoma treatment. Swelling in his thigh, leg, and foot prompted a visit to his primary 
care provider. A surgeon performed a biopsy and the pathology was positive for melanoma. He 
was referred to the cancer center in central Tennessee. The surgical oncologist examined him and 
initially concluded that he may have had a skin lesion but it was not identifiable at the time of 
exam. Upon conducting a more detailed assessment, a dark area near his anal sphincter was 
detected. Colonoscopy and biopsy of the dark area revealed mucosal melanoma. He had two 
separate surgeries: lymphadenectomy and rectal surgery. His recovery was complicated by 
wound problems and permanent lymphedema that keeps him from sitting for long periods.  
Pre-Diagnosis Experiences 
 During interviews, most participants recalled their pre-diagnosis sun-related activities and 
the identification of their suspicious lesions. Participants seemed to view these experiences as a 
way to introduce information about the diagnosis period. Growing up, most participants spent a 
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great deal of time in the sun boating or participating in other outdoor activities and sports. 
Suspicious lesions often were described by participants or their family and friends as a “funny-
looking area.” Further conversations during the interview regarding this period revealed that 
even though the area was discovered by someone else, participants often knew the area was there 
and they and/or healthcare providers had been monitoring its growth.  
Sun-related Activities 
 Most participants shared early sun-related experiences. For instance, Heidi and Linda 
spent their adolescent and early adult years on a houseboat during summers and weekends. 
Rosie, who described herself as fair-skinned and freckled, explained, “Mom kept me lathered 
with sunscreen as a child.” Rosie added, “I was outside all the time playing softball in the 
summer wearing sunscreen, but still, I mean, when you’re in the sun 15 hours a day, you know, 
how much does it really help?” Ethan shared sentiments similar to those of the other men 
interviewed by stating, “I did not use sunscreen and I still don’t care much for [it].” Taylor, who 
was adopted, described his sun exposure mainly came from activities with his dad during the 
summer and weekends. He said, “I grew up around it [the sun]” because his dad owned a body 
shop and often had his shirt off while working in the sun. Robyn had the most to say about her 
sun-related activities as a teenager and how that extended into her early adulthood. She 
elaborated: 
I’m the generation of… no sunblock, only iodine and baby oil and holding up aluminum 
reflective out on the deck at college… so we could get the maximum. I’m ah, an outdoors 
person and… grew up, spending all summer long—Memorial to Labor Day—on the 
water, in the lake, lifeguard, swim instructor, sailing instructor, water skiing, so I was 
maximum exposure to the sun with no protection at all. I was really bad to my skin. I… 
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just went out in the sun and didn’t put anything on it and maybe I’d throw aloe on it… I 
was a lifeguard all through college, too. I gauged the summer by the number of layers 
that came off my nose, like how many times it would burn and peel, burn and peel, burn 
and peel, that was a hot summer. Gosh, I think I had eight noses that summer.  
Suspicious Areas 
 Most participants identified a spouse, family member, significant other, or friend who 
initially recognized the unusual area. Fewer participants identified the areas themselves, and two 
participants named providers who found the areas incidentally. Clifton explained that during his 
yearly routine military physical exam, “a mole was found on my back and was removed by the 
surgeon at [the base hospital].” Two participants noticed an unusual mole and went for 
evaluation after some bleeding occurred. Karen, an RN, explained, “I had a mole on my lower 
abdomen and one day I noticed that it bled a little bit, just out of the blue, and went to my family 
doctor.”  
 More commonly, the mole or unusual area was identified by the spouse, significant other, 
family member, or friend (n=10). Heidi stated, “My husband thought the one on my back looked 
funny,” and Ethan reported, “My wife found it on my back and she said that the black spot did 
not look right.” A few women interviewed reported being very upset, scared, and in shock at 
being diagnosed with melanoma. For example, Heidi stated, “I was mad, I cried and then I was 
mad, and then I wanted it out of me... I thought this can kill you.” Arlene had similar reaction, “I 
just felt um, pretty scared and alone… I needed any and all cancer out of me and off of me as 
soon as possible.” Karen responded with “I was in shock.” However, Rosie (a physician resident 
who was 19 when diagnosed) commented, “I wasn’t scared then but now, knowing everything I 
know, I’m a lot more nervous about it.” Robyn explained, “I didn’t go down the panic rabbit 
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hole” but she also elaborated that she received the news from a healthcare provider in a calm and 
encouraging manner. Robyn offered another explanation for her calm response, “I tend to look 
[at] the silver lining, like well this is going to be great ‘cause I know a plastic surgeon who can… 
[fix me up] so, so I wasn’t scared or worried.”  
 Darron (military retiree who does administrative work for the National Forest) had a very 
different take, “Well, you just go in there [and] have it removed” and “let’s get it done.” Clifton 
(military retiree now working as a county paramedic) shared that his mom died of pancreatic 
cancer when he was a young child and so he kept in shape, ate a balanced diet, and had regular 
check-ups in order to “avoid” what his mom had suffered. He remarked, “I can honestly say that 
melanoma was the last thing I thought I needed to worry about.” Jeanie, whose melanoma was 
discovered by her boyfriend, commented about getting a skin exam, “I wanted to go, but was 
scared it was skin cancer, you know from the sun.” As participants shared their stories about the 
initial recognition of the suspicious area, they often revealed that they had seen or been aware of 
the area.  
Diagnosis Experiences 
Initial Biopsy 
 Most participants were diagnosed by either a dermatologist or their primary care 
provider. All participants described their initial biopsy and diagnosis in detail, many even 
remembering the date and time they received the results. Randall, a 94 year-old retired farmer, 
explained, “It (mole) came off by accident when I was out in the barn, but it sure did bleed all 
over the place.” My son took me to the ER to get it sewed up, but a piece was left, so when the 
doctor called me, he said, “you’ll need to go see the surgeon in town”. Even 29 years later, Karen 
(RN) remembered,  
63 
 
I went to the doctor right away [after the mole on her abdomen bled] and he did… a[n] 
office biopsy and removed it. I’ll never forget what he said after he got it out, as he 
handed the specimen to the nurse he said, get this to lab stat, and as soon as he said that I, 
I was… kind of drained out, it’s like, oh my gosh this is serious, you know, ‘cause I just 
thought it was gonna’ be a little mole. 
 Three participants had more than one melanoma when the initial diagnosis was made. 
Heidi had six biopsies and two were melanoma, while Robyn had 12 biopsies and three were 
melanoma. The process of recognizing a suspicious mole, getting a biopsy, and receiving a 
diagnosis can be complicated by issues of insurance coverage or care access. Griffin, a computer 
programmer with insurance said, “I really never noticed it [the mole] before, and she [his wife] 
said that it was not there [before]. So, she made me a[n] appointment to see her doctor [two 
hours away] because it would be… three months before I could get a[n] appointment with a 
dermatologist close to where we lived.” Jeanie, who was unemployed and without insurance at 
the time of diagnosis, explained, “I had to have lots of biopsies and the one on my arm had 
melanoma in it. My arm is still not right. I had to drive all over [Tennessee] to get a biopsy and 
the biopsy results took forever… too.” Most biopsies were done by dermatologists and patients 
were referred to surgeons who performed the excision surgeries, as recommended in the National 
Comprehensive Cancer Network’s (NCCN, 2016) guidelines.  
Hearing the Diagnosis  
 Hearing the melanoma diagnosis directly from a healthcare provider was very important 
for some participants. Robyn explains how she was told,  
She [the dermatology physician assistant] was very um, matter of fact and very 
transparent and very calm about it like okay, this is gonna’ be a scary word. Yes, you 
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have melanoma. Yes, it’s the bad kind, but we’ve caught it early… you know, that kind 
of thing. So it was very reassuring and um, empowering ‘cause I… didn’t feel like oh, I 
don’t know what this is or what does this mean.  
Arlene, a clinical psychology therapist, heard the news on her voicemail two weeks after the 
biopsy and could not contact the dermatologist to get any specifics. Greta, a nurse practitioner, 
stated, “I went to my little PCP and he biopsied it and he said he knew right away it was 
melanoma.” Hayden’s story is a little unusual, as his melanoma is categorized as unknown 
because no actual skin lesion was identified initially, highlighting the complicated nature of this 
disease. He said, 
I started having… lots of swelling in my right leg. I went to see my primary doctor and 
he sent me to another doctor that took a biopsy in my groin… and sent me to Dr. [T], he’s 
a surgeon, and then they sent me to a cancer doctor [surgical oncologist] in [major cancer 
center in central Tennessee] because it was melanoma. New to me, I thought melanoma 
was skin cancer; you know moles and… stuff… The cancer doc said again that the other 
doctor found melanoma in my lymph nodes… so, my colon checked out, but the biopsy 
from the dark area [near the anus]… was melanoma… [I] just did not want to hear that. 
Valentine’s Day last year… I remember when they called me to come to the office, after 
the biopsy and checking my colon… my phone showed Happy Valentine’s Day when the 
phone rang… 
Treatment Experiences 
 Participants described the treatment period in as much detail as they did the initial 
recognition and diagnosis periods. The PI elicited details about their healthcare providers, where 
care was obtained, and whether they participated in a clinical trial. For most participants, surgery 
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was the initial treatment once the diagnosis was made. The surgery generally included a wide 
excision of the melanoma and most participants had an SLB to check for any cancer cells in the 
first area of lymphatic drainage. Except for three participants, surgery was performed by a 
surgical oncologist, plastic surgeon, or general surgeon in outpatient settings. Two participants 
had surgery at military base hospitals and another spent nine days in the hospital after her 
surgery 29 years ago (Table 4.4, Appendix A). 
 Driven by prior experiences and emotions from their diagnosis, participants working in 
the healthcare field often called on friends to expedite the treatment process. In addition, 
participants and their friends and family members were concerned about ensuring they went to 
the best available facility and surgeon for their care. For example, Heidi reported that her 
dermatologist could have referred her to a local surgeon, but “I didn’t feel like… it was the best 
place to go, so I went to the [cancer referral center in Central Tennessee].” She told the 
dermatologist who she wanted to see and described the surgeon as “a surgeon/oncologist/general 
surgeon… he’s the works.” 
 Griffin explained that his wife looked up the specialist at the cancer center in Central 
Tennessee and made me an appointment “because it was the bad kind of skin cancer, that’s 
where they told my wife I needed to go, [to] see the melanoma doctor.” Griffin saw the surgical 
oncologist and was scheduled for surgery two weeks later. When asked about traveling for the 
surgery, he commented, “it is a drive from here [two-hour round trip], and [I] wish [I had] 
someone closer… we had to make arrangement for our daughter, she was in middle school at the 
time.” Linda—who was referred to a surgical oncologist at an East Tennessee cancer center—
said, “She was very nice and prepared me for the worst, but hoped for the best.” Rosie was 
referred to a local surgical oncologist and reported that “He said he was gonna’ take care of it, so 
66 
 
I thought, okay, he’s gonna take care of it.” This experience inspired Rosie to become a doctor to 
help other people. Not all participants were treated by a surgical oncologist. Randall, who was 
diagnosed after a trip to the Emergency Room with bleeding from a mole that had come off 
partially, was referred to a general surgeon who referred him to a plastic surgeon. He laughingly 
said, “My son says he is a plastic surgeon, like I need plastic surgery, didn’t before, but now I 
do.” 
 After finding out she had melanoma on her arm and two areas on her face, Robyn called a 
friend who is a plastic surgeon. She had an appointment three days later and surgery within two 
weeks. One month after being diagnosed, she was back in the dermatologist office for follow-up. 
That same day, she received a call from the plastic surgeon to which her dermatology office had 
referred her. Robyn further explained:  
I wasn’t sitting around for six weeks waiting for somebody’s office to call me to schedule 
a consult to talk about the surgery we might be having in the future. I felt I could be in 
charge of, of how I was gonna’ handle [it]. And… it quite frankly, naively, never 
occurred to me that I wouldn’t be in charge of how I handled it… I’d been waiting for 
somebody to call me for weeks on end and not hearing anything and wondering, you 
know, when am I gonna’ get this taken care of? The most disconcerting thing was I 
wasn’t anticipating… they took about an ice cream scoop’s worth of flesh out of my arm. 
So, I have a real indent, even two years later, it still hasn’t filled in. 
 Arlene initiated her visit with the dermatologist when she noticed an area on her back 
was changing. When she received a voicemail about the diagnosis two weeks later, she took 
matters into her own hands for fear it would spread. She called her aunt, who had been treated 
for breast cancer, to discuss her feelings about her diagnosis. Her aunt called her surgical 
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oncologist who treated patients with breast cancer and melanoma. After telling her dermatologist 
whom she wanted to see, Arlene was scheduled with the surgical oncologist three days after her 
Aunt made the initial call. Arlene described her encounter with the surgical oncologist:  
I saw him the first day, then um, I had an educational video that was very scary. But he 
came in and he looked at [my mole], and he felt very confident that um, he could take 
care of it and I would be okay. And that’s really what I wanted to know.  
After being notified of her diagnosis via voicemail, Arlene informed the surgical oncologist that 
she wanted direct communication with him,  
“… Please, you know, if you could not repeat that [leaving a voicemail with bad news]. 
Just… tell me and not leave [me] dangling… ‘cause… information is power and so I 
want to know what was going on, and I want to know what to do about it. And I didn’t 
know what it meant [when the dermatologist left the message]. I knew um, [that] 
melanoma kills people, that’s what I know.” 
 Two participants received care through the VA and follow-up in East Tennessee. Clifton 
stated he had “the best care and treatment the VA could offer, but ahh the wheels move slower in 
the government.” He remembered specifically that the surgeon was “very precise about making 
sure I understood about melanoma and how serious it could be. He told me that I would need to 
be followed after treatment regularly. As I recall, that was the bottom line.” Darron left the 
service after four years but had his melanoma removed at a Veterans facility when his wife (an 
RN) was serving in Puerto Rico. His understanding was “whether the mole was melanoma or 
skin cancer, it seemed to be, well, you just go in there [and] have it removed.”  
 Daisy’s melanoma was found when she was six months pregnant. She was seen by a local 
dermatologist who confirmed the diagnosis, and then was sent to a surgical oncologist who 
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performed her surgery after her daughter was born. She explained that finding a surgeon who 
accepted her insurance was difficult. She and her Dad traveled two hours round trip to the cancer 
center each time. Her dad came with her for the surgery and cared for the baby, “it was hard, my 
Dad had to come with me and took care of [my baby] each time I had to go. After all the time 
traveling back and forth, after I had the first surgery, we were tired of all that”.  
Jeanie reported that it took time to get her biopsy information and to see a surgeon:  
It took a while to find out anythin’, crazy really. After I had the biopsy, then it seemed 
like so many weeks before they could get it out… it took a long time to get… that 
surgery… [My surgical oncologist] said I would be okay once when we get it out. Glad 
for that first, but it came back again, not so glad. Let’s see, he cut a long place here on my 
arm and deep, wow, and looked under my arm for cancer there, I had to go to the cancer 
center to get everything. I didn’t have any way to get anything. Medicine and stuff they 
helped me with. I see a lot more people now …cancer doctors, social workers, nurses, 
radiation doctors… 
 Karen’s diagnosis and treatment was the standard-of-care care in 1988. She was urgently 
admitted to the hospital, stayed nine days, and did not leave the hospital without her leg stocking 
fitted to prevent lymphedema. Karen recalled that the local general surgeon was very well known 
and she had a lot of respect for him, “I really… think he did me good.” She remembered one 
incident in particular that helped her after the surgery:  
I remembered the doctor referred me to… another person that had a melanoma removed, 
and she was about my age. And I just met her briefly, but she was, uh, very encouraging 
and… made me feel better about myself, you know, that hopefully my life was gonna go 
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on, and things were gonna be okay, [that] it wasn’t a death sentence at this point so, so I 
appreciated him doing that, he got me in touch with her. 
 Ethan’s story included two surgeries because additional tissue needed to be removed. A 
dermatologist initially removed the melanoma from his back, but because the margins were still 
positive, he was referred to a surgical oncologist two hours from his house. He offered a 
humorous take on the additional surgery, “I guess [they] had to kind of take a big pork chop out 
of my back. It was probably like, four or five inches wide.” Taylor—who was adopted and had a 
twin sister who had a melanoma removed a year before—reported, “The doctor said that I was 
going to be okay once he removed the melanoma. My sister was telling me that all would be fine, 
and that’s the way things went.”  
Integrated Health-related Experiences and Post-Treatment Needs 
 In this study, the PI explored the essence of survivorship in melanoma participants living 
in the ETAR. Recurrent experiences and specific patterns and began to emerge during the 
interview, transcription, and coding processes. The researcher brought her nursing perspective 
and expertise as a healthcare provider for melanoma survivors to the analytic process. While the 
interpretive description method was used during the entire analytic process, the PI relied on it 
especially during the iterative phase as she was making sense of the findings. Thorne (2008) 
stated that “we desperately need new knowledge [in nursing and other applied disciplines] 
pertaining to the subjective, experiential, tacit, and pattered aspects of human health evidence” 
(p. 36). The contextual understanding gained from the new perspectives presented in this study 
can help guide future decisions by cancer care providers and clinicians related to melanoma 
surveillance and survivorship. 
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Thematic Overview 
 Four major themes regarding melanoma survivors’ post-treatment health-related 
experiences were derived inductively from the interview data. Participants’ post-treatment needs 
were tacit or implicit within their stories and from their perspectives as people from Appalachia 
and melanoma survivors. Theme and subthemes are described in detail with supporting 
participant quotes and narratives, and are followed by summaries of identified implicit needs 
(Table 4.5, Appendix A). 
Theme 1: Sitting in the Driver’s Seat of Follow-up Care 
 The first theme represents how participants were forced to commit to direct their own 
post-treatment follow-up care. Participants described driving across the state, negotiating follow-
up terms with providers, and involving others in their journey. Additionally, participants 
described the time involved in going to follow-up appointments, the responsibility of 
coordinating their own care, and the implied signaling to family and friends when they needed 
help (Table 4.6, Appendix A). The following three recurrent subthemes supported theme 1: 
 Subtheme 1A – On the road again; 
 Subtheme 1B – I steer my care; and 
 Subtheme 1C – Hazards on for help. 
 Subtheme 1A – On the road again. Participants covered subtheme 1A when they talked 
about traveling across the state and the time involved in their follow-up activities. Many 
participants had to make one- or two-hour round-trip visits two or three times a year. Many 
traveled from East to Central Tennessee to see a melanoma specialist or visit a cancer center. 
While some participants, like Robyn (age 56) were lucky enough to have local providers, 
“appointments are 10 miles maybe round trip” this was not a common occurrence. Hayden (age 
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61) stated, “It takes about two hours to get… to the cancer clinic… so my mom drives.” Taylor 
(age 64) said, “Lots of driving is the problem,” while Greta (age 42) reported, “When I drive 
there (two hours to the photo dermatologist), my friends go too sometimes to have an excuse to 
go shopping with me.”  
 In addition to the miles driven for appointments and check-ups, participants expressed 
other implicit needs such as transportation to and from appointments, pain and symptom 
management, and overnight accommodations needed when tests were done one day and results 
given the next. Jeanie (age 58) said, “So, he [boyfriend] has been bringing me to the doctor, 
I’m… too nervous to drive right now.” Additionally, Jeanie, who did not have local access to 
pain and symptom management, added, “The nurse practitioner helped me when I was having so 
much pain, but I had to come and see her every month and so a two-hour drive.” Hayden (age 
61) said, “We got through it [by driving to the cancer center to see the nurse practitioner for pain 
medication monthly], but for a few months it drove me batty, and my mom would get real tired.” 
Daisy (age 26) reported, “We get to stay in the resource housing area, so that’s great, my Dad 
and [daughter] can stay, too.”  
 The amount time participants spent traveling across the state also was an important aspect 
of their follow-up experiences. Linda, (age 46), who had an eight-hour round trip, explained:  
After a year, the [surgical oncologist] moved her practice to [another major city in 
Central Tennessee two hours away] and so we go there now. I don’t want to see another 
surgeon and so we started going there, she knows me, so we go see her there. We usually 
try to stay overnight and visit friends sometimes. 
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Greta (age 42), reported, “He [photo dermatologist] said that I was very high risk, and that I 
would have to come every three months, and I’ve gone to him every three months now for 14 
years [a two-hour round trip].”  
 The time involved in each follow-up visit, also affected the participants. Griffin (age 49) 
reported, “I come and see the skin cancer doctor [medical oncologist] now every six months, 
some blood work and x-rays too.” Rosie (age 29) said, “I do feel like I’ll be seeing a 
dermatologist for the rest of my life… as far as [medical] oncology… I go once a year and then 
he said… after a couple of years of once a year if everything looks good, you know maybe we’ll 
touch base in a decade.” Greta (age 42) said, “I go every three months now, like clockwork to 
[Central Tennessee], to my melanoma guy [photo dermatologist] and that’s pretty much it.” 
Robyn (age 56) explained, “I had a sense this is gonna be the rest of my life, whether it’s semi-
annually or annually.” Often, post-treatment follow-up visits were more frequent and then 
tapered off, as reported by Taylor (age 64), “I was followed the first three months, you know, in 
the office, the doctor would see me for three months, uh, I think for about a year, and then I think 
they tapered off to six months, and then, once a year.” Similarly, Ethan (age 57) said. “It may 
have been more frequently in the beginning, but it became every six months and then every 
year.”  
 Follow-up visits could take half the day if something new was found or biopsies were 
required, as noted by Heidi (age 60), “I did have another place show up, but it was a different 
kind of skin cancer and he cut it out.” Robyn (age 56) noted, “Waiting to be seen… I don’t know 
if it’s that particular practice… or… just dermatology in general, oh my gosh, half a day’s 
adventure.” Participants also reported spending time making appointments for a new suspicious 
area and finding a new dermatologist when one left or they moved to another city. Ethan (age 56) 
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said, “Well, I’ve been through or seen a few dermatologists, they move and new ones start, this 
last one I have seen three times, and [it’s] hard sometimes to get an appointment if something 
comes up.” Some healthcare providers have advanced practice nurses who provide follow-up 
care and alternate seeing patients, as reported by Jeanie (age 58), “I see the skin cancer doctor 
[medical oncologist] or… the nurse practitioner every six months.” 
 Subtheme 1B – I steer my care. Subtheme 1B is the umbrella category that explains 
participant experiences related to coordinating or navigating follow-up care. Participants viewed 
roadblocks and delays as a necessary part of the healthcare process and would find ways to 
handle the problems that arose. For example, Ethan (age 57) said, “Nobody recommends it 
[yearly follow-up with a dermatologist, because the dermatologist told him that he could follow-
up yearly with his primary care and primary care does not look at his skin] but I do it anyway,” 
while Greta (age 42) emphasized, “I got an appointment and I keep everyone”. Participants’ 
strong commitment to follow-up was evident. Robyn (age 56) stated, “I have to force myself to 
make appointments, those aren’t appointments that are set up for me, those are appointments I 
have to make…,” while Darron (age 61) said, “I mean… it’s got to start from the…patient.” 
Individual responsibility played a key role in guiding follow-up, as Darron (age 61) noted, “I 
think that… it’s the patient’s… responsibility to identify the areas and then seek… the help… for 
getting it done.” Clifton (age 60) noted, “In the service, things work slow, but eventually it all 
gets done. I retired after 25 years in the military two years ago and I still have been following up 
in the same manner.” Self-directed care included asking questions and being informed, as 
illustrated by Rosie’s (age 29) comments, “New research came out and showed that the 
bloodwork actually wasn’t helpful, and so we stopped doing that, then I said… I don’t really 
want to keep getting chest x-rays.” 
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 Subtheme 1C – Hazards on for help. Subtheme 1C reflected the survivors’ implicit 
need for help following treatment. The participants did not ask for help, but communicated their 
life events with family, friends, and others (including fellow church members) who would 
organize and provide what the individual or their family might need. Individuals in the 
healthcare field might help a survivor by calling or texting a provider to get assistance in the 
form of a providing advice or scheduling an appointment. For example, Linda (age 46) reported, 
“A few times when my husband was so nervous [about a new area], he took me to the doctor’s 
office without an appointment, and the dermatologist worked me in.” Participants found talking 
with someone else with melanoma was helpful, as relayed by Clifton (age 60), “She had 
melanoma, too and that was very helpful, I don’t know how, but maybe… talking to others out 
there that have been through it.” The implicit need for transportation by participants who lacked 
an automobile or were unable to drive was noted by Jeanie (age 58) who said, “I have to get to 
[the cancer center in] Central Tennessee every time… and wait for medicine, and have someone 
drive me home”.  
 Participants’ assumptions about sun effects and family activities showed their implicit 
need for more information on the subject. Linda (age 46) said, “I think it’s too much staying 
inside, but after what I put [my husband] through, we stick to shade and inside.” Sometimes 
participants talked about the implicit need for companionship during long car rides. Greta (age 
42) said, “Everybody’s always been real supportive, ride with me for two hours there ‘cause it’s 
so boring every three months.” Family, friends, and healthcare professionals were helpful 
starting with the diagnosis and treatment periods and continuing into the post-treatment period. 
Daisy (age 26) noted, “My aunt has been the best help, especially my dad too.” The implicit need 
for help with meals and pet care during follow-up visits also was described by Linda, “My 
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friends at church were extremely helpful with fixing meals and helping with my dogs, I have two 
large poodles that needed some attention with me gone sometimes.”  
 Even tough love was appreciated, as noted by Robyn (age 45), “My family, you know are 
helpful, you could have your arm chopped off and they would say like, well, buck up.” 
Participants also discussed getting help with day-to-day issues such as putting on leg stockings 
and handling work pressure. Hayden (age 61), said “My mom helps me get it on (fitted stocking 
for lymphedema),” while Griffin (age 49) noted, “My work, too, they just said take as much time 
as you need.” Family and friends also helped with follow-up visit and sunscreen reminders. 
Robyn (age 56) reported, “My eldest daughter will say, okay, isn’t that about time for that check-
up?” and Heidi (age 61) noted, “I do have friends who every… three or four months… say ‘so 
have you gone back for your follow-up, yet?’” Ethan (age 57) said, “My wife is… kind enough 
to remind me that I need to use it [sunscreen].” Participants also needed financial help in many 
forms. For example, Hayden (age 61) reported, “Now I’m on disability with some income, um 
but the first two years I had to keep asking people to pay for gas.” Daisy (age 26) noted, “The 
social worker helps us stay nearby when I come to town.” Participants who, like Hayden (age 
61), cared for family members also needed help, “When we would be gone all day, nobody was 
with my dad, so sometimes the neighbor or people from church looked after him.” 
 Summary of implicit needs. The implicit needs communicated by this study’s 
participants inform several important aspects of melanoma surveillance. One need is to provide 
local resources for melanoma survivors who now have to travel across the state to obtain post-
treatment care. The PI also noted an important omission: most participants were not given a 
specific survivorship care plan linking them with cancer resources. While the need for regular, 
complete skin exams is important, linking survivors with providers is equally important to ensure 
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they are reassessed periodically for cancer risk, reevaluated after any updated family history, and 
monitored for ongoing post-treatment effects like lymphedema, chronic pain, depression, 
anxiety, or a change in social resources. The PI also uncovered participants’ implicit need to 
involve their family and friends in their journey. Finally, participants had an implicit need for 
their healthcare providers to be aware of the role Appalachian culture plays in their care. The 
need included and how that culture may differ from the provider’s culture, especially if care is 
provided outside a participant’s local community. 
Theme 2: Living in a Skin World  
 The amount of information available to participants and the public regarding the risk 
factors for developing melanoma or a recurrence can make the disease seem like a secret ailment. 
One participant even commented that “melanoma is secret,” illustrating the implicit need to share 
such information with others because his melanoma developed in an area unexposed to the sun. 
Additionally, participants said they and others avoid using the “C word” (cancer) when 
discussing melanoma, instead referring to it as a spot, bump, or skin lesion, almost as a form of 
covert language. The conflict created from having just enough information to understand the 
serious nature of melanoma, while simultaneously minimizing this seriousness caused some 
confusion among participants. Throughout the interviews, participants communicated their 
implicit need to receive more information about their disease from their healthcare providers. 
Most participants had post-treatment follow-up in dermatology offices, while those with more 
advanced disease had to be seen by melanoma experts in medical and surgical oncology practices 
(Table 4.7, Appendix A). The following three subthemes supported theme 2:  
 Subtheme 2A – Melanoma is not a secret; 
 Subtheme 2B – Call it cancer; and 
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 Subtheme 2C – Defer to dermatology. 
 Subtheme 2A – Melanoma is not a secret.  Subtheme 2A covers how participants spoke 
about their understanding of melanoma-related information and risk factors. Heidi (age 60) 
commented on how melanoma can be unrelated to sun exposure, “There was one [suspicious 
area] that came up on my stomach that hadn’t seen the sun in 20 years.” One participant spoke 
about melanoma as separate from skin cancer and not in the cancer family, “Melanoma is a 
secret sometimes… when you hear about skin cancer, it’s about the sun and getting old and all.” 
Arlene (age 43) made the same point and touched on the public’s lack of knowledge about the 
disease, “I would say the average person does not realize that it’s a soft tissue disease, and it’s 
not just on your skin, and it’s not just from being in the sun. Mine was on my lower back that 
was as white as white could be.” Similarly, Taylor (age 64) said, “half of it is your heritage; it’s 
not all the sun.” Hayden (age 61) also spoke of the need for more information, “People with 
melanoma need to know about other types of it, just wish I had more to say about it, but anyway, 
maybe this will help…” 
 One aspect of the treatment period that affected participants’ post-treatment experiences 
was scarring. For some participants, the visible reminder of their experiences became show and 
tell sessions during interviews. Many participants spoke about their physical scars from 
treatment and the pain they have caused. While some participants wanted to conceal them, most 
wanted to talk about their scars as well as the dipping tissue deformities left after surgery. Many 
participants reported that their scars were painful and felt numb at the same time, while others 
described the feeling as an annoying sensation. Those with permanent swelling or lymphedema 
described pain that ran down the extremity making the area very touch sensitive. Areas where 
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skin was removed for grafts also left scars and areas of decreased sensation and/or 
hypersensitivity.  
While participants were told what to expect after surgery, including how the incision 
would look, they were not shown before and after pictures as examples. Participants described 
their scarring in different ways. After pulling up his shirt to show his scar, Ethan (age 57) said, “I 
guess he had to kind of make a big pork chop out of my back.” Rosie (age 29) pointed to her 
chest just below the scapula and reported, “It was probably like, maybe four or five inches 
wide.”  
In addition to scarring from excision, participants also mentioned skin graft scars and the 
unexpected pain from the dye tracer used to check for melanoma in the lymph nodes. Arlene 
(age 43) said of her scar, “It looks like they… took my kidney out and took about seven inches 
off my back um, but… that wasn’t the worst part. The dye tracer… was probably the worst thing 
that I initially experienced because they can’t give you anything for it, and they do… four shots 
of dye around your cancer spot.” Linda (age 46), relayed that “[the surgical oncologist] took 
some skin from my thigh, which was really painful after surgery, worse than anything, and now 
it looks like I have alligator skin”. 
 Several other aspects of melanoma miscommunication also were discussed: surgery as 
treatment, treatments for recurrences, and the role of clinical trials. For example, Ethan (age 57) 
noted, “There were two surgeries but… no real treatment.” Karen (age 65), who was followed 
for 29 years by her primary care provider, reported, “There was no chemo available… 
specifically for melanoma and radiation wasn’t called for back then… they were just gonna’ 
watch me because no other treatments were available… I had one positive lymph node, then the 
second one [recurrence] was just here recently…” Arlene (age 43) noted, “I could not believe it, 
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of all the things to be told, that you have melanoma and a surgeon would have to remove the area 
and make sure it stays away.”  
 Subtheme 2B – Call it cancer. Subtheme 2B incorporates how participants viewed 
communication about melanoma as a “real” cancer. Participants described family and friends 
implying that melanoma may not be one of the real cancers like breast or colon cancer. Many 
participants were familiar with these other cancers from experiences with family and friends. The 
implication was that unless they are undergoing major surgery and weeks or months of 
chemotherapy or radiation, their melanoma is not really cancer. Taylor (age 64) stated, “I think 
of colon cancer as cancer.” Robyn (age 56) elaborated, “It’s funny, I don’t really think of it 
[melanoma] as cancer like breast cancer or like my dad has lung cancer now… I guess because 
you know he [my dad] went for radiation and chemo from lung cancer, and then with breast 
cancer my friend… had a full double mastectomy. I mean I think of those things of cancer… and 
I… thought of this [area on her nose] as…I have this spot, or these spots.” 
Participants described these cancer-labeling experiences in different ways. Darron (age 
61) said, “Melanoma or skin cancer seemed to be… you just go in there have it removed… I 
look at…this little bit of skin cancer [scar from melanoma removal] on the skin, I don’t call that 
melanoma.” Robyn (age 56), noted, “It always jogs my memory… when you fill out any history 
[form] and they say, check this box if… you had cancer, and I have to remind myself to check 
Yes… [my friends say]… you have cancer, and I’m like, I had a spot on my nose, so again, a 
little bit…of the denial…” Taylor (age 64) emphasized the seriousness of the diagnosis, “It 
was… not… you have skin cancer… it was more, you (pause) Have (pause) Skin (pause) 
Cancer.”  
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 Participants shared experiences in which healthcare providers minimized the seriousness 
of melanoma recurrence or surveillance. For example, Rosie (age 29) said, “The surgeon 
[surgical oncologist] said it’s no big deal. We’re gonna’ take care of it, and it’s gonna’ be done.” 
Heidi (age 60) noted, “One time, they [the photo dermatologist and office nurse] saw something 
that changed, and they didn’t tell me they were concerned, and they cut it off and they were 
worried about it, but it came back fine.” Ethan (age 57) said, “Some [dermatologists] have been 
good, the one I have now is ah, one of those who just wants to get you in and out just as quickly 
as possible.” 
 One participant described her melanoma experience as a spiritual journey. During the 
interview with Arlene (age 43), it seemed for a moment that we were not talking about 
melanoma, but rather a personal growth experience.  
 I think cancer for me was something that was always, I wonder if I’ll  
 ever get it? And I did, and I’ve survived and… it continued… my  
 relationship with God a lot… and so I just… don’t see it as a bad  
 thing. I see it as something that was really scary, but… I met a  
 lot of really great people… I did a lot of personal growth in it, and  
 so, I wouldn’t wish it on anybody because I don’t know what the future  
 is, but… I learned a lot.  
Some participants looked at having melanoma from the practical perspective of educating other 
types of healthcare providers. After her dermatologist told her to tell the gynecologist what to 
look for, Rosie (age 29) said, “I never thought about [how] you should tell your gynecologist to 
check for melanoma, so that when they do your pap smear, they can look for spots on your 
cervix.” Similarly, Arlene (age 43) noted that when her surgical oncologist told her what to have 
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the dentist to look for, “I did share it with my dentist, and so he does track it when he does my 
exams, he looks for spots.” 
 Leaving the words cancer and melanoma completely out of the narrative worked for 
Robyn (age 56),  
… I don’t call it cancer. I don’t call it melanoma. I will say… I had something removed. 
Someone will say, ‘Oh, I went to the dermatologist and, oh my gosh, I had this spot 
removed’ and I’ll say yes, when I went, oh my gosh, I found out I had to have all these 
things removed. I don’t… really say I had melanoma… I’ll say well it turned out I had a 
skin issue. 
Subtheme 2C – Defer to dermatology. Subtheme 2C refers to participant experiences of 
being referred to a dermatologist by primary or specialty care providers for any suspicious or 
unusual skin lesions. Arlene (age 43) said, “Anything that looks funny, we biopsy immediately.” 
Robyn (age 56) noted, “She (dermatologist) just wanted to take ‘em [abnormal looking moles] 
off.” Similarly, Greta (age 43) said, “I knew they’d have to be cut off.”  
 Often the dermatologist defined the follow-up process for the participant after treatment. 
Greta (age 43) reported, “The dermatologist let me know about follow-up, I then had a sense that 
this is gonna’ be the rest of my life.” Robyn noted that melanoma follow-up visits are treated like 
any other appointment, “It’s just like any other office visit, it’s not a special like whoa, you get 
the special VIP treatment… It’s go and sit in the waiting room for hours on end.” Heidi (age 60) 
emphasized the amount of time involved, “You might as well block out your day. I mean, it… 
doesn’t matter what time of day I’m there (dermatology), it seems like if I go for a 9 am 
appointment, I’m finally out by 1:30 pm.”  
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 A few participants talked about the stressful experience of anticipating a biopsy or 
excision. For example, Robyn (age 56) said, “I know every time I go back… it’s gonna hurt… 
it’s not like she’s happy to cut me… but it’s just… [that] I know every time I go, I’m gonna have 
stitches.” Jeanie (age 58) reported, “My dermatologist checks my skin extra careful now, and I 
worry about another biopsy, they hurt, and I get real nervous.”  
  Generally, primary care providers refer patients to the dermatologist for melanoma 
follow-up. Darron (age 61) said, “she’ll [primary care provider] say something like, so are you 
going back to see the dermatologist? I mean she’ll kind of do an inquiry about when I go.” 
Griffin (age 49) reported, “I told my doctor about it [a new area of concern] and he sent me to a 
dermatologist to take it off, and see if some of the other areas on my back needed attention.” 
Taylor (age 64) noted, “The dermatologist sometimes checks it [skin]… [and] asks if I have any 
new moles.”  
 The type of exam done in the dermatologists’ office varied among participants. Taylor 
(age 64) reported, “The dermatologist looks at my arms and face, and asks if I have any 
problems, stuff like that.” Arlene (age 43) noted, “Anytime I see the dermatologist, I just ask, is 
there anything you want to cut off?” Greta was committed to her follow-up, emphasizing, “I just 
religiously go to him.” 
 Summary of implicit needs. One implicit need identified from the data was for timely 
information, preferably face to face or via phone conversation when getting biopsy results. 
Additionally, participants needed information about long-term treatment effects and access to 
resources for managing physical complaints such as lymphedema and chronic pain. Participants 
also indicated that they have benefited from talking and sharing stories with other survivors who 
have had similar experiences.  
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Theme 3: Once Bitten Twice Shy  
 Participants explained that all new suspicious areas on their skin resulted in anxiety and 
the implicit need to have them evaluated quickly—waiting was not an option. The Chinese 
proverb about a person who has been bitten by a snake feeling suspicious, even when seeing a 
piece of rope (Oxford Dictionary of Proverbs, 2015) depicts the essence of this theme; however, 
the American version seemed more appropriate for this research section. Participants found 
strength within themselves and by sharing with others. This process, which began in the 
diagnosis and treatment periods and continued post-treatment, gave participants a sense of hope 
and camaraderie that helped them get through the rough periods (Table 4.8, Appendix A). The 
following three subthemes provided a way to think about these experiences: 
 Subtheme 3A – Waiting is not an option;  
 Subtheme 3B – Everything looks like melanoma; and 
 Subtheme 3C – Sources of strength. 
 Subtheme 3A – Waiting is not an option. Subtheme 3A pertains to participants already 
being aware of a suspicious lesion at the time they were told it should be removed. Participants 
recalled that their primary care provider or dermatologist watched the lesion change, but most 
did not remember being told that the area could be or become melanoma. Due to guilt at having 
waited before their initial diagnoses and/or the desire to take better care of themselves in the 
future, most participants were determined not to wait when they found another suspicious lesion. 
Worry, anxiety, and distress about possible recurrence played a role in their sense of urgency. 
Arlene (age 43) said, “I noticed a new mole that I thought looked darker.” Darron (age 61) also 
noted, “Right now… I’ve got a couple spots that need to get checked.” Robyn (age 56) noted, 
“Something came up on my face, over here by my cheek.” Griffin (age 49) reported, “Something 
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new showed up a couple of years ago, and my wife said, ‘We are not waiting.’” Arlene (age 43) 
told her dermatologist, “If you think it could turn, take it now!” Any suspicious area felt like a 
threat until the results were known. Although not explicitly termed ‘I did self-skin 
examinations’, the participants reported examining their skin or designating a spouse or close 
friend to do so. Most participants could identify areas of concern or areas that were recently 
removed.  
 Subtheme 3B – Everything looks like melanoma.  Subtheme 3B reflects the participant 
experience of feeling that any new suspicious area could be a melanoma recurrence. Because the 
suspicious areas looked either similar or different from the original melanoma, each participant 
had to make a decision based on their previous experiences. Heidi (age 60) noted, “I thought it 
looked the same,” while Jeannie (age 58) said, “I wanted to go, but was scared it was melanoma 
again.” Robyn (age 56) reported, “Another new area resulted in a frenzy to get someone to 
address it.” For example, Greta (age 42) said she had “a few things removed, but no more 
melanoma… he’ll see me the next day and cut it off.”  
 Subtheme 3C – Sources of strength. Subtheme 3C represents participants developing 
skills to cope with melanoma and continue to live their lives. The sources of strength were 
relationships with family, friends, and the community within the Appalachian culture. Many 
participants found strength in talking with other melanoma survivors. Clifton appreciated being 
able to “talk to other people with melanoma,” while Jeanie (age 58) noted, “It was helpful talking 
with someone with melanoma in the hospital.” Faith also was a source of strength for some 
participants. Karen (age 65) emphasized, “My faith has been a constant, my friends have prayed, 
I prayed, my husband has prayed… double.” Karen also demonstrated optimism, “It wasn’t a 
death sentence at this point,” while Greta (age 42) said, “I hope I don’t die.”  
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 Summary of implicit needs.  Participants explained that all new areas resulted in anxiety 
and the implicit need to have them evaluated quickly without waiting. Like the Chinese proverb, 
once melanoma survivors were bitten by the disease, they were suspicious of any area that could 
be a recurrence. The participants’ sources of strength—including family, friends, and their 
community—were able to meet many immediate needs. This source of strength may be 
connected to the Appalachian culture of close-knit bonds and the tendency not to ask for help 
from outsiders.  
Theme 4: Watch Me like a Hawk  
 Participants responded to interview questions about their physical exam experiences with 
dermatology, primary care, and specialty providers. They described in detail experiences in 
which healthcare providers gave them reassurances to help ease their worry or anxiety. In fact, 
participants often sought out providers who empowered them and gave them confidence. The 
participants also shared their experiences during uncertain times when they were worried about 
melanoma coming back, having more surgery, needing new treatments, and dealing with life-
long issues as they age. This theme incorporates participants’ expectations going forward as they 
continue living with melanoma (Table 4.9, Appendix A). The following subthemes supported 
theme 4: 
 Subtheme 4A – Follow-up visits; 
 Subtheme 4B – Reassurance offered; and 
 Subtheme 4C – Uncertain times. 
 Subtheme 4A – Follow-up visits. Subtheme 4A highlights specific visit details of 
participants’ primary care, dermatology, specialty, and cancer care visits. Participants described 
what was done during visits when providers were aware of their melanoma history. While these 
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findings suggest that most of the participants’ routine follow-up checks were conducted by 
dermatologists, the participants implicitly expected all providers to be able to identify anything 
that looked like a recurrence or validate they did not have one. Overall, participants were 
healthy, had little comorbidity, and were not on routine medications. Participants indicated that 
they see few if any specialists who would be assessing them regularly besides dermatologists. 
Melanoma follow-up was crucial for these participants, as they acknowledged that any 
symptoms they have could be related to melanoma and would need to be ruled out as such before 
being treated. Most primary care providers have not been trained in cancer surveillance, and 
therefore generally do not provide this type of care to other cancer survivors. Taylor (age 64) 
was one of the few participants reporting that his primary provider does a more comprehensive 
yearly exam, “I see the primary doctor [at a clinic] once a year for blood work, chest x-ray. [He] 
listens to my lungs, checks everything out, checks my blood pressure, you know, the drill. In the 
primary clinic they do check the lymph nodes in my neck and armpit.”  
Most participants do not put on a gown for either their primary care or dermatology 
office visits. From the participant’s point-of-view, wearing a gown signals a more thorough 
examination by a clinician. In addition, from a practical perspective, having a patient put on a 
gown for a complete skin examination adds approximately 20 minutes to the visit, while primary 
care visits in a busy clinic are scheduled every 10 to 15 minutes. A skin exam can be done by 
lifting clothes, an approach more fitting a post-operative check. For the participants, their 
melanoma journey started with their skin and therefore it makes sense to continue with their skin, 
while most know the disease goes beyond it. Providers generally did not discuss their decision-
making process in determining which type of examination to perform. Participants described 
their primary care provider office visit experiences. Heidi (age 60) noted, “All the doctors say 
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the same thing, you go to him [dermatologist], why would I look [at your skin]?” When asked if 
his primary care provider had him put on a gown for a skin check, Ethan (age 57) said, “Not 
routinely, that’… something they only do at… annual checkups. But I haven’t had one in two or 
three years.” Griffin (age 49) reported, “He listens to me with the stethoscope, front and back, 
listens to my gut, listens to my neck, checks my blood pressure, [does] lab work, then I’m done.” 
Linda (age 46) stated, “I don’t put on a gown when I see my PCP and usually that 
appointment is pretty quick, I’ve changed a few times.” While smiling at me and pointing to his 
cheek, Randall (age 94) said, “When I see my primary doctor, I do not put a gown on, the 
melanoma was on my cheek.” In contrast, Arlene (age 43) remarked, “I put a gown on for 
everybody except my eye doctors, so anyone who would look at a part… I’m at least half-naked, 
if not fully, and they all look for cancer… I am just naked all the time now, I do put on a gown 
and she checks me.” Darron (age 61) noted, “No… the primary doesn’t [have me put on a 
gown]… which it kind of surprises me that… the primary doesn’t do an assessment for… skin.” 
Robyn (age 56) said, “I did see my primary care provider right after it was diagnosed, but no 
taking off… my clothes or putting on a gown in… their office, no that wouldn’t be appropriate 
for why I was there.”  
 Participants also described physical exams performed by their dermatologist, the provider 
participants viewed as the front line in recurrence prevention. Heidi (age 60) described her visits, 
“My dermatologist checks my skin extra careful now, and I am always asking about this, and I 
have had a few more things removed but no cancer, thank goodness.” Sometimes the visits are 
short, as Taylor (age 64) reported, “The dermatologist looks at my arms and face, and asks if I 
have any problems, stuff like that.” Griffin (age 49) said, “The dermatologist checks my skin, 
asks if anything new has shown up, [and] I have had small things removed from my back, but all 
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have been benign.” Taylor (age 64), who sees a local dermatologist while his wife wants him to 
see a one an hour away, said, “There’s nothing anybody can do except what he does, which is 
just look at ‘em.” Greta (age 42), who sees a photo dermatologist and has exams that can last up 
to an hour, stated, “I said this is not the photoshoot that I was looking forward to (laughing), and 
then he takes… pictures of everything the first time, and… he compares them every time.” 
 Of her visits to the gynecologist, Greta (age 42) said, “My gynecologist checks 
everything… I mean everything; she always has including lymph nodes under my arms and 
groin.” Arlene (age 43) also spoke of her gynecologist visits, “He has to check for stuff in places 
that my surgeon doesn’t feel he needs to check every time, and he encourages me to have him 
check all those places.” In contrast, Robyn (age 56) reported, “No skin checks, she 
(gynecologist) doesn’t do anything that’s not specific to why I’m there to see her.”  
 Surgical oncologists also see patients for follow-up, as noted by Linda (age 46), “He 
[surgical oncologist] checks lymph nodes under my arms and in my groin.” Griffin (age 49) 
stated, “I put a gown on and you know the typical cancer questions, and then they check my skin 
and ask me if I’m having any symptoms. My lymph nodes are always checked all the time.” 
Hayden (age 61) said, “Yes, they look at my skin and feel and check my lymph nodes under my 
arms and groin area too, they check both.” Arlene (age 43) appreciated her provider’s 
responsiveness, “I mean the doctor’s amazing, seriously… like when I texted this week and I had 
something else that I found… he just said come in Monday.”  
 Subtheme 4B – Reassurance offered.  Subtheme 4B serves as the label for participant 
experiences in communicating with their healthcare providers and clinicians. Reassurance is a 
therapeutic intervention that has origins in the field of medicine. Reassurance can be defined as a 
statement or comment than removes someone’s doubts or fears and has the intent to help another 
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feel less worried or anxious. Participants implicitly reported positive experiences when they 
received information from professionals who were confident about melanoma recurrence 
monitoring. Many participants received reassurance from their providers. For example, Heidi’s 
dermatologist told her, “You know this one on your stomach looks kind of weird, it’s probably 
nothing.” Rosie (age 29) reported, “I went to a new dermatologist, and she kind of opened my 
eyes to some other things, she said… not only should you be wearing sunscreen, you really 
shouldn’t be in the sun at all.” Jeanie (age 58) stated, “The surgeon [surgical oncologist] said I 
would be okay once we get it out. Glad for that, but it came back again, not so glad.” Greta, (age 
42) said, “Every now and then my primary care provider will say… he thinks I need to have PET 
scan, and then my [photo dermatologist] always disagrees.” Speaking of his primary care 
provider, Ethan (age 57) stated, “He was surprised, it seemed. He looked at the area on my back 
and asked if someone was following me for that.” Arlene (age 43) spoke at length about the 
assurance she received: 
He [surgical oncologist]… was just amazing… very… caring, very… personable, and 
was very reassuring, and wanted to make sure at every step of the way that I knew 
exactly what he was doing, and what he was saying. And so he clarified, clarified, 
clarified. Yeah, I can’t actually imagine not going to see him, too [surgical oncologist], 
because actually, [I] feel like when I’m seeing him, I don’t have cancer. They [PCP, 
surgical oncologist, medical oncologist, and dermatologist] all knew [about each other 
and that I had melanoma]… they all communicate; they are one big, happy, faxing-each-
other family.  
 The participants also spoke about the reassurance they received from office nurses and 
radiological staff. Arlene (age 43) described, “They explained to me the whole time what was 
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happening um, so that was very humbling because even while I was there, I knew that other 
people went through this and that was hard… I was very appreciative of his nursing staff to 
really walk me through.” Friends and family also offered words of encouragement, as that noted 
by Taylor (age 64), “My sister was telling me that all would be fine, and that’s the way things 
went.”  
 Of his surgical oncologist, Ethan (age 57) said, “He was gonna take care of it, so I 
thought okay, he’s gonna take care of it.” Arlene (age 43) commented,  
The surgeon [surgical oncologist] was very precise about making sure I understood about 
melanoma and how serious it could be. He told me that I would need to be followed after 
treatment regularly. As I recall, that was the bottom line, he wanted me to know exactly 
what was happening at all points, and he does that ‘till this day. 
For some participants, the precedent set during the diagnosis and treatment periods extended into 
post-treatment as well. For example, Arlene (age 43) emphasized, “It was very reassuring and… 
empowering ‘cause…I didn’t feel like oh, I don’t know what this is, or what does this mean, and 
he still treats every visit like that.”  
 Subtheme 4C – Uncertain times. Subtheme 4C describes participant comments related 
to insecurity and worry about recurrence. Many participants offered suggestions to other 
melanoma survivors based on their own experiences. For example, Darron (age 61) advised, 
“Make sure you go to the best dermatologist you can find… continuity is important, so if you can 
stay with the same provider and you like that person, then you should do that” Arlene (age 43) 
emphasized, “It’s your body, if you care about it, you fight for it, don’t wait for someone else to 
fight for it.” Greta (age 42) said, “If I had quit following up, then I’d have a metastatic 
melanoma, and I might… not be here now.”  
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 About a suspicious area that turned out not to be melanoma, Arlene said “I was safe with 
that, because I knew that if he did it, he would do it like a melanoma cut, and I would never have 
to worry about that spot again.” Clifton (age 60) reported,  
Recently, they found new areas in my lungs and brain… No problems for 18 years, I 
have… stayed in shape, healthy. Then they saw something new on the chest x-ray, and 
that started this ball rolling. No symptoms, no symptoms at all. That’s the unbelievable 
part, really [sigh]. I am going to Bethesda to participate in a clinical trial.  
Robyn (age 56) advised, “Force yourself to make the appointment, force yourself to stay on top 
of it because had I… not had…what I think… is that God moment, that guardian angel, that 
discussion with my friend, had we not been talking about that, I probably still wouldn’t have 
gone.”  
 Summary of implicit needs. Participants need access to local resources that can help 
with overall long-term melanoma effects and related psychosocial issues. Survivors need 
assurance and access to local primary care providers and cancer specialists to coordinate their 
melanoma surveillance plans. Moreover, they also need a more streamlined appointment follow-
up system and access to current, relevant melanoma resources for recurrences. Additional 
information regarding the specifics of self-skin examination as well as the appropriate roles in 
melanoma surveillance of the dermatologist, primary care physician, and other specialists also 
would be helpful. 
Chapter Summary 
 The four themes and accompanying subthemes that emerged from data analysis are 
important findings. Noteworthy experiences included the need to drive across the state for 
follow-up appointments. Another finding was that dermatology served as the front line for 
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melanoma follow-up, with very little coordination with cancer surveillance plans or resources. 
Primary care played a small role in melanoma follow-up, with providers deferring skin exams 
and recurrence monitoring to dermatology. Inconsistent monitoring of melanoma surveillance 
increased the burden for survivors who many not have the resources to continue traveling for 
follow-up access.  
 The Appalachian culture seemed to influence the way some participants responded to 
interview questions. These survivors are self-sufficient, self-directed individuals who rely on 
family, friends, and community resources for transportation needs, meals, and help with family 
obligations. Often the help provided to meet essential needs was unsolicited and came from a 
robust support system. Most participants experienced post-treatment follow-up in dermatology 
offices, while participants with advanced disease required melanoma experts in medical and 
surgical oncology practices. 
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Chapter Five: Discussion 
 Sixteen melanoma survivors living in the ETAR shared their health-related experiences 
that occurred during the diagnosis, treatment, and follow-up periods of their cancer journeys. 
Interestingly, the post-treatment needs were not explicitly shared in the interviews, but rather 
implied from participant discussions. In this chapter, findings are compared and contrasted to 
those of other melanoma survivorship studies, and implications from the Appalachian kinship 
and social literature are discussed. Implications are presented for registered and advanced 
practice nurses, nursing education, primary care, dermatology, and cancer specialist providers 
working with melanoma survivors in Eastern Tennessee and surrounding regions. Healthcare 
policy and research suggestions also are presented.   
Toward An Interpretive Explanation 
 This study’s research question was What are the post-treatment health-related 
experiences and needs of melanoma survivors living in the ETAR? While further analyzing the 
data, the PI sought interpretive explanations of the whole while continuously looking back as the 
individual participant data. Interpretive explanation is the “most fully integrated of qualitative 
analytic products” (Thorne, 2008, p. 165). The goal of an interpretive explanation is to “create a 
thematic structure for showcasing the main elements of a phenomenon in relationship with one 
another, if not within a conceptual or thematic schema” (Thorne, 2008, p. 164). The connections 
and linkages constructed from this study’s data—the interpretive explanations—provide new 
knowledge that helps advance this field of study.  
 For this study, the current literature related to melanoma survivors’ post-treatment 
experiences and needs was divided in three areas: research related to QOL measures, 
psychological impacts, and health and well-being practices. The post-treatment health-related 
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experiences and needs of melanoma survivors from the ETAR share some similarities with 
melanoma survivors in the U.S. Pacific Northwest, Texas Panhandle, and Northeast regions. 
Common experiences between this study’s participants and other U.S. survivors included sun-
protections behaviors, satisfaction with providers, worry about recurrence, and psychosocial 
factors (more common among younger survivors and those with limited financial resources). 
Additionally, melanoma survivors in this study share several commonalities with those from the 
UK, Australia, Germany, Netherlands, Ireland, and Canada: sun-protection behaviors, anxiety, 
and feelings of uncertainty.  
 The ETAR melanoma survivors used self-directed behaviors to coordinate their own 
follow-up treatment without a specific surveillance plan. Many of these participants travel 
numerous miles for the assurance their providers and clinicians provide. Their knowledge about 
melanoma and commitment to stay cancer free keep them coming back. While the uncertainty 
the participants experienced is similar to that of sufferers of other systemic cancers, melanoma 
survivors are not followed within the cancer healthcare system unless they have advanced stage 
disease. The threat of recurrence caused some participants to experience ongoing stress and 
anxiety, which lead to urgency when new suspicious areas developed. They managed these 
situations by receiving care that was self-directed or coordinated by a designated person, and 
being determined to stay ahead of the disease through frequent follow-up, travel to experts across 
the state, and/or finding a support group where they could be seen and heard. The four major 
themes identified in this study provide an organized way to discuss the findings and the 
melanoma survivorship literature about health-related experiences, post-treatment needs, and 
Appalachian cultural influences. 
 
95 
 
Theme 1: Sitting in the Driver’s Seat of Follow-up Care 
 From the ETAR, participants drove across the state to follow-up visits in Central 
Tennessee and locations in between. The terrain across Tennessee involves major highways as 
well as many small cities and rural towns. Once melanoma survivors established a relationship 
with a provider during either the diagnosis or the treatment periods, those bonds remained. Even 
if a practice moves, survivors generally will continue to follow-up the same provider. From the 
interviews, the PI concluded that the survivor-provider relationship usually is survivor-directed 
and collaborative. This commitment to guide their own follow-up care is driven by several 
factors within participants’ narratives. Survivors wanted to continue partnerships with providers 
who adhered to a realistic and confident assurance that they would take care of the survivor, 
provided direction about care, and/or kept them informed. Survivors’ care management extended 
to coordinating any needs including transportation to appointments along with help from family 
and friends and when choosing which providers— local or distant—to see. In one Australian 
study, Morton (2013) briefly mentioned participants reporting “inconvenience of travel.” 
However, these participants had a more advanced disease stage than the study participants 
discussed in chapter four making travel very difficult and confounding.  
 In addition to travel, many participants mentioned the amount of time they spent in office 
visits. A dermatologist visit could take a whole morning or afternoon and require work release. A 
medical or surgical oncologist visit with labs or scans could take two days to complete. Often 
family and friends would drive and/or accompany participants depending on resources like 
owning a car or having gas money for the trip. Participants did not report traveling to any visit 
alone. As seen in typical close-knit family relationships in Appalachia, support for the participant 
included accompanying them on the trip, and depending on participant resources, making a day 
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of it by stopping to visit, shop, or have a picnic. Only two participants said they would not travel 
to see the doctor when a local doctor could do the job. In their literature review, researchers 
Murchie and Delaney (2010) noted that melanoma survivors appreciated a less rushed 
appointment that included a more thorough examination. However, that study involved 
melanoma survivors who saw either a primary care provider who had received additional 
melanoma surveillance education or a melanoma specialist for post-treatment follow-up.  
 The personal and social support expressed from participants was familiar within the 
Appalachian culture discussed earlier. Abramson & Haskell (2006) discuss the rural Appalachian 
people who refer to their family members and neighbors as kin. Communities within close 
proximity to one another support each other during illness and turmoil (Biggers, J., 2006). 
Extended family living locally or those moved out of the Tennessee Appalachian region return to 
provide support depending on the need.  
Theme 2: Living in a Skin World 
 This study’s participants often avoided using the word “cancer” when communicating 
with friends and family members. Many also avoided having serious conversations about 
melanoma with their family members, especially their children because the stigma related to 
cancer and dying. While more than half of the participants reported having family members with 
cancer, many did not know if they had a family member who died from melanoma. Some 
participants expressed that they had melanoma, a cancer that can spread anywhere, anytime, and 
then talked about what they have done to avoid recurrence. Participants did not offer reasons for 
not referring to melanoma as cancer, but the choice seemed to be a culturally influenced behavior 
to keep some health issues private. Although some participants did not grow up in the 
Appalachian region but migrated there, the area’s customs may have influenced them. While 
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Palesh et al. (2014) reported that melanoma survivors from Northern California did not discuss 
ways to reduce recurrence with family or friends but they did not specifically mention avoidance 
of the word cancer. 
 Participants described avoiding the word cancer when they spoke about whether 
melanoma was considered a real cancer. Some participants reported that they and their family 
members did not consider melanoma a real cancer such as colon or breast cancer. The rationale 
given by participants was that colon or breast cancer involves a large surgery and weeks or 
months of chemotherapy or radiation, as well as the symptoms associated with these treatments. 
McLoone et al. (2012) reported that many of the Australian melanoma survivors in their study 
did not see themselves as cancer survivors because melanoma is visible and can be detected and 
cured at an early stage.  
 Two participants traveled up to two hours round trip to the regional cancer center for pain 
management because local facilities or providers were unavailable. Only one study in the 
literature specifically addressed pain management for melanoma survivor’s post-treatment. Kuo 
et al. (2012) investigated physical scars and pain in 19 melanoma outpatient clinics in the UK. 
This study is an example of the implicit identification of needs in the post-treatment period. The 
pain scores were recorded using a survey that asked about pain from any cause. Kuo et al. (2012) 
concluded that melanoma patients in the outpatient setting commonly experience chronic and 
undertreated pain. Half of the patients suffered from pain from non-cancer sources, often with a 
neuropathic component, and many could benefit from better management. Similarly, participants 
in the current study need local pain management resources so they do not have to drive two 
hours round trip every month to get help with their pain.  
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Stavia et al. (2006) conducted a large cohort study at MD Anderson in Texas with 
patients from a melanoma specialty clinic (N=996). These researchers examined melanoma 
survivors’ quality of life compared to that of other cancer survivors. Survivors who had surgery 
as their sole treatment (N=577) reported their only health problems were arthritis, osteoporosis, 
cataracts, and heart problems, but they had them much more frequently than did other cancer 
survivors. Similarly, the participants from the current study were generally heathy with few 
quality of life issues except for arthritis and hypertension. 
Talking about cancer remains a stigma within the overall narrative of participants in this 
study. The dichotomy between privacy and Appalachian folklore, participants spoke about the 
difficulty of not only sharing their diagnosis with others as ‘melanoma’ but also hesitancy about 
using the word ‘cancer’. The ‘cancer’ stigma also involved participants meeting resistance when 
asking or probing relatives to share specifics of the ‘cancer’ or ‘melanoma’ history to understand 
their risk. 
Theme 3: Once Bitten, Twice Shy 
Participants were very vocal about their urgency to continue following-up even when 
they knew a biopsy would involve pain if a new area was identified and a biopsy had to be done. 
Many participants wanted any newly identified suspicious area resected the next day, often 
texting the surgeon to get in urgently. Some called a friend who was a plastic surgeon or family 
practice provider to see if they had time to do a biopsy. Others described moving themselves to 
the front line by dropping by the dermatologist office without an appointment in order to be 
worked in. Participants reacted to a new suspicious area as if it were melanoma. No studies in the 
literature mentioned survivors having a sense of urgency with new suspicious areas or what level 
of familiarity they had with their providers or clinicians.  
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Participants reported worry and anxiety about melanoma recurrence. In a study of the 
benefits of long-term follow-up, Morton et al. (2013) reported anxiety among melanoma 
survivors as the follow-up date drew near. Livingstone et al. (2015) looked at the first two years 
after diagnosis and found that some survivors had high psychological stress (anxiety and 
uncertainty) and might benefit from additional education and psychosocial support. Palesh et al. 
(2014) found that melanoma survivors with anxiety could benefit from greater health provider 
involvement to address psychosocial needs and develop treatment guidelines for managing 
clinically relevant levels of post-treatment distress. McLoone et al. (2012) reported that 
melanoma survivors from a high-risk clinic in Australia suffered from fear and persistent 
uncertainty. Bird et al. (2015) reported that melanoma survivors viewed their needs as unique 
compared to other people with cancer, often speaking about continuing follow-up to avoid dying.  
 Many participants described the strength needed to live with melanoma and continue 
follow-up for a lifetime. Some participants spoke about how their personal growth contributed to 
inner strength, while others referenced their faith. The religious roots within the Appalachian 
culture extended to an even deeper expression of faith created by the collective ‘power of prayer’ 
during illness and stressful time. Participants appreciated friends and family members providing 
friendly follow-up reminders and asking them how their visit went, if a biopsy was done, or how 
things were going. Again, these participant experiences and needs may be influenced by the 
Appalachian culture milieu.  
Theme 4: Watch Me like a Hawk 
Skin examination was a major focus of many participants’ narratives. Most participants 
regularly saw a dermatologist who examined their skin and evaluated any new or suspicious 
areas. Some participants remembered their initial diagnosis in which a mole that had been 
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watched closely was finally biopsied and turned out to be melanoma. After this kind of 
experience, participants often wanted suspicious areas removed right away to avoid recurrence. 
The data indicated that primary care providers generally do not have participants remove their 
clothes and put on a gown or examine their skin. Instead, most primary care providers refer 
anything skin related to the dermatologist. Occasionally, a physical exam would include the 
standard assessments of listening to the lungs, heart, and abdomen and recording any new 
symptoms. Many participants described specialists, such as gynecologists, who perform a 
thorough exam to look for other places melanoma may develop, and check lymph nodes in the 
axilla or groin. Participants expressed puzzlement regarding why providers did not look at their 
skin during their office visit and made concessions for this with statements such as, “he did not 
have time” or “that’s not why I am there.” 
Studies focused on sun-protection behaviors and self-skin examinations were abundant in 
the literature. Oliveria et al. (2013) examined sun-protection behaviors, follow-up practices, and 
psychological concerns. Bowen et al. (2012) studied melanoma risk-reduction behaviors in 
survivors among the general population in the Pacific Northwest. Most survivors saw a 
dermatologist who checked their skin thoroughly and many reported doing regular self-skin 
examinations. Individuals reported wearing long sleeve shirts, sunscreen, or a hat when 
necessary. The topic of sun protection behaviors did come up in the interviews with participants 
from ETAR when they were asked if they did anything now that they did not do before being 
diagnosed with melanoma. Most women reported changing many sun-related behaviors 
including wearing more sunscreen and avoiding direct sun. Men reported wearing a hat or 
reluctantly using sunscreen if prompted by a loved one.  
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Most participants (or significant others) had direct lines of communication with needed 
providers from either familiarity or community connections. Small towns and family connections 
often facilitated a path for making a phone call to be seen soon regarding a new area to the skin 
or new symptoms causing worry or anxiety. Provider action during an office visit where concern 
about the new area, the sense of touch, inquiry regarding new symptoms, and facilitating 
appointments, or answering questions provided assurance for survivors faced with ongoing 
psychological distress and uncertainty.  
Recommendations 
Nursing Practice 
 This study has several implications for nursing practice. Overall, nurses need a 
heightened awareness of the experiences melanoma survivors to inform their conversations with 
these patients about survivorship and follow-up care. Several strategies could be incorporated 
into practice, such as including nursing history and assessment questions about survivorship for 
cancer survivors. Further, the addition of a patient navigator (identify barriers to follow-up or the 
type of follow-up) for melanoma survivors could improve long-term patient outcomes. Finally, 
nurses could help identify and provide resources needed by melanoma survivors during 
transitions and across the life span.  
Nursing Education 
 The National League of Nursing (2015) identified a comprehensive list of priorities in 
nursing education, one of which was fostering inter-professional practice. One challenge within 
nursing education is to gauge the effectiveness of approaches to foster development of clinical 
reasoning in situated patient care contents (simulation). Advanced practice nurses need to be able 
to examine patients effectively and make critical decisions based on those assessments. 
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Additionally, knowledge and critical thinking skills are needed to treat problems, make referrals, 
and coordinate follow-up care. An undergraduate nursing student should be able to perform a 
basic skin examination, while a student in a graduate nursing program focusing on clinical 
practice should be able to perform a full-body skin examination. Advanced practice nurses are 
uniquely qualified to step-up and provide additional care for melanoma survivors in primary 
care, specialty care, and inter-professional practice settings. The American Cancer Society 
recommends melanoma survivors have full-body skin examinations at least yearly. However, 
such surveillance also includes monitoring long-term issues, providing education, and screening 
for psychosocial needs. 
Primary Care, Specialty Care, Advanced Practice 
 The National Cancer Institute’s (2015) cancer survivorship goals focus on the role 
healthcare provider’s play in establishing a care plan for cancer survivors. Although melanoma 
survivors need regular skin exams and dermatology follow-ups, survivorship should include 
access to the cancer circle where resources and ongoing information are available. Melanoma 
survivors need accurate, consistent information regarding melanoma post-treatment survivorship. 
At least one visit to a medical oncologist or nurse navigator could allow survivors discuss their 
issues, receive information and resources, and a referral to someone the survivor and/or family 
can call if cancer-related issues arise. Survivors also need opportunities to talk with other 
survivors and develop support that may not be available through family or friends. Additionally, 
survivors need access to relevant, up-to-date information as new melanoma research findings or 
breakthroughs develop that relate to their current health status.  
 Programs that use a team approach to melanoma surveillance could give survivors more 
care continuity and assurance. Clinicians need more knowledge about melanoma surveillance to 
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create local community networks for Tennessee survivors across the state. Local facilities 
providing cancer care could offer a contact person who could answer general questions and 
provide information about genetic links between melanoma and other cancers.  
 Dermatology and primary care providers can play a larger role in melanoma survivorship, 
by focusing on melanoma as a systemic cancer rather than a skin disorder during patient visits. 
Additionally, dermatologists and primary care providers and clinicians could refer melanoma 
patients to survivorship programs, whether or not these patients are seen by a medical oncologist. 
The standards and goals for cancer survivorship are focused on cancer survivors in general. 
Unfortunately, melanoma survivors may not be referred to or see a cancer care provider or nurse 
navigator who can help facilitate care and follow-up. 
Policy Implications 
 Recognizing the challenges of providing cancer care in resource-constrained settings, the 
National Cancer Policy Forum (2017) convened to make recommendations to help communities 
build networks. Additionally, the NCI (2015) reported that some of the most basic psychological 
and social issues affecting cancer patients are not being addressed, including support and 
ongoing follow-up and monitoring for recurrence. Patients need to be relieved of the burden of 
coordinating their own melanoma surveillance, whether doing so improves outcomes or not. 
Melanoma survivors need the same standard-of-care that other cancer survivors concede, before 
they have a recurrence or develop metastasis. Nurses are uniquely qualified to provide a voice to 
improving public awareness and applying public pressure to encourage government actions to 
improve cancer care. Regionally, the ARC addresses critical infrastructure (transportation) and 
ready workforce (health of residents) issues within Tennessee and other Appalachian states.  
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Future Research 
 The results of this study introduce opportunities for future qualitative and quantitative 
research on the topic of interest. Other researchers should consider conducting research with 
melanoma survivors from other Appalachian areas and making comparisons with other rural 
groups. Studies exploring information provided to post-treatment melanoma survivors could give 
insight into current clinical practice. In addition, measuring patients’ understanding of recurrence 
symptoms before and after an intervention could validate a program’s effectiveness.  
 Researchers also could investigate the role of reassurance versus assurance in cancer 
survivorship, along with the struggle for power seen in some patient-provider relationships. 
Another important aspect of cancer survivorship is better understanding the perspectives and 
needs of caregiver survivors, persons who cared for a melanoma patient who died. Additional 
information about melanoma survivorship in diverse populations and situations also is needed. 
Research is needed to examine community resources and regional access options for surveillance 
in areas lacking local hospitals or regional cancer center services. Responsible melanoma 
surveillance care needs to move beyond offering reassurance and into providing a solid 
foundation and confidence to help survivors deal with the real threat of recurrence. 
Limitations 
 While this study is limited by its geography, it is enhanced by a PI with experience as an 
advanced practice nurse providing care for melanoma survivors. None of this study’s participants 
was cared for by the PI. Instead, the PI traveled the east Tennessee region visiting public areas 
like libraries, local diners, and community centers to become more familiar with the setting. 
Participants often contacted the PI after seeing having someone give them a flyer. Although, the 
PI sent numerous flyers to dermatology and primary care practices in the geographical area, no 
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direct office referrals were made. To meet study recruitment requirements, the initial eight-
county recruitment area was expanded to include all 45 counties in the ETAR. Therefore, only 
limited information regarding where participants live (including the specific counties) will 
remain connected with the confidential research documents. The shared social and cultural 
backgrounds among the study population strengthened the study findings with the consistency 
found in the state of the science and important implications locally and regionally. The 
participants in this study do not represent all melanoma survivors living in Tennessee or the 
ETAR. However, the research results can provide a new perspective for all who serve cancer 
survivors generally, or melanoma survivors specifically.  
Significance 
 This addresses a gap in the literature regarding the post-treatment health-related 
experiences and needs of melanoma survivors in the ETAR. Before this study, little was 
understood about melanoma survivorship for those who live in this region. Data from participant 
narratives provided important links to the current body of knowledge as well as new insights for 
future exploration. This work is important in light of increases in the number of cancer survivors, 
including those with melanoma, who will need resources related to surveillance and life-long 
follow-up. Additionally, lack of resources for melanoma survivors in this geographical area 
poses barriers to care for this population.  
Conclusion 
 Melanoma survivor’s experiences reflected a dynamic process of disjointed care and a 
lifetime of worry and uncertainty in this study, which is consistent with the extant literature, 
related to post-treatment survivorship. The needs within the melanoma survivors interviewed 
were implicit which may reflect cultural influences or their acceptance for self-directing their 
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own survivorship care with the help of family, friends, and providers that accommodate. 
Participants in this study were found to live with the guilt of feeling they or providers may have 
‘watched the cancer grow’, suffer the agony of frequent biopsies, sometimes excessive 
appointments, disfigurement from treatments, and ongoing side-effects only to find follow-up 
consisting of trying to procure a complete skin exam traveling across the highways in Tennessee. 
The interpretive description method and the naturalistic paradigm provided an appropriate lens 
for discovery of new knowledge in this study. Exploring and describing participants’ narratives 
gave voice to and understanding of a previously unheard population. The goal was not to 
generate an exhaustive list of all topics that might be linked to melanoma survivorship, but rather 
to create a thematic structure for highlighting the main elements of interest.  
 These findings contribute to the body of knowledge related to cancer survivorship 
generally, melanoma survivorship specifically, health research within Appalachia generally, and 
within the ETAR specifically. These findings also identified the important experiences and needs 
of melanoma survivors from an area in the U.S. where melanoma incidence is higher than state 
and national rates. The study findings provide important insight into the support needed for 
melanoma survivors from a local and state perspective and implications for all clinicians who 
care for cancer survivors. The overarching goal of this study was congruent with current federal 
and state healthcare goals regarding cancer survivors. The participants interviewed represent a 
small sample of the many individuals who live with melanoma. Using their words, the PI 
described and interpreted some ways healthcare can improve general practices when following 
melanoma survivors over time. These suggestions offer practitioners opportunities to take action 
and make a difference for this population. While it is easy to become complacent within 
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healthcare practice, this study was conducted in the hopes that others can view the results as a 
challenge to become more sensitive to the needs of all the patients they serve. 
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Appendix A  
Figures and Tables 
 
 
 
Figure 1.1. Tennessee Appalachian recruitment area 
Map of Tennessee Appalachian and Non-Appalachian regions. Appalachian Region Commission 
(2008). Retrieved from 
https://www.arc.gov/images/appregion/AppalachianRegionCountiesMap.pdf  
Used with permission from the Appalachian Region Commission 
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Figure 1.2. Cluster of eight ETAR counties with high melanoma incidence rates  
Generated from data with Surveillance, Epidemiology, and End Results (SEER, 2017). Retrieved 
from http://seer.cancer.gov/csr/1975_2014 and 
American Cancer Society (ACS, 2017). Retrieved from http://cancerstatisticscenter.cancer.org 
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Figure 1.3. Appalachian Region States and Counties 
From the Appalachian Region Commission (ARC, 2017) Retrieved from 
https://www.arc.gov/images/appregion/appalachianRegionCountiesMay.pdf 
Used with permission from the Appalachian Region Commission 
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Table 1.1. NCCN Clinical Practice Guidelines in Oncology for Melanoma  
  
 Thin Lesion Treatment Thick Lesion Treatment Thicker Lesion / Recurrence 
Treatment 
Initial 
Treatment 
Wide excision 
Sentinel node biopsy 
(+/-) (negative) 
Wide excision 
Sentinel node biopsy (+/-) 
(positive) 
Lymphadenectomy (+/-) 
Clinical trial (+/-) 
Wide excision (+/-) 
Sentinel node biopsy (+/-) 
Lymphadenectomy (+/-) 
Clinical trial (+/-) 
 
Scans  CT scan, PET/CT, MRI (+/-) CT scan, PET/CT, MRI (+/-) 
 
Adjunctive 
Therapy 
 Observation 
Nodal basin ultrasound (+/-) 
Interferon alpha (+/-) 
Immune therapy 
Immune therapy (+/-) 
Radiation (+/-)  
Chemotherapy (+/-) 
Created with information from NCCN Version 3.2016 
 
 
 
 
Table 4.1. Individual Participant (n=16) Characteristics 
 
Participant 
Pseudonym 
 
Age 
 
Gender 
Education 
Completed 
 
Usual work/Employment Status 
Years Since Dx/ 
Recurrence (Y/N) 
 
Arlene 
 
43 
 
Female 
 
Master’s 
 
Psychology Therapist/Working 
 
2 years/N 
Clifton 60 Male Technical Paramedic/Working 18 years/Y 
Daisy 26 Female 11
th
 Grade Cashier/Unemployed 1 year/Y 
Darron 61 Male Bachelor’s Park Ranger/Working 20 years/Y 
Ethan 57 Male Master’s Engineer/Working 8 years/N 
Greta 42 Female Master’s Nurse Practitioner/Working 14 years/N 
Griffin 49 Male Some college Computer Programmer/Working 5 years/N 
Hayden 61 Male 10
th
 Grade Computer Repairs/Disability 5 years/N 
Heidi 60 Female Bachelor’s Registered Nurse/Working 51/2 years/N 
Jeanie 58 Female High School Sales/Disability 3 years/Y 
Karen 65 Female Some college Registered Nurse 29 years/Y 
Linda 46 Female Bachelor’s Real Estate Agent/Working 4 years/N 
Randall 94  Male 10
th
 Grade Farmer/Retired 10 years/N 
Robyn 56 Female Master’s Health Educator/Working 2 years/N 
Rosie 29 Female Master’s  Medical Resident/Working 11 years/Y 
Taylor 64 Male GED Electrician/Retired 9 years/N 
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Table 4.2. Group Participant (n=16) Demographics  
 
Characteristic n % 
 
Age at time of interview (years) 
 20-40 
 41-60 
 61-80 
 >81 
 
  
2 
9 
4 
1 
 
  
13% 
56% 
25% 
7% 
 
Ethnicity 
 Non-Hispanic or Latino 
 Unknown 
 
 
15 
1 
 
 
94% 
6% 
 
Highest education level completed 
 Less than 12
th
 grade 
 High School, GED, or equivalent 
 Some college 
 College graduate 
 Graduate School 
 
 
3 
2 
3 
4 
4 
 
 
19% 
12% 
19% 
25% 
25% 
 
Employment status  
 Unemployed 
 Disability 
 Working 
 Retired 
 
 
1 
2 
11 
2 
 
 
6% 
13% 
69% 
13% 
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Table 4.3. Participant (n=16) Melanoma Information  
 
Characteristic n % 
  
Length of time since diagnosis (years) 
 0–5 
 6–10 
 11–15 
 16–20 
 >20 
 
 
  
8 
3 
2 
2 
1 
 
  
50% 
19% 
13% 
13% 
6 % 
Family member with melanoma 
 
5 31% 
Travel time for follow-up (hours round trip) 
 <1 hour 
 2 hours 
 4 hours 
 
 
7 
8 
1 
 
44% 
50% 
6% 
Current follow-up schedule 
 At least once a year 
 Twice a year 
 Four times a year 
 
5 
7 
4 
 
31% 
44% 
25% 
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Table 4.4. Participant (n=16) Treatment Information  
 
Characteristic n % 
 
Melanoma location  
 Abdomen 
 Forearm 
 Back 
 Chest 
 Face 
 Thigh 
 Mucosal 
  
Recurrence (n=8) 
  
Location 
 Abdomen  
 Arm 
 Back 
 Metastasis 
 Neck 
 
 
 
1 
3 
5 
2 
2 
2 
1 
  
8 
  
  
2 
1 
2 
2 
1 
 
 
6% 
19% 
30% 
13% 
13% 
13% 
6% 
  
50% 
  
 
25% 
13% 
25% 
25% 
13% 
Length of time since diagnosis (years) 
 0–5 
 6–10 
 11–15 
 16–20 
 >20 
 
 
8 
3 
2 
2 
1 
 
50% 
19% 
13% 
13% 
6% 
Family member with melanoma 
 
5 31% 
Surgical treatment type 
 Wide excision only  
 Wide excision w/negative SLB 
 Wide excision w/positive SLB 
 Lymphadenectomy 
  
Systemic Treatment type  
 Interferon 
 Immune therapy 
 Clinical trial participation 
 
 
2 
7 
7 
6*  
 
 
2 
1 
2 
 
13% 
44% 
44% 
 
 
 
13% 
6% 
13% 
 Current yearly follow-up 
 At least once 
 Twice a year 
 Four times a year 
 
5 
7 
4 
 
31% 
44% 
25% 
*One participant with a positive SLB did not have a lymphadenectomy due to metastasis 
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Table 4.5. Themes and Subthemes in ETAR Melanoma Survivors  
 
Theme Subthemes 
 
Theme 1: Sitting in the Driver’s Seat of Follow-up Care 
 
Subtheme 1A: On the road again  
Subtheme 1B: I steer my care 
Subtheme 1C: Hazards on for help 
 
Theme 2: Living in a Skin World  Subtheme 2A: Melanoma is not a secret 
Subtheme 2B: Call it cancer 
Subtheme 2C: Defer to dermatology 
 
Theme 3: Once Bitten, Twice Shy Subtheme 3A: Waiting is not an option 
Subtheme 3B: Everything looks like melanoma 
Subtheme 3C: Sources of strength 
 
Theme 4: Watch Me like a Hawk  Subtheme 4A: Follow-up visits 
Subtheme 4B: Reassurance offered 
Subtheme 4C: Uncertain times 
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Table 4.6. Theme 1 and Subthemes 
  
Theme 1: Sitting in the Driver’s Seat of Follow-up Care 
 
Subthemes Essential Quotes 
1A:  
On the Road 
Again 
 
Distance 
 “Appointments are 10 miles maybe round trip…” 
 “It takes about 2 hours to get there” 
 “Lots of driving is the problem.” 
 “No problems just a long drive, Umm, I haven’t been working so coming up with gas 
money sometimes... We get to stay in the resource housing area so that is great, my 
Dad and Sarah can stay too.”  
 “So, he (my boyfriend) has been bringing me to the doctor, I’m um, ah, too nervous to 
drive right now.” 
 “They found a surgeon but I had to drive a few hours to get it done… with a new baby 
it was hard, my dad had to come with me and took care of my daughter each time….”  
 “Usually I set the appointment up when I leave, sometimes I had to change it. My wife 
would drive and I’d work…” 
 “Uum, well, getting to the cancer clinic is a two hour drive, so my mom drives.”  
 “When I drive there (2 hours away to the photo dermatologist), my friends go too 
sometimes to have an excuse to go shopping with me.” 
 “Yes the nurse practitioner helped me when I was having so much pain but I had to 
come and see her every month and so a two-hour drive, we got through it but for a few 
months it drove me batty and my mom would get real tired.” 
 “Yes, well after a year, she (surgical oncologist) moved her practice to [another major 
city in Middle Tennessee, 4 hours away] and so we go there now. I don’t want to see 
another surgeon and so we started going there, she knows me so we go see her there. 
We usually try to stay overnight and visit friends sometimes.”  
Time 
 “He (photo dermatologist) said that I was very high risk and that I have to come every 
3 months… I’ve gone to him every 3 months… for 14 years (2 hours each way).” 
 “He (surgical oncologist) followed me close for a while because of the problems with 
getting things healed. I did see the medical oncologist (at the cancer center) about the 
interferon and then once it was started then another doctor (medical oncologist) here 
(near home) was the one taking care of me. I still see him (medical oncologist) near 
home every six months.”  
 “He (surgical oncologist) said, you know this isn’t something to take lightly. Um, this 
is something you’ll deal with and ah, take care of the rest of your life.” 
 “I come and see the skin cancer doctor (medical oncologist) now every 6 months, 
some blood work and x-rays too.” 
  “I go every 3 months now, like clockwork to [middle Tennessee], to my melanoma 
guy [photo dermatologist] and that’s pretty much it.” 
 “I had a sense of “this is gonna be the rest of my life,” whether it’s semi-annually or 
annually.” 
  “So I went every three months, so I did it four times last year and I’m on my every 6 
months follow-up now.” 
 “Waiting to be seen is the only thing. That particular, I don’t know if it’s that particular 
practice that or if it’s just dermatology in general, oh my gosh, half a day’s adventure.” 
 “Well, um, I see the skin cancer doctor [medical oncologist] or yea the nurse 
practitioner every 6 months and I get a x-ray and blood work next time.” 
 “You have to schedule a new patient appointment and it takes 8 months to get in 
(dermatology).” 
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Table 4.6. Continued 
 
Theme 1: Sitting in the Driver’s Seat of Follow-up Care 
 
Subthemes Essential Quotes 
Subtheme 1B:  
I steer my care 
 “Every time I’ve gone, she (dermatologist) cuts on me, she freezes me and I appreciate 
it and understand that.” 
 “I actually went to a big skin cancer group down in Georgia and I have seen them um, 
a few times in the past couple years. There were a couple of others (dermatologists) 
locally (Tennessee) but I wasn’t super excited about going to them either.” 
  “I figure it (follow-up) was forever.” 
 “I go to a (support) group now.”  
 “I got an appointment and I kept it and then I kept, I keep everyone.” 
 “I have to force myself to make appointments (dermatologist). Those aren’t 
appointments that are set up for me, those are appointments I have to make you know.” 
 “I have to force myself to make those appointments because I know every time I go, at 
least so far, she cuts on me every time.”  
 “I just ah, make an appointment ah, when I go you know.” 
 “I mean it um, ah, it it’s got to start from the, it’s got to start from the patient.”  
  “I think that ah, you know it’s the patient’s um, responsibility to identify the areas and 
then seek the, you know, you know, seek the help for, for getting it done.” 
 “I think the people around me were a little bit more um, in tune or intense, than I was, 
cause I was like “you know we’ve found it. It’s coming out. It’s a spot,” and my 
friend’s like “no, you’re a cancer survivor now.”  
 “I was alternating seeing him (dermatologist) and seeing the oncologist (surgical 
oncologist) so I was seeing somebody every 6 months.”  
  “It starts with the patient…” 
 “My dermatologist checks my skin, extra careful now and I am always asking, ‘what 
about this?’ and I have had a few more things removed but no cancer, thaaank 
goodness.” 
 “My wife has tried to get me to see someone in a bigger city or cancer center but I’m 
not driving all over to just get my skin looked at, he…my wife can do that (check my 
skin), you know what I mean?” 
 “Right now, there are, you know, I’ve got a couple spots that need to get checked.” 
 “You just don’t cancel.” 
Subtheme 1C:  
Hazards on for 
help 
 “A few times when my husband was so nervous he took me to the doctor’s office 
without a appointment and the dermatologist worked me in…” 
 “Another paramedic, she had melanoma too and that was very helpful, I don’t know 
how but maybe uuh, others out there that have been through it.”  
 “At the cancer center, well, they have umm, helped me a lot for sure. I have to get to 
middle Tennessee every time, ahh, and wait for medicine, and have someone drive me 
home.”  
  “Friends who had gone through this, who are cancer survivors, so that support was an, 
an encouragement.”  
 “I just felt um, pretty scared and alone and so I called my aunt who had breast cancer. 
She immediately, just linked me in with her surgeon and so before my doctor 
(dermatologist) pretty much had done anything, I had already kind of started my path 
within a couple hours after finding out.” 
 “Everybody’s always been real supportive, rides with me for two hours there ‘cause 
it’s so boring every 3 months.” 
  “I was helping my dad and now he helps me.”  
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Table 4.6. Continued 
 
Theme 1: Sitting in the Driver’s Seat of Follow-up Care 
 
Subthemes Essential Quotes 
Subtheme 1C:  
Hazards on for 
help 
  “The good thing is she (my aunt) lives in Kentucky and came to help us after my 
surgery.” 
 “Most of my friends understood about the times when…uum… I just wanted to keep to 
myself.” 
 “My aunt has been the best help especially my dad too.” 
 “The social worker helped us stay near-by when I come to town.”  
 “My good friend asks the church to help when I have to go for appointments.” 
 “My daughter was like ‘mom’, 'cause it was right after Thanksgiving. She’s like ‘I’m just 
staying after Thanksgiving. I’m not going back to D.C.’ I’m like “Why, it’s so, it’s I’m 
gonna be ok.” She’s like “mom, you’re gonna have surgery on your face for cancer, I’m 
staying.”  
 “My family, you know are helpful, you could have your arm chopped off and they would 
say like, “well, buck up.” 
 “My husband is retired from the service and worked from home with consulting work 
when I was recuperating, thank goodness.”  
 “My mom helps me get it (fitted stocking for lymphedema) on.” 
 “My wife changed the dressings.” 
  “My wife is ah, kind enough to remind me that I need to use it (sunscreen).” 
 “My wife, my daughter, wow! My work too, they just said take as much time as you 
need.” 
 “Now I’m on disability with some income, um but the first two years I had to keep 
asking people to bring me.” 
 “Well my husband has been here the whole time with me.”  
 My sister lives near-by and she helps too. 
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Table 4.7. Theme 2 and Subthemes 
 
Theme 2: Living in A Skin World 
 
Subthemes Essential Quotes 
Subtheme 2A:  
Melanoma is 
not a secret 
 
  “Ah, no care. Just been check-ups.” 
 “There was one that came up on my stomach that hadn’t seen the sun in 20 years.” 
 “Melanoma is a secret sometimes and I wanted to help with the study. When you hear 
about skin cancer, it’s about the sun and getting old and all. Melanoma is melanoma it 
seems when people talk about it.” 
 “Well, at least it’s not breast cancer!”  
 “I could have had it done here but I didn’t feel like you know it was the best place to go 
so I went to the [cancer center].” 
 “Injection in my lymph nodes and none of that came back cancer.”  
 “Actually when I went in for my surgery, they were laughing because they were saying 
‘you’re one of the healthiest people we’ve ever seen except for that cancer right there’.” 
 “Man, my mom has diabetes and my dad had melanoma and I got em both.”  
 “I’ll tell you what has been more helpful has been talking with someone who has had 
melanoma too.” 
 “I said ‘no, it’s not just skin cancer, you dumb…’.”  
 “I was mad, I cried and then I was mad and then I wanted it out of me, out of me.”  
 “I thought ‘this can kill you’.” 
 “I didn’t talk about it around the kids.”  
 “I had a good friend who said ‘oh my god. I’m sorry, what are you gonna’ do? where 
you gonna go’?” 
 “Half of it is your heritage; it’s not all the sun.” 
 “I was afraid to go out.” 
  “Not sure I have any advice but talk to other people with melanoma.” 
 “New to me, I thought melanoma was skin cancer, you know, moles and sh…stuff…” 
  “All you hear about skin cancer is sun, sun, sun… No sun gets back there for sure…” 
 “Other people with melanoma need to know about other types of it, just wish I had more 
to say about it, but anyway, maybe this will help…” 
 “He [PCP] asks if anybody is following me for my melanoma.”  
 “I guess he had to kind of make a big pork chop out of my back. It was probably like, 
what you think, maybe 4 or 5 inches wide.” 
 “There were 2 surgeries but ah, I mean there was no real treatment.” 
 “My twin sister had melanoma and she was diagnosed about a year before me. I guess 
that’s why my wife was looking at things a little closer…” 
 “There was no chemo available that was out there, uh, specifically for melanomas and 
radiation wasn’t called for, and um, they were just gonna' watch me, I did have uh, and I 
had one positive lymph node. The second one [recurrence], was just here recently uh, it’s 
been 29 years.” 
 “I’ve had no recurrences in 29 years, and then just, um, I noticed a little mole again on 
my back and it was hard for me to see because it was on my back, but I noticed a mole 
that I thought looked darker.” 
 “I knew enough people that I knew I had resources to go to the best places” 
 “I had the big-wide excision to my leg or rather my thigh and also to my back. The 
needles to put the dye in to check my lymph nodes in my neck and my groin were very 
painful if I remember right.” 
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Table 4.7. Continued 
 
Theme 2: Living in A Skin World 
 
Subthemes Essential Quotes 
Subtheme 2A:  
Melanoma is 
not a secret 
 
  “She [surgical oncologist) took some skin from my thigh which was really painful after 
surgery, worse than anything.” 
 “I had a couple of drains that my husband had to help me with” 
 “It’s been four years now but I get swelling in my left leg all the time now, lymphedema, 
and wear a stocking every day.” 
 “I know I’m very fortunate. Had I not gone, I mean I know this is as sure I’m sitting here 
because I know of what, what kind it was, had I not gone in, I might not have, it might 
not have been caught before mine metastasized.” 
 “My aunt had some kind of skin cancer when she was young but nobody mentioned it 
until after I was diagnosed. I always thought she died of brain cancer.” 
 “I don’t know anyone with melanoma or at least that has had this, all this kind of 
surgery, so really just to help someone else maybe…” 
 “Well you know my mom died of it. Um, ah so it seems like there’s um, ah, there’s 
history in the family.” 
 “I knew um, melanoma kills people, that’s what I know.” 
 “It looks like they just went and took my kidney out and took about 7 inches off my back 
um, but it, that wasn’t the worst part. The dye tracer that was probably the worst thing 
that I initially experienced because they can’t give you anything for it and they do um, 4 
shots of dye around your cancer spot.” 
 “The only thing that was kind of the intimidating thing about melanoma is it’s not just 
like a skin cancer, it’s a system like cancer so it can show anywhere, anytime and so that 
was a bit um, humbling as well.” 
 “So knowing and you know when they took the lymph nodes, it could be anywhere in 
my body beside just that little mole that I’ve had my whole entire life on my back. Um, it 
was pretty scary.”  
 “Yeah, he was very clear. He said you know this isn’t something to take lightly. Um, this 
is something you’ll deal with and ah, take care of the rest of your life.” 
 “I had a couple moles removed when I was 28 and they weren’t concerned they were 
cancer, but they were concerned that maybe at some point they could turn. I have had all 
of them my whole life and I knew that one was my darker one.”  
 “I called my friend [plastic surgeon], he was on his way to a game and I said ok, I have 
this is on my face and it’s on my arm and my nose and my forehead, yeah, every place 
and he said, ‘I’ll see you next Monday’ and I went in he saw it and then I had surgery a 
week later.” 
 “I got the cancer plan from my friends.” 
 “She (my aunt) said she’d talk me off the ledge anytime 'cause she said ‘once you get 
that word’ she said ‘unless you have had that word, you don’t fully wrap your head 
around what it means to hear it’.” 
 “I did start a clinical trial later after the melanoma came back. I was real sick from the 
medication and they had to stop it.”  
 “It’s very scary is what it is in retrospect.” 
 “After they took the lymph nodes under my arm, umm, more cancer came back to my 
arm above this scar, then I had radiation, too.”  
 “It did influence me though to go into medicine I will say.” 
 Something that I think made me realize how fortunate I am because I had a plastic 
surgeon friend, because I was able to kind of get to the front of the line, because I met 
with him the next week and he scheduled surgery the next week, I had the surgery, had 
the recovery, had already gone back for my follow-up with dermatology and then 
received a call from the office of the plastic surgeon that they normally do work with.” 
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Subthemes Essential Quotes 
Subtheme 2A:  
Melanoma is 
not a secret 
 
  “The surgery, they went, they went, as far as, clear margins which resulted in a lot 
more, which was a lot more um, invasive than I thought it was gonna be. I have a 
whole new nose it’s a totally different shape now.” 
 “It’s important to follow-up because you just never know…” 
 “If I had quit following up, then I’d have a metastatic melanoma and I might, may not 
be here now.” 
 “After I called and talked to you about the interview, I realized I could help someone 
maybe think about melanoma more and take it serious.” 
 “Follow-up is important and can keep you from dying, ahh, that simple really.”  
 “Whenever I do hear a story about melanoma, it’s usually not good. It’s usually a very 
bad story and that’s very scary to me but it’s also scary to me for people who will 
never go to a dermatologist or whose primary care physician will never look at their 
skin.”  
 “People need to talk more about it [melanoma].” 
 “So, finally my wife got me a appointment with a doctor at the cancer center because it 
was the bad kind of skin cancer, that’s where they told my wife I needed to go, to see 
the melanoma specialist.” 
 “It was a while before I could have the surgery because the place on my thigh just 
would not heal, took forever, my wife had to pack it and change all that and she does 
not like blood or anything like that, she was a trooper for sure. That took several 
months and then I went for the lymph node surgery in my groin area and that would 
not heal either.”  
 “Nothing showed up on there but degenerative disc disease in my back and my wife 
saw x-rays of my brain so we had a good laugh about that…” 
  “Well you know my mom died of it [melanoma]. Um, ah so it seems like there’s um, 
ah, there’s history in the family.” 
 “I didn’t really say anything to my friends or people at work, not really the thing to 
do.” 
Subtheme 2B:  
Call it cancer 
  “Yeah and the last time I went, oh my gosh in September, I had some spots ah, just, I 
thought it was chapped lips.” 
 “I did not have any melanoma in my lymph nodes.” 
 “I wanted to go but scared it was skin cancer, you know from the sun.”  
 “I had to go to part time work but I was off for 7 months all together.  
 “I have a lot of numbness to this area on my thigh that bothers me sometimes. You 
know you think a numb area would not hurt but yes it does.”  
 “So anyone who would look at a part, yeah, I’m at least half naked, if not fully.” 
 “It always jogs my memory, it always does because when you fill out any history and 
they say ‘have you, have you had cancer’ and I have to remind myself to check ‘yes’.” 
 “I look at you know this little bit of skin cancer on the skin, I don’t call that 
melanoma.”  
 “I was told to check my lymph nodes in between visits.” 
 “The spot looked just this. It looked no different than that. It didn’t have any of the 
markers. It wasn’t rough. It wasn’t um, odd shaped. It wasn’t… but I mean it looked 
like an age spot.” 
 “I did see a medical oncologist after the surgery and I go back once a year for follow-
up. I get x-rays sometimes and blood work to look for cancer.” 
 “Work gave me time off, I sell real estate, and I had to cut back. I just did not have the 
stamina to work the hours that I was.” 
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Subtheme 2B:  
Call it cancer 
 “The clothes I wear are completely different. I wore skirts and sleeveless shirts in 
summer and not anymore.”  
 “I check my skin, my husband checks my skin, I even ask Mary and Molly if they see 
anything (loud laughter)…those are my fur babies…” 
 “High blood pressure is the main one and I have some arthritis in my hands, I am 
pretty healthy except for all this with the melanoma.” 
 “I told my gynecologist about the melanoma. She has done surgery for the 
endometriosis since I had this all done (pause)…She took biopsies but no signs of any 
cancer.” 
 “I had to have some physical therapy with my leg and they were soo great, they really 
helped me with the stiffness and all the tightness every time I walked, I do exercises 
that help too.” 
 “I never thought about, ‘you should tell your gynecologist so that when they do your 
pap smear, they can look for spots on your cervix’.” 
 Yes, um I did share it with my dentist and so he does track when he does my exams. 
He looks for spots. 
 “Well and it’s interesting too because I um, I don’t call it that. I don’t call it melanoma. 
I will say ‘oh yeah, I had something removed…’ Someone will say ‘oh, I went to the 
dermatologist and oh my gosh, I had this spot removed’ and I’ll say yes, when I went, 
oh my gosh, I found out I had to have all these things removed. I don’t, I don’t really 
say I had melanoma. .. I’ll say well, it turned out I had skin cancer.” 
 “I just thought it was gonna be a little mole.” 
Subtheme 2C:  
Defer to 
dermatology 
  “Now I’m much more aware of my skin.” 
 “Anything that looks funny, we biopsy immediately.” 
 “She just wanted to take em [abnormal looking moles] off.” 
 “I knew they’d have to be cut off.”  
 “My dermatologist checks me” 
 “I said this is not the photoshoot that I was looking forward to.” 
 “I got an appointment and I kept it and then I kept, I keep everyone.” 
 “The dermatologist let me know about follow-up, I then had a sense that this is gonna 
be the rest of my life, whether it’s semi-annually or annually.” 
 “My friend who’s a cancer survivor ironically, so here’s the thing I go and do this [get 
a skin assessment with the dermatologist] and then she made her husband go cause 
she’s like ‘you know what, that spot looks like hers’. Turned out he had the same 
thing.” 
 Seen different ones [dermatologist] over the years. 
 “It’s just like any other office visit. It’s not a special like whoa, you get the special VIP 
treatment, um, you know. It’s go and sit in the waiting room for hours on end.” 
 “You might as well block out your day. I mean, it, it doesn’t matter what time of day 
I’m there [dermatology], it seems like if I go for a 9 a.m. appointment, I’m finally out 
by 1:30.” 
 “She’ll [primary care] say something like, so are you going back to see the 
dermatologist? I mean she’ll kind of do a inquiry about follow-up.” 
 “I’ll go in and, and the first thing I’ll say is ‘now, I have something new….’ She said, 
stop. Do not tell me what you’re worried about. Let me do the full body look and I’ll 
tell what I’m worried about. I’m like ‘ok’. And then when she’s all done, she’ll say 
‘now, I’m not worried about anything but you show me what you’re worried about.” 
 “Typically, I think when people think about melanoma, they think about a 
dermatologist.” 
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Subtheme 2C:  
Defer to 
dermatology 
 “Ahh, it took a long time to get me to get that surgery. I had to drive all over to just get 
a biopsy. The biopsy results took forever…too.”  
 “Well, that did come up a few times [needing to see someone when a new area came 
up] and it did take a while to get it checked out. Between my work and dermatologist 
appointments backed up, it did take about 2-3 weeks each time.” 
 “I told my primary doctor about the melanoma, other than the dermatologist, that’s all 
I see.” 
 “See the dermatologist every year. I did have another place show up but it was a 
different kind of cancer and he cut it out.” 
 “No, they (dermatology office) take me in just to wait you know, wait on late people.” 
 “The biopsy was done by the dermatologist.”  
 “Well, the dermatologist looks at my arms and face and asks if I have any problems, 
stuff like that.”  
 “I had a mole on my back and I went to see the dermatologist.” 
 “I got a voicemail about 2 or 3 weeks later and the voicemail said that I had melanoma 
and would be referred to a [surgical] oncologist.” 
 “You have to schedule a new patient appointment and it takes 8 months to get in.”  
 “I just religiously go to him.” 
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Table 4.8. Theme 3 and Subthemes 
 
Theme 3: Once Bitten, Twice Shy 
 
Subthemes Essential Quotes 
Subtheme 3A:  
Waiting is not 
an option 
 
 I could not deal with it…at the time. I stayed away for three months I think and then 
went back.  
 I didn’t look at it too closely 
 I’ve had this mole my whole entire life 
 it looked totally normal 
 I think that over time, I’ve definitely gotten a little more lax 
 If I had quit following up, then I’d have metastatic melanoma 
 Whenever I do hear a story about melanoma, it’s usually not good 
 It was the bad kind of skin cancer 
 Size was on the thicker side 
 Melanoma is in my lymph nodes 
 I waited too long after my surgery so it come back again. 
 Never been to dermatologist, never had a baseline screening, na, never had done 
anything 
 It looked no different than that. It didn’t have any of the markers. 
 “Wow, if hadn’t…” 
 Went to see the surgeon to cut it out. 
 I wanted to go but scared it was skin cancer 
 Don’t wait, don’t wait, I might have waited too long, maybe 
Subtheme 3B:  
Everything 
looks like 
melanoma 
 Yes, I could not believe it. Of all the things to be told that, you have melanoma 
 Oh my gosh this is serious, you know, cause I just thought it was gonna be a little 
mole. 
 I wanted to go but scared it was skin cancer 
 Anything that looks funny, we biopsy immediately. 
 I have had these moles forever and no one ever told me to get them removed, well 
except the one on my leg, I didn’t remember it at all, umm, no I don’t remember seeing 
it. 
 Had a few times when my husband was so nervous he took me to the office without a 
appointment 
 It did take about 2-3 weeks each time. 
 I have all of them my whole life and I knew that one was my darker one.  
 They look at my skin and feel it, check my lymph nodes 
 Follow-up is important and can keep you from dying 
 They saw something new on the chest x-ray and that started this ball rolling. 
 Good luck,” getting a, an appointment 
 It’s the patient’s um, responsibility to identify the areas 
 At the end of that appointment, she had taken 12 biopsies, done 6 freezes 
 They took about an ice cream scoops worth of flesh out of my arm 
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Theme 3: Once Bitten, Twice Shy 
 
Subthemes Essential Quotes 
Subtheme 3B:  
Everything 
looks like 
melanoma 
 The path for this melanoma sometimes is um, to the lungs The revisits to (tapping) ah, 
the dermatologist and she cuts on me every time 
 I had some spots ah, it just I thought it was chapped lips 
 I’ve had two episodes of melanoma 
 I’ve had several biopsies since then 
 Anything that looks funny, we biopsy immediately. 
 Everybody’s awful ah, hypersensitive about my moles. 
 It’s just opening Pandora’s box. 
 He’ll see me the next day and cut it off 
 They wanted to do some genetics or genetic testing on my sister and me but when they 
found out we were adopted, we uum didn’t qualify. 
Subtheme 3C:  
Sources of 
strength 
 It happened to me  
 I just felt um, pretty scared and alone 
 It’s very scary is what it is in retrospect 
 I know a plastic surgeon who can,” you know so, so I wasn’t scared or worried 
 This experience is well…can, ahh change things, it did for me. 
 “I need something to calm me down.” 
 I would need to be watched like a hawk. 
 I don’t know anyone with melanoma 
 My faith has been a constant. My friends have prayed, I prayed, my husband has 
prayed…double 
 Felt um, pretty scared and alone 
 Melanoma kills people, that’s what I know. 
 It continued um, my relationship with God a lot um, and so I just, I don’t see it as a 
bad thing. 
 My daughter said she was scared 
 Took a while to get my mind cleared up after the Interferon. I cannot run like I did 
 I can honestly say that melanoma was the last thing I thought I needed to worry about 
 Talk to other people with melanoma. 
 She died from it 
 I guess I was more disappointed because I thought it was over 
 It wasn’t a death sentence at this point 
 I hope I don’t die 
 There’s nothing anybody can do…just look at them 
 I thought melanoma was skin cancer… found melanoma in my lymph nodes 
 Just did not want to hear that. 
 I still have swelling in my leg, never goes down… 
 It made me real sick and more nervous 
 I have pain sometimes and get pills 
 Have someone drive me home 
 I go crazy worryin’ about all this 
 Starting to have some female problems 
 I still wear my cover over my scar 
 Other people need to know about, about this…melanoma 
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Theme 4: Watch Me like a Hawk 
 
Subthemes Essential Quotes 
Subtheme 4A:  
Follow-up 
visits 
 It looks a little abnormal, so we’re gonna biopsy it and so he did and it came back as 
melanoma  
 Well, we’d rather go to an oncologist 'cause it seems like they know more about 
cancer. 
 Yeah, we’re taking care of those six right now.  
 You should tell your gynecologist so that when they do your pap smear, they can look 
for spots on your cervix. 
 I just hadn’t heard any great things about any, ar any dermatologists around here at the 
time 
 He (surgical oncologist) set me up for surgery which I had two weeks later.  
 He (photo dermatologist) thinks I have malignant nevus syndrome and so he tells me 
to stay out of the sun as much as I can but it’s probably gonna' come back.  
 I don’t want to see another surgeon, she [surgical oncologist] knows me so we go see 
her there (4 hours round trip). 
 She said [dermatologist] I’m 60% not concerned and I thought that was really 
interesting, instead of saying I’m 40% concerned. 
 Anytime I see the dermatologist or my surgeon [surgical oncologist], I just ask is there 
anything you want to cut off. 
 If I text, like when I texted this week and I had something else show up that I found 
um, he just said come in on Monday. 
 Follow-up is important and can keep you from dying. 
 You know if you see something, go get it checked out. 
 We’re gonna’ take care of it and it’s gonna’ be done. 
 He’s older and he [photo dermatologist] has told me that probably if something 
happens to him, that he, you know, he will have a plan for his high-risk people. Um, I, 
ah, I feel better, I, I trust him. 
 I had some spots ah, it just, I thought it was chapped lips. 
 I know surgeons better than he does.  
 Well give me whatever you take. 
 I could have had it done here [locally] but I didn’t feel like, you know, it was the best 
place. 
 He’s the works. 
 I’ve been going there probably at least 5 years every 6 months. 
 He (photo dermatologist) compares them every time.  
 He looks me over and chops things off here and there. 
 Prepared me for the worst but hoped for the best.  
 I get x-rays sometimes and blood work to look for cancer.  
 I would need to be watched like a hawk.  
 My dermatologist checks my skin, extra careful now and I am always asking, what 
about this and I have had a few more things removed but no cancer, thaaank goodness. 
 He’s an oncology surgeon so he’s my follow-up 
 I see the dermatologist or my surgeon (surgical oncologist); I just say is there anything 
you want to cut off? 
 When she does my lab work, they do um, a blood test to look for tumors.  
 I said well what about that one and they (doctors in general) would say it looks fine. So 
now, when they say it looks fine for now, I don’t like that word. I’m like if you think it 
could turn, take it now. I don’t want it to turn again. 
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Subtheme 4A:  
Follow-up 
visits 
 We found out about him (surgical oncologist), and he went and we loved him from the 
first time so we just kept going back to him. 
 The surgeon (surgical oncologist) said I would need to follow-up with him and 
dermatology. The [medical oncologist] checks my x-rays and blood work, not sure 
how long, uum so far I’m still here and want to keep it that way.  
 Not much, just asked me who follows me for melanoma and how often. He was going 
to get the records. 
 The dermatologist checks my skin, asks if anything new has shown up. 
Subtheme 4B:  
Reassurance 
offered 
 Actually they took it out (melanoma) and ah, then they had to redo it because they 
didn’t take out enough the first time [needed wider margins] 
 Surgeon told me he was gonna’ take care of it so I thought ok, he’s gonna’ take care of 
it.  
 He’s the works 
 They did scans and could see that it didn’t spread anywhere so that was a good thing. 
 They [surgical oncologist] were highly efficient. They had me in the office in about 3 
days. Um, when I saw him the first day, then um, I had an educational video that was 
very scary, but he came in and he looked at it and he felt very confident that um, he 
could take care of it and I would be ok and that’s really what I wanted to know. 
 Very well known and I’ve got a lot of respect for him, I really, I really… think he did 
me good. 
 Yeah, he (surgical oncologist) just immediately um, he was just amazing. I mean very 
um, caring, very um, personable and was very reassuring and wanted to make sure at 
every step of the way that I knew exactly what he was doing and what he was saying 
and so he clarified, clarified, clarified.  
 Yeah, I can’t actually imagine not going to see him (surgical oncologist), because I 
actually feel like when I’m seeing him, I don’t have cancer 
 I went in and saw him [plastic surgery friend] on Monday and then I had surgery two 
weeks later. 
 I’ll see you next Monday and I went in saw him [plastic surgeon friend] the next 
Monday and then I had surgery two weeks later. 
 She (surgical oncologist) specifically said I would need to be watched like a hawk.  
 The ideal plan is I’m supposed to try to scatter my doctors so that they are throughout, 
so that I’m technically being seen around the year, so as much as I can do that with the 
insurance allowing, I do. 
 The surgeon (surgical oncologist that removed the melanoma) said, do not take her to 
the Emergency Room, please bring her to the office in the morning. 
 She [her aunt] just linked me in with her surgeon and so before my doctor pretty much 
had done anything, I had already kind of started my path within a couple hours. 
 I mean the doctor’s amazing, seriously. Um, if I text, like when I texted this week and 
I had something else that I found um, he just said come in Monday 
 My doctor was very clear that I will always be a cancer patient. 
 I had the surgery, had the recovery, had already gone back for my follow-up with her 
[dermatology PA) and then received a call from the office of the plastic surgeon that 
they normally do work with. 
 I had to go to the cancer center to get everything. I didn’t have any way to get 
anything. Medicine and stuff they helped me with it all.  
 So it was very reassuring and um, empowering cause I, it, it ah, I didn’t feel like oh, I 
don’t know what this is or what does this mean 
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Subtheme 4B: 
Reassurance 
offered 
 So she [dermatologist] gave me information and the option rather than just this is what
we are going to do and did it in person. I like better than over the phone. After she
scheduled the appointment…I called my sister I’m like, it was really great she
scheduled an appointment the same week to come back.... 
 I felt I could be in charge of, of how I was gonna handle and it never, it quite frankly,
naively never occurred to me that I wouldn’t be in charge of how I handled it but if I’d
been waiting for somebody to call me for weeks on end and not hearing anything and
wondering you know when am I gonna get this taken care of, I think I would have felt
really different.
 I felt very comfortable that I had good um, clinician’s diag ah, diagnosis, good doctors.
 I wasn’t sitting around for 6 weeks waiting for somebody’s office to call me to
schedule a consult to talk about the surgery we might be having in the future.
 I was safe with that because I knew that if he did it, he would do it like a melanoma cut
and I would never have to worry about that spot.
 I mean the doctor’s amazing, seriously.
 She was very nice and prepared me for the worst but hoped for the best.
 It’s not she’s so, so happy to cut into to me but it’s just so I know every time I go, I’m
gonna’ have sti, stitches.
 I just felt safe with that.
 They ah, referred me to another dermatologist. He’s a photo dermatologist.
 He looks me over and chops things off here and there but there hadn’t been any more
melanoma.
 Once they know that I’m going to somebody, they don’t really touch on it.
 I tell the eye doctor too.
 Oh, I have endometriosis too I forgot, I told my gynecologist about the melanoma. She
has done surgery for the endometriosis since I had this all done…She took biopsies but
no signs of any cancer.
 So because I have melanoma, they um, check my eye so I have eye people. I have a
freckle on my eye and it’s never changed or anything like that.
 My primary care just asked me who follows me for melanoma and how often. He was
going to get the records. Meantime, my knee settled down after I took a week of
steroid pills to get the swelling down. I go back to see him in three months.
 All the other people are very hypersensitive to it and always want me to ah, have all
these tests done.
 I feel like he’s been the, the most supportive and anytime I’ve ever called him and said
oh this thing started bleeding on my face, he’ll see me the next day and cut it off.
 No but my primary doctor asks if I have had any swelling or anything.
 My [dermatologist] is very informative.
 It’s no big deal. We’re gonna’ take care of it and it’s gonna' be done.
 Um, but yeah, I still don’t really think of it and it’s funny, I don’t really think of it as
cancer like breast cancer or like my dad has lung cancer now.
 The cancer doctor and cancer surgeon were…helped me…talked to me. The nurses
and folks were always nice and called me back.
 I think it made me realize how fortunate I am because I had a plastic surgeon friend,
because I was able to kind of get to the front of the line.
 I was going to have the surgery to take more nodes but my x-rays showed the
melanoma somewhere else.
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Subtheme 4C: 
Uncertain 
times 
 I was referred to an [medical] oncologist. Um, uh, and he recommended just, he said
there was no chemo available that was out there, uh, specifically for melanoma and
radiation wasn’t call for, and um, they were just gonna watch me.
 It looks a little abnormal, so we’re gonna biopsy it and so he did and it came back as
melanoma
 Well, we’d rather go to an oncologist 'cause it seems like they know more about
cancer.
 Yeah, we’re taking care of those six right now.
 You should tell your gynecologist so that when they do your pap smear, they can look
for spots on your cervix.
 I just hadn’t heard any great things about any, ar any dermatologists around here at the
time
 I remembered the doctor referred me to, uh, another person that had a melanoma
removed, and she was about my age, and I just, met her briefly but she was, uh, very
encouraging and, and just made me feel better about myself, you know, that hopefully
my life was gonna go on, and things were gonna be okay, um, it wasn’t a death
sentence at this point so, so I appreciated him doing that, he got me in touch with her.
 My doctor [surgical oncologist] was very clear that I will always be a cancer patient.
 Anytime I see the dermatologist or my surgeon [surgical oncologist], I just ask is there
anything you want to cut off.
 If I text, like when I texted this week and I had something else show up that I found
um, he just said come in on Monday.
 I could have had it done here [locally] but I didn’t feel like, you know, it was the best
place.
 He’s the works.
 I’ve been going there probably at least 5 years every 6 months.
 He (photo dermatologist) compares them every time.
 I mean very um, caring, very um, personable and was very reassuring and wanted to
make sure at every step of the way that I knew exactly what he was doing and what he
was saying and so he clarified, clarified, clarified.
 When she does my lab work, they do um, a blood test to look for tumors.
 Not much, just asked me who follows me for melanoma and how often. He was going
to get the records.
 The dermatologist checks my skin, asks if anything new has shown up.
 I was just getting to know where I was about every 6 months then I had something else
come up last year and it was precancerous and so he [surgical oncologist] took it off
versus my dermatologist just because I asked him what he preferred and he said that he
would prefer to remove it and I was safe with that because I knew that if he did it, he
would do it like a melanoma cut and I would never have to worry about that spot.
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